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ABSTRACT
Equine chondrocyte metabolism under hypoxia 
Siriporn Peansukmanee
The avascular nature of articular cartilage limits oxygen supply within the 
tissue. Cartilage, therefore, is under physiological hypoxic conditions. 
Oxygenation gradients are estimated from 10% at the surface to 1% at the 
deepest layer. Nonetheless, chondrocytes have been reported to be able to 
survive and are well-adapted to such an environment. We hypothesised 
that low oxygen tensions favour chondrocyte metabolism based on their 
nature and literature reviews.
Our study focused on investigation of three major functions of 
chondrocytes, which are glucose transportation, catabolism and anabolism 
under a low oxygen environment compared to atmospheric condition. A 
key regulator of cellular responses to hypoxia, HIF, was also included in 
this study. However, due to a limitation of the detection techniques, we 
were not able to identify the expression of oxygen-sensitive unit, HIF-la in 
equine chondrocytes.
Study of glucose transportation showed increases of glucose uptake and 
expression of GLUT1 protein (FACS analysis) and mRNA of equine 
chondrocytes under hypoxia indicating their metabolic adaptation to low 
oxygen environment. We also demonstrated downregulation of GLUT1 
mRNA in pathologic cartilage such as found in OA and OCD which may 
indicate compromised glucose transportation leading to failure of tissue 
repair.
Hypoxia had only a very small effect on cytokine-induced cartilage 
degradation. Although we found reduced amounts of TNF-stimulated 
MMP-13 activation under hypoxia, GAG and collagen releases were not 
affected by oxygen levels.
Hypoxia showed variable effects on cartilage matrix synthesis, depending 
upon different joint sources of chondrocytes and the number of then- 
passage. This may indicate interaction of hypoxia and such factors that 
needed to be considered in cartilage engineering study.
Overall, our study clearly showed metabolic adaptation of chondrocytes 
under different oxygen levels. Hypoxia, while having no obvious effect on 
cartilage degradation showed contradictory results in cartilage neo-genesis 
suggesting complex factor involvement.
l
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C h a p t e r  I
GENERAL INTRODUCTION 
Joint structure
Diarthrodial joints consist of several structures, including the articulating 
surfaces of bones covered by articular cartilage, the synovial membrane, 
the fibrous capsule, a cavity containing synovial fluid, and the supportive 
ligaments (Fig 1.1). The synovial structure is designed to facilitate joint 
movement and load bearing. Surrounding ligaments stabilise the joint and 
prevent over-flexion or -extension. The capsule composes of two layers, 
the outer membrane which is a fibrous layer, defining the joint boundary 
and the inner layer or synovial membrane, which contains and is 
responsible for synthesis of synovial fluid. The synovial fluid lubricates the 
joint to prevent inflammation and pain during movement and also allows 
diffusion of nutritive substances from the highly vascularised synovial 
membrane to joint tissues (Simkin and Pizzomo 1974).
Articular Cartilage
Articular cartilage is the connective tissue lining the ends of bones within 
diarthrodial joints. The resident cells within this tissue, the chondrocytes, 
secrete and organise a unique extracellular matrix, which is glassy or
1
hyaline in appearance and is deformable, facilitating a smooth gliding 
movement and load distribution.
Bone
Fibrous Articular 
Joint Cartilage 
Capsule
Synovial Fluid Synovial 
m Joint Cavity Membrane
Synetdfivd
mJoMCowy
Synodal Mm toarm 
A/tcxkn Cantag*
BfaodVfaW
Articular Carnage
Synovial Fluid 
In Jorrt Cavity
Synoviocyte 
Blood UecaeJ
Fig 1.1 Diarthrodial joint structure and vascular supply. Cartilage has no direct 
blood supply but is nourished by nutrients diffused from synovial membrane 
through synovial fluid (note that subchondral vasculature also supplies essential 
nutrients) (www.holistichorsehealth.com).
Cartilage protects the underlying bone by its resistance to various forces, 
e.g. compressive, tensile and shearing stresses. Articular cartilage has no 
vascular supply but derives the essential nutrients by diffusion through 
synovial fluid from the vascular network within synovial membrane 
(Levick 1995). Articular cartilage can be divided into four zones according 
to the arrangement of chondrocytes and matrix microstructure as described 
below (Freeman 1979):-
1. Superficial zone; adjacent to the synovial space. Cells have 
discoidal shape. Both cells and the matrix fibres are oriented 
parallel to the surface of cartilage.
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2. Intermediate zone; cells are evenly distributed and of spherical 
shape. Fibres arrange themselves into an interlacing meshwork.
3. Deep zone; spherical cells are arranged in columns. Fibres are 
mostly in radial orientation to the surface.
4. Calcified zone; adjacent to the subchondral bone. Matrix is 
deposited and mineralised by crystals of calcium salts. There are 
only few cells in this zone.
Chondrocytes
Chondrocytes are the only cell type resident in cartilage. Although 
cartilage contains relatively small number of cells, which comprise 
approximately 1-10% of the tissue volume (Hammerman and Schubert 
1962), they can be very active. Chondrocytes are responsible for cartilage 
matrix synthesis and resorption to maintain the balance of the tissue 
turnover. Chondrocytes from immature cartilage are capable of undergoing 
cell division, in contrast to those from adult tissue, whose mitosis is almost 
undetectable. Chondrocyte morphology and metabolism can be altered as 
consequences of cell-cell interaction and between the cells and surrounding 
environment. For example, chondrocytes maintained in three-dimension 
(3-D) environment such as in pellet, suspension or alginate bead cultures 
are spherical in shape and much more active in matrix synthesis than those 
grown in monolayer, which are elongated in shape and active in DNA 
synthesis and cell division (Stockwell 1979). These differentiations of
3
chondrocytes are also interchangeable. Dedifferentiated monolayer 
chondrocytes, which are fibroblastic, are able to re-differentiate back to be 
chondrogenic when they are re-cultured in 3-D structures. However, this 
property is limited only to the early passaged chondrocytes (Domm et al. 
2002; Murphy and Polak 2004).
Cartilage extracellular matrix
Cartilage matrix has important roles not only to facilitate joint function but 
also to maintain homeostasis of the chondrocyte environment. Although 
cartilage seems to be a very simple tissue and homogeneous in gross 
appearance, there is histological variation depending on various factors 
such as species, age, sites and functions. Articular cartilage is categorized 
as a hyaline cartilage, containing a complex of macromolecular structure 
including a collagenous fibril meshwork, primarily made of type II 
collagen, a highly hydrated ground substance composed mainly of 
proteoglycans (mainly aggrecan), and other non-collagenous protein, 
including link protein, fibronectin, cartilage oligomeric matrix protein and 
small proteoglycans (Fig 1.2). Cartilage has a very high water content, 
which explains the glossy appearance of the tissue, approximately 70% by 
weight in mature cartilage. On a dry weight basis, equine articular cartilage 
contains about 50% collagen, 35% proteoglycan, 10% glycoprotein, and 
other minor components (Mcllwraith and Trotter 1996).
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Fig 1.2 The example of major components of hyaline cartilage extracellular 
matrix (Chen et al. 2006). Collagens (type II, IX and XI), proteoglycans (primarily aggrecan 
and other small PGs such as decorin, biglycan and fibromodulin), and non-collagenous protein (link 
protein, fibronectin and cartilage oligomeric matrix protein/ COMP) are shown.
Collagens
The collagens are a family of proteins that are distributed throughout the 
body providing a broad range of extracellular matrix functions. At least 30 
members of the collagen family have been identified and classified 
(reviewed by Kadler et al. 2007) (Table 1.1). Collagens are synthesized as 
procollagen molecule containing N- and C-terminal which are cleavable by 
N- and C-proteinases (Greenspan 2005). Each collagen fibre is made up of 
tropocollagen molecules, which consist of three polypeptide a-chain 
forming a triple helix structure. Differences among the various types of 
collagens are due to varying combinations and modifications of the 
different chains within the triple helix (homotrimer; same three a-chains, 
heterotrimer; three different a-chains or heterotypic; combination of two a-
5
chains from one collagen type and an a-chain from another type (Cremer et 
al. 1998). The peptide sequence within the collagen triple helix is (Gly-X- 
Y) where X and Y are often proline and hydroxyproline, respectively. The 
helical structure provides resistance to proteolytic enzymes except matrix 
metalloproteinases (Cremer et al. 1998).
Collagens provide structural support, strength and biological properties. 
There are many types of collagen expressed in articular cartilage (Table 
1.2). Among these, type II collagen is the major type of collagen in hyaline 
cartilage. It copolymerises with two other minor collagens, called types IX
Table 1.1 Collagens and their classification (adapted from Kadler et al. 2007)
C la ss ifica tio n C o lla g en
Fibril forming 1, II, III, V , X I, X X IV , X X V II,
N etw ork  form ing IV, V III, X
B ea de d  filament form ing V I, X X V I, X X V III
F A C I T  (F ib e r-A sso cia te d  C olla ge n s w ith Interrupted Trip le  helices) IX , X II, X IV , X V I, X I X  X X  X X I, X X II
T ra n sm e m b ra n e X III, X V II, X X III, X X V , Ectodysplasin  A , G liom edin
Endostatins X V , X V III
A nchoring fibril VII
and XI to form a complex fibril heteropolymeric or heterotypic fibril (Fig 
1.3).The dense fibrillar collagen network is embedded within a very high 
concentration of proteoglycan aggregated with hyaluronan, which draws 
water into the tissue and expands the collagen network (Mcllwraith and 
Trotter 1996). Type VI collagen is found in the pericellular region and is
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thought to help bind the cell surface to matrix collagen and proteoglycans 
(Poole et al. 2001). Destruction of the collagen network is believed to be an 
irreversible stage of cartilage damage as chondrocytes are poor at replacing 
the collagen architecture and this leads to many joint problems such as 
osteoarthritis (Eyre 2004).
Table 1.2 Collagen molecules of articular cartilage and their functions (adapted 
from Poole et al. 2001)
C o llag en C o m m en ts Fu n ction
T y p e  II Principle com ponent of fibril Te n s ile  strength
T y p e  VI Fo rm s microfibrils In pericellular sites Unknow n
T y p e  IX C ross-linked to surface of fibril Te n s ile  properties and/or fibril- 
interfibrillar connections
T y p e X A ssociated  with fibril and present in pericellular 
network. O n ly  synthesized by hypertrophic 
chondrocytes. O n ly  usually present in calcified 
layer
U n c le a r but m a y add 
structural support
T y p e  XI Present within and on fibrils N ucleates fibril form ation
T y p e  XII and X IV E a ch  is hom otrim eric P robably part o f fibril
Fig 1.3 Schematic of heteropolymer of collagen MX/XI in a thin cartilage 
collagen fibril. (Blue: collagen II molecule; yellow: collagen XI molecule; red: 
collagen IX molecule). Collagen XI microfibrils are at the fibril core, surrounded 
by collagen II microfibril and collagen IX at the surface. The N-terminal of 
collagen XI are shown extending from the core microfibrils onto the fibril surface 
(Kadler et al. 2008).
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Proteoglycan
Proteoglycan, a class of glycosylated proteins, provides a compressive 
resistance to cartilage by acting as a sponge that absorbs water into the 
tissue. Proteoglycan molecules consist of core proteins to which are 
(covalently) attached chains of glycosaminoglycans (GAGs). GAG chains 
are polysaccharides made of repeating disaccharides, typically a repeat of 
40-100 units. Most GAGs such as chondroitin sulphate, keratan sulphate, 
dermatan sulphate, heparan sulphate are modified by sulphation within 
their disaccharide units, with hyaluronan being an exception. The GAG 
components of proteoglycan are shown in Table 1.3. The biological 
function providing compressive resistance of proteoglycans, primarily 
aggrecan and also perhaps versican (Matsumoto et al. 2006), derive mostly 
from the strong negative charge of glycosminoglycan sulphation that 
attracts counter ions which causes water influx due to the Gibbs-Donnan 
equilibrium (Kovach 1995).
Aggrecan is the major proteoglycan of cartilage, found in complex 
multimolecular aggregates comprised of numerous monomers non- 
covalently bound to hyaluronic acid (Kiani et al. 2002). The core protein 
has three globular domains, which are G l, G2 and G3, and three extended 
domains; IGD, KS and CS (Fig 1.4). Aggrecan forms a stable complex in 
ECM by interaction between its Gl domain and hyaluronan, which is 
strengthened by link proteins. Between Gl and G2 domain is an inter- 
globular-domain (IGD) (Kiani et al. 2002). The chondroitin sulphate
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chains, either 4-sulphated, 6-sulphated, or sometimes both, are attached to 
the long, extended domain between G2 and G3. Keratan sulphate chains 
are more widely distributed but preferentially located towards the N 
terminus.
Table 1.3 Glysosaminoglycan components of proteoglycan found in cartilage 
(adapted from McDwraith and Trotter 1996)
d y c o s a m in o g ly  
c a n  n a m e
P r im a r y  c o r e  
p ro te in
W e t
w e ig h t
o f
c a rtila g e
(%r
W e t
w e ig h t
(n m o l/ g
mr
O th e r
n a m e s
R e p e a tin g  u n it in  
g ly c o s a m in o g ly c a n
Chondroitin Aggrecan 5-10 1-10 PG-LA1 N-acetylgalactosamine-¡1(1-4)^sulphate glucuronic acid-f)(1-3)
Dermatan sulbte Decorin 0.03-0.12 0.3-0.6 PG-S2 N-acetylgalactosamine-p(1-4)-
PGII glucuronic acrd-p(1-3)
Biglycan 0.06-0.24 oaso .5 PG-S1 N-acetylgaiactosamine-a(1-4)-
PGI idurontcactd-a(1-3)
Keratan sutfate Aggrecan PG-LA1 N-acetytglucosamine-p(1 -3)-
ga lactose-« 1-«)
Fibromodulin o.i-oa 1-5-5 58-kOa N-acetylglucosafnine-« 1 -3)-
protein galactose-« 1-4)
Hyaluronan None 0.05-0.25 0.03-0.08 Hyaluronic N-acetylglucosamine-«1-4)-
acid glucuronic acid-p(1-3)
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Fig 1.4 Schematic representation of aggrecan monomer and link protein structure 
(adapted from Dudhia et al. 1990). The domains [Gl, G2, G3 and interglobular- 
domain (IGD)] with keratan sulphate- and chondroitin sulphate- rich regions are 
shown.
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Cartilage oligomeric matrix protein (COMP)
Cartilage oligomeric matrix protein, also called thrombospondin 5, is an 
abundant non-collagenous protein component of cartilage matrix (Hedbom 
et al. 1992). COMP has a pentameric form of five subunits arranged in a 
bouquet-like structure, a central cylindrical structure radial with five 
globular-domain ended arms (Morgelin et al. 1992) (Fig 1.5). COMP can 
be degraded by ADAMTS-12 (Liu et al. 2006) and has been used as a 
biomarker of cartilage destruction in osteoarthritis and rheumatoid arthritis 
(Dahlberg et al. 1994; Lohmander et al. 1994; Mansson et al. 1995; Sharif 
et al. 1995) although COMP is also a marker of synovitis as synovial cells 
can also produce this molecule (Recklies et al. 1998). Mutation of the 
COMP gene results in skeletal disorders such as pseudoachondroplasia and 
multiple epiphyseal dysplasia (Briggs et al. 1995; Hecht et al. 1995). 
However, the precise function of COMP in cartilage is still not clear. 
COMP is distributed throughout cartilage matrix but preferentially 
localised in the interterritorial zone (Murphy et al. 1999). It has been 
shown that COMP can interact with type II and IX collagens (Rosenberg et 
al. 1998; Holden et al. 2001; Thur et al. 2001) and also aggrecan (Chen et 
al. 2007) (Fig 1.5). It is therefore suggested that COMP may play a role in 
cartilage matrix integrity. Recently, COMP was shown to have anti- 
apoptotic properties for chondrocytes (Gagarina et al. 2008) and can 
support chondrocyte attachment to the ECM through integrins (Chen et al.
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2005). Taken together, COMP has complex roles in maintaining both 
cartilage matrix and chondrocytes.
Type II collagen
Fig 1.5 Diagram of cartilage oligomeric matrix protein (COMP) structure and 
interaction with other cartilage matrix molecules e.g. collagen fibrils and aggrecan 
(adapted from http://www.cmb.lu.se/ctb/html/COMP.htm and Reginato and Olsen
2002).
Cartilage homeostasis
Cartilage homeostasis reflects a balance between synthesis and degradation 
of matrix components, which is in part mediated by chondrocytes. 
Surrounding tissues such as synovial membrane and subchondral bone are 
also influential in signalling matrix turnover processes especially under 
pathological conditions. Cartilage is a dynamic tissue, in which there is 
remodelling of the matrix and degradation and synthesis of matrix 
molecules. However, in the adult, turnover of collagen for example can be 
really slow with tl/2 values in the order of 70+ years (Maroudas et al. 
1992). Enzyme inhibitors and anti-inflammatory cytokines participate in 
the anabolic process to stimulate extracellular matrix formation and cell 
proliferation. On the other hand, proinflammatory cytokines and enzymes
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participate in the catabolic process, which results in the destruction of the 
cartilage matrix and a reduction of cell proliferation. The enzymes that play 
a key role in the degradation of the cartilage matrix are the proteases, 
which are inducible by a number of cytokines and growth factors. Among 
the different families of proteases, matrix metalloproteinases (MMPs) are 
the most commonly associated with ECM degradation process. The 
AD AMTS (a disintegrin and metalloproteinase with thrombospondin 
motifs) enzymes are also involved in cleaving hyaluronan-binding 
proteoglycan (hyalectan). Under physiologic conditions, the net activities 
of these enzymes are regulated by their physiological inhibitors called the 
tissue inhibitor of metalloproteinases (TIMPs) (Murphy et al. 1994).
Cytokines
Cytokines are soluble or cell-surface molecules that play an essential role 
in mediating cell-cell interactions. In general, cytokines act on cells that 
produced them or in the area surrounding the cells, although in certain 
situations they may enter the circulation and act in an endocrine fashion. 
They interact with target cells by binding to specific receptors present on 
the cell surface. It is possible to classify (Table 1.4) the cytokines into 4 
categories (Goldring and Goldring 2004):-
1. Catabolic cytokines; regulate cartilage remodeling, acting on target 
cells to increase synthesis and release of products that enhance 
matrix degradation.
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2. Anticatabolic cytokines; tending to inhibit or antagonise the 
activity of the catabolic cytokines.
3. Anabolic cytokines (e.g. growth factors); acting on chondrocytes to 
increase synthetic activity
4. Modulatory cytokines; these cytokines are grouped based on their 
capacity to modulate the activities of the other cytokines
Table 1.4 Chondrocyte-Cytokine Interactions (Goldring and Goldring 2004)
C a ta b o lic M od u la to ry A n ti-C atab o lic A n a b o lic
IL -1 IL -6 IL -4 IG F -1
T N F -o t L IF IL -1 0 T G F -P 1 .2 .3
IL -1 7 I L -1 1 IL -1 3 B M P -2 .4 .6 ,7 ,9 ,1 3
IL -1 8 IL -1 ra
O S M
1. Interleukin 1 (IL-1)
IL-1 is generally found to induce a catabolic response. It induces 
chondrocyte-mediated cartilage degradation by stimulating the degradative 
proteinases involved in this process, inhibiting the synthesis of 
macromolecules essential for matrix integrity, and also inhibiting 
proliferation of chondrocytes induced by serum or TGF (Goldring and 
Goldring 2004). There are three members of the IL-1 family, IL-1 alpha, 
IL-1 beta and IL-lRa. The first two isoforms bind to the same cellular 
receptor that transmits intracellular signals in inflammation whilst IL-lRa
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competes for their receptor binding, blocking their role in immune 
activation (Dinarello 1994).
2. Tumor Necrosis Factor-alpha (TNF-a)
TNF is a member of a superfamily of proteins, each with 157 amino acids, 
which induce necrosis of tumor cells and posses a wide range of 
proinflammatory actions. TNF established its role in tissue destruction in 
rheumatoid arthritis and related inflammatory joint disorders (van den Berg 
2001; Van den Berg 2002). It has similar effects to IL-1, stimulating 
matrix-degrading protease activity levels and suppressing cartilage matrix 
synthesis, effect that are susceptible to synergistic enhancement when these 
cytokines are combined together (Berenbaum et al. 1996).
3. Oncostatin M (OSM)
OSM is a member of the IL-6 family of cytokines (Rose and Bruce 1991). 
It is considered a multifunctional cytokine that affects the growth and 
differentiation of several cell types and participates in both catabolic and 
anabolic processes. Whilst increasing mediators that inhibit inflammatory 
mechanism such as IL-IRa and TIMPs, OSM also stimulates the 
inflammatory response. However, the influence of OSM in matrix 
degradation is obviously magnified when it is combined with IL-1. There 
are several studies using human and bovine cartilage, showing a synergistic 
effect between OSM and IL-1 in upregulation of MMP genes (Hui et al. 
2001; Barksby et al. 2006 a) and increasing cartilage matrix degradation 
(Milner et al. 2001; Morgan et al. 2006).
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4. Transforming Growth Factor-beta (TGF-P)
The transforming growth factor beta family of molecules is a group of 
anabolic cytokines that are involved in several extracellular matrix 
formation processes such as wound healing, skeletal morphogenesis and 
carcinogenesis (Chin et al. 2004). TGF-P also promotes cartilage formation 
(Frenkel et al. 2000). Specifically, TGF-P has been reported as being able 
to promote type II and type IX collagen synthesis and also aggrecan 
synthesis (Chu et al. 1995) and is also able to down-regulate the effects of 
cytokines that stimulate chondrocyte catabolic responses (van Beuningen 
et al. 1993).
5. Insulin-like Growth Factor-1 (IGF-1)
IGF-1 is a peptide with a potent anabolic impact on cartilage homeostasis. 
It stimulates the proliferation of chondrocytes and favours matrix synthesis. 
It has been shown to drive equine cartilage proteoglycan and collagen 
matrix production in vitro (Fortier et al. 1999). IGF-1 also blocks collagen 
breakdown and down regulates MMP-1, 3, 8 and 13 mRNA expression in 
bovine nasal cartilage (Hui et al. 2001).
Matrix metalloproteinases (MMPs)
The matrix metalloproteinases (MMPs) are a superfamily of proteolytic 
enzymes responsible for extracellular matrix degradation (Birkedal-Hansen 
et al. 1993). MMPs are necessary in tissue remodelling and are involved in 
wound healing, angiogenesis, and tumour cell metastasis. They are called 
metalloproteinases because they need zinc or calcium atoms for their
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function. MMPs are secreted as a latent form, which is determined by their 
N-terminal propeptide of 77-87 amino acids with a conserved region. The 
interaction between cysteine within the conserved region and zinc is the 
characteristic of the proenzyme form. Destablisation of this interaction by 
sequential cleavages can modify the enzyme conformation and allows 
activation to the active form (Murphy et al. 1994). There are currently 24 
members (Nagase et al. 2006) within this superfamily, which can be 
subdivided into six major categories, collagenases; gelatinases; 
stromelysins; matrilysins, membrane-type (MT) MMP and others, 
according to their domain organisation and substrate preference (Nagase et 
al. 2006). MMP-1, -8, -13 and -18 are grouped as collagenases, which 
cleave collagen types I and II into 3/4 and % fragments. Among these, 
collagenase 3 (MMP-13) is a powerful collagenolytic enzyme that 
preferentially cleaves type II collagen, the main collagen in cartilage. 
Gelatinases (MMP-2 and MMP-9) have a specific domain, called 
fibronectin type II motif (Fig 1.6), which binds to gelatin and also collagen, 
allowing the enzyme to digest these substrates. However, the 
collagenolytic activity of gelatinases is much weaker than MMPs from the 
collagenases group (Nagase et al. 2006). Stromelysins are involved in 
many MMP activations, degradation of proteoglycans and 
depolymerisation of the heterotypic collagen fibril by cleaning the non- 
collagenous regions of collagen type II and XI (Wu and Eyre 1995). 
Although their domain arrangement is similar to collagenases, stromelysins
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have no collagenolytic activity at all (Nagase et al. 2006). Membrane-Type 
matrix metalloproteinases (MT-MMPs) are activated intracellularly before 
they are transferred to the cell surface so that these enzymes can work in 
this precise location. MT-MMPs also participate in proMMP-2 and 
proMMP-13 activation (Knàuper et al. 1996 b).
Collagen»« 
Family 
M M P-l, 8, 
13, 16
Gelatin»« 
Family 
MMP-2. 9
Membfane-Type
Family
MMP-M, 15. 
16.17
Matnlysm 
MMP-7
Fig 1.6 Structural domains of matrix metalloproteinases. The schematic shows 
signal peptides, prodomains, catalytic domains, hinge regions and hemopexin-like 
domains of each MMP type. The transmembrane domain is shown in MT-MMP, 
while hemopexin-like domain is not presented in matrilysin. 
(http://www.emdbiosciences.com/html/cbc/matrix_metalloproteinase_MMP.htm)
MMPs can be regulated at many levels. Their expression is 
transcriptionally controlled by inflammatory cytokines, growth factors, 
hormones, cell to cell and cell to matrix interactions (Nagase and Woessner 
1999). MMP activity is mediated by activation of the zymogens, which can 
be inhibited by the endogenous inhibitors, tissue inhibitors of 
metalloproteinases (TIMPs).
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A disintegrin and metalloproteinase with thrombospondin motifs 
(ADAMTS)
The ADAMTS are a group ofproteinases which are also found in cartilage. 
Nineteen human ADAMTS have been identified. ADAMTS-1, -4, -5, -8, - 
9 and -15 cleave the hyalectan (hyaluronan-binding proteoglycan) (Jones 
and Riley 2005) and ADAMTS-4 and -5 have been implicated as the 
aggrecanases involved in aggrecan degradation in osteoarthritis (OA) 
(Malfait et al. 2002). Studies in ADAMTS-4 and -5 knockout mice 
revealed that they were phenotypically normal and indistinguishable from 
wild-type littermates, indicating that each enzyme was dispensable for 
normal development (Glasson et al. 2004; Glasson et al. 2005; Stanton et 
al. 2005).
Tissue inhibitors of metalloproteinases (TIMPs).
The activity of the metalloproteinases is regulated by the enzymes’
physiological inhibitors and activators. The endogenous inhibitors of the 
MMPs are the TIMPs (tissue inhibitors of metalloproteinases/ Four TIMPs 
(TIMPs 1-4) have been identified to date (Gomez et al. 1997). TIMPs 
consist of 184-194 amino acids, which are subdivided into an N-terminal 
and a C-terminal subdomains. (Nagase et al. 2006). TIMPs form a 1:1 
complex structure with the catalytic domain of MMPs to effect inhibition 
and all TIMPs can inhibit every identified MMPs so far but to a different 
degree (Nagase et al. 2006). However, TIMP-3 has been implicated as a
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major regulator of metalloproteinase activities in vivo (Fata et al. 2001; 
Leco et al. 2001).
Metabolic energy of chondrocytes
The primary energy resource of chondrocyte metabolism is mainly 
provided by extracellular glucose, which is metabolised as a substrate for 
ATP production to control cellular respiration and homeostasis 
(Richardson et al. 2003; Windhaber et al. 2003). In addition to the energy 
supply, glucose is the carbon skeleton resource of many biological 
substances, such as protein, lipid, nucleic acids and complex 
polysaccharides, and is also an important component for extracellular 
matrix synthesis e.g. it is incorporated alongside glusosamine sulphate and 
other sulphated sugars to produce glycosaminoglycans (Windhaber et al.
2003) .
Since the cell membrane is impermeable to glucose, transport of glucose 
into and out of the cell is manipulated by facilitated diffusion through 
membrane protein carriers called glucose transporters or GLUTs. GLUTs 
are located in the plasma membrane and have glucose binding sites both 
inside and outside the membrane. Besides transporting glucose, GLUTs 
also play another role as transporters of diascorbic acid, which is an 
important co-factor of collagen and glucosamine synthesis (Shikhman et al.
2004) .
19
Glucose transporters are part of the GLUT or SLC2A gene family which 
belong to a larger super family of proteins known as the major facilitator 
superfamily (MFS) (Saier et al. 1999). GLUTs are distinct from the 
SGLT/SLC5A family of Na+-dependent sugar transporters (Wood and 
Trayhum 2003). GLUT proteins are characterised by the presence of 12 
membrane spanning helices and several conserved sequence motifs (Pessin 
and Bell 1992) (Fig 1.7). GLUT isoforms (at least 13 members have been 
identified) differ in their substrate specificity and tissue distribution (Table 
1.5). Human chondrocytes express a number of glucose transporter 
proteins (Table 1.6).
Fig 1.7 Glucose transporter structure (Pessin and Bell 1992) showing 12 
membran-spanning segments (Ml-Ml2) and the position of exon boundaries in 
the protein.
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Table 1.5 GLUT expression in mammalian tissues (adapted from Mobasheri et
al. 2002 a)
G L U T S M ain  t is s u e s  e x p re s s in g  G L U T s
G L U T1 Red blood cell and endothelial cells
G L U T 2 Liver and pancreatic cells
G L U T 3 Neuron and platelet
G L U T 4 Muscle and adipose tissue
G L U T 5 Intestine and testis
G L U T 6 S e e  G L U T 9
GLLTT7 Liver and other glyconeogenlc tissues
G L U T 8 Testis  and placenta
G L U T 9 Kidney and liver (also In placenta, lung, blood and peripheral leukocytes, heart, 
skeletal mucle, spleen and brain)
G L U T 1 0 Liver and pancreas
g l i t t h Heart and skeletal muscle
G L U T 1 2 Skeletal muscle, adipose tissue and small intestine
G U J T 1 3 H +myo-inositol transporter and brain
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Table 1.6 GLUTs in human cartilage (adapted from Richardson et al. 2003)
Protein Gene name Proposed physiological Functions
GLUT1 SLC2A1 Housekeeping glucose transporter; ubiquitously expressed. Its
expression appears to be up-regulated by glucose deprivation and 
prolonged hypoxia ischemia.
GLUT3 SLC2A3 Fast glucose transporter. High affinity transporter specialized for glucose 
uptake where substrate concentration are low.
GLUT4 SLC2A4 Insulin sensitive glucose transporter (expressed only in developing 
cartilage)
GLUT5 SLC2A5 Fructose transporter
GLUTS (alias GLUTS) SLC2A6 See GLUT 9
GLUTS (alias GLUT X1) SLC2A8 Down regulated by glucose deprivation and prolong hypoxia
GLUTS (alias GLUT X) SLC2A9 Glucose transporter expressed in kidney, liver, and cartilage
GLUT11 SLC2A11 Glucose transporter with several transcription variants (product of mRNA 
splicing)
GLUT12 SLC2A12 GLUT-12 may comprise a second insulin-sensitive glucose transport 
system
22
The avascular nature of cartilage results in low supplies of glucose and 
oxygen to chondrocytes. Limited oxygen drives chondrocytes to generate 
energy mainly by anaerobic glycolysis (Lee and Urban 1997), which 
produces 18-19 times less ATP per molecule of glucose than aerobic 
respiration (Ahlqvist 1984) (Fig 1.8). Therefore, chondrocytes must be able 
to manage glucose transport and metabolism effectively to provide 
sufficient energy within the anatomical and physiological constraints of 
cartilage.
A n a e ro b ic
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Fig 1.8 Cellular energy generation from anaerobic and aerobic respiration. Under 
aerobic conditions, a cell gains net 36-38 ATPs from glycolysis and oxidative 
phosphorylation per molecule of glucose while under anaerobic condition, cell 
produces 2 ATPs from glycolysis only.
Among GLUTs expressed within cartilage, GLUT1 and GLUT3 are 
hypoxia responsive isoforms and are regulated by the transcription factor 
and oxygen sensor protein, hypoxia-inducible factor 1 (HIF-1) (Mobasheri 
îvf et al. 2005 a).
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Cartilage physiology under hypoxia
Articular cartilage is an avascular tissue. Nutrients and oxygen are 
delivered by diffusion from blood vessels of the underlying bone and from 
synovial fluid, which lubricates the joint (Lee and Urban 1997). Because of 
this limitation, compared with other tissues, which are maintained by 
capillary networks, cartilage is under hypoxic and nutrient deficient 
conditions. It is well known that there is a physiological oxygenation 
gradient within articular cartilage. It has been estimated that chondrocytes 
at the articular surface are exposed to 6-10% oxygen while the deepest 
layer can access only 1% or less oxygen (Falchuk et al. 1970; Lund-Olesen 
1970; Treuhaft and McCarty 1971; Silver 1975; Kiaer et al. 1988; Ferrell 
and Najafipour 1992). However, chondrocytes appear to be very well 
adapted to such environments (Rajpurohit et al. 1996). It was found that 
the anabolism and cell survival of cartilage were maximized when it was 
cultured in vitro under low oxygen tension compared to normoxic and 
anoxic conditions (Grimshaw and Mason 2000; Hansen et al. 2001; Domm 
et al. 2002; Schneider et al. 2004). Therefore it may be that hypoxia is the 
natural or physiological state of chondrocytes.
Avascular tissue such as cartilage is able to modulate its physiology to 
survive in low oxygen environment by organisation of hypoxia-inducible 
factor-1 (HIF-1), which is responsive to cellular oxygen concentration. The 
important roles of HIF-1 in cell survival have been reported (Schipani et al.
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2001; Mazure et al. 2004; Yudoh et al. 2005). It is known that HIF-1 
rescues oxygen-scarce cells by regulation of vital gene expression.
HIF-1 and its regulators
HIF-1 is a heterodimer composed of 2 subunits, H IF-la and HIF-1 p. HIF- 
ip  is expressed constitutively while H IF-la is hypoxic responsive 
(Semenza 2001 a; Semenza 2001 b). Both of them are relatively large 
proteins in size and contain a basic helix-loop-helix motif (bHLH) (Dery et 
al. 2005). The basic domain is essential for DNA binding while the HLH 
domain is responsible for subunit dimerization. Another common structure 
of both proteins is the Per-ARNT-Sim (PAS) domain, which identifies a 
protein superfamily (Fig 1.9). The instability of HIF-1 a under high oxygen 
level comes from its unique structure, the oxygen-dependent degradation 
(ODD) domain, found between residues 401-603. This domain is highly 
oxygen-regulated.
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Fig 1.9 HIF-1 a and HIF-1 p structures (Déry et al. 2005) . Functional domains 
and binding domains with co-factors are shown. Hydroxylation, acetylation and 
phosphorylation sites are indicated. bHLH = basic helix-loop-helix; ODD = 
oxygen-dependent degradation domain; TAD-N and TAD-C = N- and C-terminal 
transactivatioin domain; NLS = nuclear localisation signal; PAS = Per-ARNT- 
Sim.
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The main regulation of HIF-1 by oxygen is performed on the a subunit. 
HIF-la has been found to be extremely labile under normoxic condition 
with a half life of less than 5 minutes (Déry et al. 2005). This is due to 
destruction of the a subunit which results in lack of dimérisation to another 
subunit and blocks the functional HIF-1 complex formation. The stability 
of HIF-la is regulated by various factors, including HIF-prolyl 4- 
hydroxylases (PHDs)(Mazure et al. 2004). PHDs are iron-dependent 
enzymes, which comprise 3 homologues; PHD1, PHD2 and PHD3 
(Masson et al. 2001). These enzymes have been shown to be able to 
hydroxylate the proline residues, Pro402 and Pro564, which are located in the 
ODD domain of human HIF-1 a. This process needs oxygen to transform 
prolines into hydroxyprolines, which can be recognized by von Hippel- 
Lindau tumour suppressor protein (pVHL) and become the destroyed 
target of the proteosome pathway, von Hippel-Lindau tumor suppressor 
protein (pVHL) has been shown to be the recognition component of the E3 
ubiquitin-protein ligase complex (Lisztwan et al. 1999). The capture of this 
protein and hydroxylated HIF-1 a, therefore, activate the destruction of 
HIF-la by ubiquitin-dependent proteolysis.
Under normoxic condition, HIF-1 a  is mainly destroyed by hydroxylation 
at two proline residues, Pro 402 and Pro 564 into hydroxyprolines. It has been 
shown that PHD2 plays the major role in this process (Berra et al. 2003).
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However, under long-term hypoxic stress, PHD1 and PHD3 have been 
reported to be involved (Berra et al. 2003). On the other hand, under 
hypoxic conditions, or via hypoxic mimicking effects of iron antagonists 
such as cobalt chloride, the hydroxylation of H IF-la by PHD is blocked 
(Dery et al. 2005). HIF-la is released from pVHL and translocates into the 
nucleus, where it heterodimerizes with HIF-1 p to form the HIF-1 complex. 
The kinetics of HIF-1 a in various tissues under normoxia and hypoxia has 
been reported (Stroka et al. 2001). This complex molecule binds to the 
HIF-1 binding site (HBS) of hypoxic response elements (HRE) in the 
target gene and starts to regulate the transcription of its downstream genes 
(Fig 1.10) (Semenza 2001 a).
As seen in other cells, HIF-1 a has been shown to be responsible for energy 
generation and cellular survival of hypoxic chondrocytes. HIF-1 a null 
chondrocytes cannot maintain their viability, energy generation, and matrix 
production under both normoxic and hypoxic conditions (Yudoh et al.
2005). Also, HIF-1 a  null chondrocytes showed accelerated IL-ip-induced 
apoptosis, suggesting that H IF-la has an important role in the survival of 
chondrocytes (Yudoh et al. 2005).
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Fig 1.10 Examples of HIF-1 target genes (adapted from Semenza 2001 a). EPO 
= erythropoietin; IGF = insulin-like growth factor; TGF-ß = transforming growth 
factor-beta; VEGF = vascular endothelial growth factor.
Hypoxia and Joint disease
Joint disease is one of the most important causes of lameness in horse and 
has a major impact on equine athletic performance. In Great Britain, a 
study in 1985 found that the greatest cause of attrition of young 
Thoroughbreds from racing was lameness and among these, joint diseases 
figured prominently (Rossdale et al. 1985). Traumatic joint injury 
represents one of the most common causes of joint diseases of the horse 
and results in osteoarthritis in most severe injuries or following inadequate 
treatment. Osteoarthritis (OA; also called degenerative joint disease) is the 
stage of progressive and permanent loss of articular cartilage. It involves 
all joint structures undergoing morphological alterations while it is 
progressing. Another common joint abnormality in the horse is
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osteochondritis dissecans (OCD), which is categorised as a developmental 
orthopaedic disease. It involves a failure of endochondral ossification 
which is associated with a failure of vascular invasion from the underlying 
subchondral bone, leading to development of dissecting lesion of cartilage 
from the underlying subchondral bone. The abnormal cartilage in horses 
can become detached and they then undergo endochondral ossification at a 
later date (Mcllwraith 2002).
Changes in the synovial membrane due to inflammatory processes at the 
beginning of OA may seriously alter the oxygen transfer from the 
capillaries of the synovium to the synovial fluid, which is subject to 
oxygen fluctuation as a consequence of ischemia-reperfusion, pathologic 
acceleration of tissue metabolism and sustained abnormal strains on the 
joint (Blake et al. 1989). Similarly to pathologic articular changes in OCD, 
lack of blood supply from underlying bone can cause ischemia within the 
cartilage. It has been reported that a considerably reduced oxygen transfer 
across the synovial membrane occurs in the acute stage of experimental 
osteoarthritis (Svalastoga and Gronlund 1985). Another study using in vivo 
measurement has provided evidence that oxygen tensions are decreased in 
the osteoarthritic joint (Kiaer et al. 1988). Two separate studies in rabbit 
and horse also showed significant increases in oxygen consumption in 
acutely osteoarthntic and inflamed joints indicating an increase in oxygen
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demand in pathologic conditions (Svalastoga and Granlund 1985; Hardy et 
al. 1998).
The survival and function of chondrocytes depends on their adaptation to 
surrounding conditions. Degeneration of articular cartilage may directly 
influence the chondrocyte environment (Yudoh et al. 2005), especially 
cellular adaptation to changes in oxygen level, and could directly affect the 
maintenance of articular cartilage matrix. It has been demonstrated that 
HIF-la is expressed in OA cartilage (Coimbra et al. 2004) and this was 
suggested to be a chondrocyte survival factor in this disease (Yudoh et al. 
2005). Failure in adaptation to oxygen alteration by chondrocytes may 
cause a serious metabolic imbalance and lead to deterioration of the 
cartilage matrix.
Hypoxia and chondrogenicity
Articular cartilage lacks the ability to heal itself due to the avascular nature 
of this tissue. Therefore, numerous studies have explored therapies for 
repairing damaged cartilage such as tissue engineering. However, it 
remains a major challenge to create a non-vascularised homogeneous 
cartilaginous tissue in this way. Living in a physiologically-limited oxygen 
environment, chondrocytes may suffer from hyperoxic shock, i.e. damage 
from reactive oxygen species (Henrotin et al. 2005), when they are cultured 
in atmospheric conditions. Factors mimicking the in vivo environment of 
articular chondrocytes such as hypoxia might influence their ability to
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maintain chondrogenic phenotypes. Changes in behaviour of isolated 
chondrocytes at different oxygen tension have been reported. A positive 
effect of hypoxia has been found in equine chondrocyte viability studies 
(Schneider et al. 2004), on bovine articular cartilage matrix mRNA 
expression (Barry and Murphy 2004) and production (Domm et al. 2002) 
and redifferentiation ability in bovine articular cartilage (Domm et al. 
2002) and in human nasal cartilage (Malda et al. 2004 a). However, 
another study in bovine articular cartilage could not identify effect of 
altered oxygen tension in stabilizing chondrogenicity (Saini and Wick 
2004). This controversy results in unclear understanding of the effects of 
oxygen on cartilage matrix synthesis. Moreover, there is no report, to my 
knowledge, concerning hypoxia and its influence in neo-cartilage synthesis 
of equine chondrocytes, which could be useful information for further 
studies of equine cartilage tissue engineering.
Hypotheses
Low oxygen tension (defined here as equal to or less than 5% 0 2) is 
considered to be physiological condition of articular cartilage. Chondrocyte 
metabolism observed in culture under higher oxygen tension 
(approximately 20%) may not reflect cell behaviour in the native tissue. 
Studies of the effects of low oxygen levels on major chondrocyte functions 
may provide information applicable to in vitro culture systems. There is 
evidence to support the adaptation of chondrocytes to various oxygen
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tensions and several studies have reported beneficial effects of low oxygen 
level on chondrocyte survival and chondrogenicity. The hypotheses 
investigated within this thesis are that low oxygen tensions 1 ) would alter 
chondrocyte glucose consumption to maintain cellular energy status 2) 
would antagonise cartilage matrix catabolic processes and 3) favour 
extracellular matrix synthesis by chondrocytes.
Aims of the study
To investigate the above three hypotheses, the studies are divided into three 
main parts in order to cover the major functions of equine chondrocytes in 
cartilage homeostasis using established in vitro techniques. The first aim 
was to investigate changes in basic glucose transportation using monolayer 
equine chondrocytes under hypoxic environments (also an observation of 
glucose transporter expression in pathologic cartilage is included). The 
second aim was to study the effect of hypoxia on cartilage catabolism 
using cytokine-induced equine cartilage explant model. The final aim was 
to investigate the effect of hypoxia on cartilage matrix production using the 
chondrocyte pellet culture model. Also, a preliminary study of hypoxia 
inducible factor and its regulator using equine chondrocytes is reported in 
this study.
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C h a p t e r  II
GENERAL MATERIALS AND METHODS 
General reagents
General chemical reagents were from Sigma-Aldrich Company Ltd. and 
VWR International Ltd. General tissue culture reagents were from 
Invitrogen Ltd.
Cases and controls
All cartilage samples were provided by Prof. Pete Clegg. Samples were 
collected in accordance with institutional guidelines with ethical review 
and written informed consent from the animal owners. Cartilage samples 
from normal equine joint were used in all studies except study of GLUT 1 
mRNA expression in osteoarthritis and osteochondritis dissecans cartilage.
Cartilage samples
1. Normal cartilage
Normal equine articular cartilage was obtained post mortem from two 
sources, a horse abattoir and the Philip Leverhulme Equine Hospital, 
University of Liverpool. The cartilage from Equine Hospital cases was 
biopsied from trochlear ridges and medial femoral condyles of the femur of 
healthy stifle joints of horses aged between 2-25 years old which had been 
euthanased for clinical reasons not related to joint problems. The cartilage
33
samples from the abattoir were collected post-mortem from the 
metacarpophalangeal/tarsophalangeal joints within an hour of euthanasia.
2. Osteochondritis dissecans (OCD) cartilage
Full thickness cartilage biopsies from OCD lesions of the lateral trochlear 
ridge of the femur (LTRF) were harvested from 5 horses (aged 4-7 years) 
during therapeutic arthroscopic debridement of the lesions.
3. Osteoarthritic (OA) cartilage
Full thickness cartilage biopsies were harvested immediately post-mortem 
from the medial femoral condyle of 8 horses (aged 2-9 years) that were 
euthanased as a consequence of lameness due to severe osteoarthritis of the 
medial femorotibial joint. Gross post-mortem indicated the presence of 
osteoarthritis in all cases.
Processing cartilage
Cartilage was transported to the laboratory in Dulbecco’s modified Eagles 
medium (DMEM) with 300unit/ml penicillin G sodium, 300pg/ml 
streptomycin and 7.5pg/ml amphotericin B. Before any processing, 
cartilage was rinsed at least three times with the same media. Where tissue 
was harvested for mRNA isolation, the cartilage was placed in RNAlater™ 
and then transferred on ice to the laboratory for further processing.
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Chondrocyte culture
1. Monolayer cultures
Rinsed cartilage was cut into small pieces and digested overnight with
0.1% type I collagenase (Sigma C-0130; EC 232.582.9 from Clostridium 
histolyticum) in the same rinsing medium at 37°C. The digest was filtered 
through a 40 pm cell strainer and centrifuged at 1400 rpm for 10 minutes. 
The resulting chondrocytes were washed again by resuspension and 
centrifugation before culturing as a monolayer in DMEM with 1 g/1 
glucose, L-Glutamine and pyruvate, supplemented with 10% foetal calf 
serum, 100 unit/ml penicillin G sodium, 100pg/ml streptomycin and 
2.5pg/ml amphotericin B. All subsequent experiments were performed on 
first passage cells unless stated otherwise, in which case they were 2 nd or 
3rd passage. Chondrocytes were not used in any experiment beyond the 
third passage because it has been clearly shown that their phenotype 
changes after multiple passages (Domm et al. 2002; Murphy and Polak 
2004).
2. Encapsulated alginate bead cultures
Low viscosity alginate (Sigma; A-2158) was slowly dissolved in 0.15M
NaCl on a warm plate to 1.2% (w/v) and clarified by centrifugation at 
3000g for 15 minutes. The solution was autoclaved-sterilised before use. 
Prepared chondrocytes were washed in 0.15M NaCl prior to being 
suspended at 30,000 cells per ml of the alginate solution. This cell 
suspension was gently mixed by pipetting and transfer to a sterile
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disposable plastic 5 ml syringe equipped with a 21 gauge needle. The 
suspended chondrocytes were slowly expressed in a dropwise fashion into 
40ml of gently agitated 0.1M CaCl2. The immediately formed alginate gel 
beads were allowed to set at room temperature for 10 minutes on a roller. 
The CaCl2 solution was decanted and the beads were washed three times in 
0.15M NaCl and once in DMEM. The encapsulated chondrocytes were 
cultured in a square petri dish with 25ml of DMEM supplemented with 
10% FCS and antibiotics, as described in monolayer culture medium 
except amphotericin B was omitted because of known interference to HIF- 
la  expression (Pfander et al. 2005). Alginate beads containing cells were 
allowed to equilibrate for at least one week but not more than six weeks 
before starting any experiments. To recover the encapsulated chondrocytes, 
the culture medium was decanted from the alginate beads and the beads 
were washed twice with 0.15M NaCl. Three volumes of a dissolving buffer 
containing 0.1M sodium citrate were added per volume of packed beads. 
The suspension was gently agitated until the beads were completely 
dissolved. The liberated chondrocytes were pelleted by centrifugation at 
1400 rpm for 10 minutes and washed with 0.15M NaCl.
3. Explant cultures
After rinsing, cartilage was cut into small pieces, approximately 2x5x2 mm 
and cultured in 12 well tissue culture plates: each well contained a piece of 
cartilage explant with 0.5ml serum-free DMEM containing 25mM HEPES,
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lOOunit/ml penicillin G sodium, 100pg/ml streptomycin and 2.5|xg/ml 
amphotericin B.
4. Pellet culture
The cell pellet culture method was developed in a 96-well plate system by 
Penick and co-workers (2005) to reduce cost and time to produce 
chondrogenic aggregates which were in the same quality with those 
cultured in original 15ml polypropylene tubes (Penick et al. 2005). For 
freshly isolated chondrocyte pellet cultures, rinsed cartilage was diced into 
small pieces and chondrocytes were isolated using 0.4% pronase (Sigma P- 
5147; EC 232.909.5 from Streptomyces griseus) at 37°C for 30 minutes 
followed by 0.3% type II collagenase (Invitrogen 17101-015 from 
Clostridium histolyticum) at 37°C for up to 2 hours with cell harvesting and 
washing at 30 minute intervals prior to pelleting. For first passage 
chondrocyte pellet cultures, chondrocytes were isolated and cultured in 
monolayers as described previously (see monolayer cultures) until the first 
passage and were trypsinised from tissue culture flasks. Chondrocytes, 
either fresh or dedifferentiated, were rinsed with phosphate buffer saline 
and centrifuged for 10 minutes at 1400 rpm. The supernatant was discarded 
and the cells were resuspended with chondrogenic medium (DMEM F-12 
supplemented with 1% insulin-transferin-selenium-x (ITS; Invitrogen), 
50pg/ml ascorbic acid, 100units/ml penicillin G sodium, 100pg/ml 
streptomycin and 2.5pg/ml amphotericin B). The cells were counted in a 
hemocytometer and the suspension volume was adjusted to give a final cell
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density of 1.25 million cells per ml in the chondrogenic medium (to obtain 
2.5 x 105 cells per pellet). In growth factor treated samples, TGF-P3 was 
added to cell suspensions to a final concentration of lOng/ml. Aliquots of 
200pi were dispensed into the wells of autoclave-sterilised 96-well, V 
Bottom, 300 ul PCR plates (Thermo-fast ® 96; AB 0900, ABgene) using 
large orifice tips to allow smooth delivery. A sterile tissue culture plate lid 
was placed on the plate and temporarily sealed before centrifugation for 5 
minutes at 500g to create the pellets. The seal was removed before the 
pellets were cultured in defined culture environments, e.g. 20% 0 2 or 1% 
0 2. The pellet aggregates were released from the bottom of the wells after 
24 hours of culture by aspiration and releasing lOOul of the medium. The 
medium was changed every other day to avoid acidification. The cultures 
were maintained for periods of up to 14 days.
Culture of other cell types
A human prostate cancer cell line (PC3) and a human chondrosarcoma cell 
lines (C28/I2, a gift from Mary Goldring; Cornell University, USA) were 
selected as positive controls for HIF-la protein expression. The cell lines 
were cultured only in monolayer systems because of their aggressive 
growth. C28 cells were cultured in DMEM supplemented with 10% foetal 
calf serum, lOOunit/ml penicillin G sodium and 100pg/ml streptomycin. 
PC3 cell line was cultured in RPMI-1640 containing the same supplements
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as in DMEM above. The cell lines were subcultured twice a week owing to 
the brief time taken to attain confluence.
Culture under different oxygen conditions
Unless stated otherwise, tissue cultures were prepared and maintained at 
37°C with different gas phase oxygen concentrations, 20% (using CO2 
incubator; Sanyo MCO-17AIC) and 1% 0 2,(using 0 2/C 02 incubator; 
Sanyo MCO-18M), in the present of 5% C 02 with the remaining gas being 
nitrogen.
Laboratory methods
1. Total protein extraction from cell cultures
Confluent monolayer cells (-500,000 cells) were washed twice in
phosphate buffer saline (PBS). All steps were carried out at 0-4°C. Cell 
layer were scraped from flasks in RIPA buffer (PBS with 1% Igepal CA- 
630[Sigma], 0.5% sodium deoxycholate and 0.1% SDS) with freshly 
added 1% (v/v) protease inhibitor cocktail (Sigma P-8340) and transferred 
to a microcentrifuge tube. The suspension was homogenised using a 
syringe fitted with a 21 gauge needle and incubated for 1 hour on ice. The 
cell lysate was separated from sediment by centrifugation at 10,000g for 10 
minutes at 4°C. The supernatant fluid containing cell lysate was collected 
and kept at -80°C until use.
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2. Nuclear extraction
Confluent monolayer cells (-500,000 cells) were washed twice in PBS 
before being resuspended in a low salt buffer containing lOmM HEPES pH 
7.9, lOmM KC1, lOmM EDTA, lmM dithiothreitol (DTT), and 1% (v/v) 
protease inhibitor cocktail (Sigma P-8340) and incubated for 10 minutes on 
ice with gentle shaking. All steps were carried out at 0-4°C. The cellular 
suspension was then transferred to a microcentrifuge tube and centrifuged 
at lOOOOg for 10 minutes at 4°C to separate the soluble cytosolic fraction. 
The pellet was resuspended in a high salt buffer, containing 20mM HEPES 
pH 7.9, 10% glycerol, 400mM NaCl, lmM DTT and 1% (v/v) protease 
inhibitor cocktail (Sigma P-8340). The suspension was homogenized by a 
Dounce homogeniser and incubated for 2 hours with gentle shaking and 
centrifuge at 15,000g for 10 minutes at 4°C. The supernatants containing 
the nuclear extract were collected and stored at -80°C until use.
3. Protein analysis
Protein measurement was performed using the Folin and Ciocalteau’s 
phenol reagent with a method adapted from Lowry et al. (1951). 3% 
Na2CC>3 in 0.2M NaOH and 1% CUSO4.5H2O in 2% Na-K tartrate were 
freshly prepared as solution A and solution B respectively. Two millilitre 
of solution B was added to 48ml solution A to become a working solution. 
Standards were prepared from bovine serum albumin at concentrations 
from 0 to 250pg/ml. Aliquots (200pi) of standards and samples were 
mixed well with the prepared working solution and allowed to stand for 10
40
minutes at room temperature. 50pl of the Folin and Ciocalteau’s phenol 
reagent was then added and mixed. The samples were read after 10 
minutes incubation at room temperature in a spectrophotometer at OD 640.
4. DNA measurement
Double stranded DNA was measured by Quant-iT™ PicoGreen® dsDNA 
reagent (Invitrogen), which is a fluorescent nucleic stain. The assay is able 
to detect DNA in a range of 1-1000 ng/ml. Samples and DNA standards 
were diluted in Tris EDTA buffer and 100 pi of each sample and standard 
were loaded into a black 96-well microplate followed by 100pi of 
PicoGren reagent. The plates were incubated for 5 minutes at room 
temperature before reading on a plate reader with excitation at 480nm and 
emission at 520nm.
5. DMMB assay
Tissue culture media and cartilage or papain digests were assayed for 
sulphated glycosaminoglycan using a modification of the 1,9- 
dimethylmethylene blue dye binding assay (DMMB)(Famdale et al. 1986). 
Chondroitin sulphate C (from shark cartilage) at 0-50pg/ml was used as 
standard. The assays were performed in duplicate using 96 well-plates. 
Samples or standard (40pl) were mixed with 200pl DMMB solution and 
read immediately at 525nm absorbance. The data were analysed by Ascent 
software (Thermo Labsystems).
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6. Hydroxyproline assay
Collagen degradation was determined by measuring released 
hydroxyproline, which is found primarily in collagenous sequences and is 
therefore used as an indicator of collagen content. The assay was adapted 
from the method decribed by Cawston et al. (1999). In brief, oxidant 
solution and colour reagent (Ehrlich’s reagent solution) were freshly 
prepared on each day of assay. Oxidant reagent consisted of 7% (w/v) 
chloramine T diluted 1:6 in assay buffer (57g sodium acetate, 42.74g tri 
sodium citrate, 5.5g citric acid and 400 ml propan-2-ol per litre water). 
Colour reagent was made from dimethylamino benzaldehyde (DAB) 
solution (in proportions of 2g DAB to 3 ml of 60% perchloric acid) diluted 
1:5 in propan-2-ol. Samples were hydrolysed in 6M HC1 at 110°C for 24 
hours and then the hydrolysates were freeze-dried to remove the acid. The 
freeze-dried hydrolysates were reconstituted in distilled water and 
centrifuged at full speed for 10 minutes to separate insoluble material, as it 
interferes with the assay. Serial dilutions (l-10pg/ml) of hydroxyproline 
(Sigma) were used as standards. The assay was performed in 96 well-plates 
in duplicates. Both standards and samples (30pl) were mixed with 70pl 
diluent (1:3 diluted propan-2-ol in water), following by adding 50pl of 
oxidant reagent and 125 pi of colour reagent. Plates were incubated at 70°C 
for 20 minutes and left to cool to room temperature before reading at 
550nm absorbance. The data were analysed by Ascent software (Thermo 
Labsy stems).
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7. Sodium dodecyl sulphate polyacrylamide gel electrophoresis 
(SDS-PAGE)
Polyacrylamide gels were prepared according to the method of Laemmli 
(1970) on the Biorad mini-gel apparatus. Unless stated otherwise, 7% 
acrylamide resolving gels were used in most experiments. Samples were 
diluted in sample buffer (with addition of 5mg/ml DTT or ß- 
mercaptoethanol at 1:20 dilution in reduced samples) and boiled for 4 
minutes prior to electrophoresis. Gels were run within running buffer at 
200V for approximately 45 minutes. The resolved proteins were either 
transferred for western blotting or stained with 0.2% Coomassie brilliant 
blue. The reagents that were used are shown in Table 2.1.
Table 2.1 SDS-PAGE and staining reagents
Reagent Amount Reagent Amount
Resolving gel (7% acrylamide for 2 gels) Stacking gel (4% acrylamide for 2 gels)
30% acrylamide 3.11 ml 30% acrylamide 0.523 ml
1M Tris HCIpH 8.8 5 ml 1M Tris HQ pH 6.8 0.41 ml
10% SDS 0.133 ml 1% SDS 0.33 ml
HjO 4.64 ml H20 1.878 ml
1.5% APS 0.433 ml 1.5% APS 0.167 ml
TEMED 17 pi TEMED 7 Ml
Sample buffer(1X) Running buffer (500 ml; 10X)
1M Tris HCIpH 6.8 4 ml Tris 15g
20% (wAr) SDS 7.5 ml Glycine 72 g
Glycerol 5 ml SDS 5 g
Bromophenol blue 300 pi Coomassie stain (0.2%)
HjO 3.2 ml Brilliant blue 1g
Destain Methanol 150 ml
Methanol 150 ml Glacial acetic acid 50 ml
Glacial acetic add 35 ml H20 300 ml
h 2o 315 ml
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8. Western Blots
Proteins resolved by SDS-PAGE were electrotransferred (BioRad minoblot 
apparatus) to polyvinylidene fluoride (PVDF) membrane using buffer 
containing 250mM tris and 200mM glycine at 150 V for 1 hour. The 
blotted membranes were blocked by 5% skimmed milk in PBS with 0.5% 
Tween-20 (PBST) for 1 hour on a rocking platform. After being washed in 
PBST, the blots were probed by primary antibody diluted in PBST for 1 
hour and then washed at least three times (10 minutes each) before 
applying secondary antibody and incubated for another 1 hour. The 
dilutions of primary and secondary antibodies and their substrates are 
shown in Table 2.2. For chemiluminescence, the blots were developed by 
enhanced chemiluminescent reagents (PIERCE) for 5 minutes before 
exposing to the x-ray films.
Table 2.2 Antibodies and substates used in Western blots
P rim a ry  a n tib o d y D ilu tio n S e c o n d a r y
a n tib o d y
D ilu tio n S u b s tra te
H IF -1  a  polyclonal antibody 
(S a nta  C ru z )
1 :20 0 A nti-rab bit IgG  
conjugated  with 
H R P '
1 :50,000 C h e m ilum in escen t 
reagents (P IE R C E )
H IF -1 a  m onoclonal
antibody
(B D  transduction)
1:250 A n ti-m o u s e  IgG  
conjugated  w ith 
H R P '
1 :10 ,0 00 C h e m ilum in escen t 
reagents (P IE R C E )
T y p e  II collagen 
(A V T 6 E 3 )"
1 :10 A n ti-m o u s e  IgG  
conjugated  with 
alkaline 
phophatase
1 :5 ,0 0 0 S IG M A  F A S T ™  
B C IP / N B T " "
G L U T -1 " ' 1 :2 ,0 0 0 A nti-rab bit IgG  
conjugated  w ith 
alkaline 
phophatase
1:5,000 S IG M A  F A S T ™  
B C I P / N B T "
* Horse radish peroxidase
Antibody was donated from Dr Anne VaugharvThomas (University of Liverpool, United Kingdom) 
*** Antibody was donated from Dr S A  Baldwin (University of Leeds, United Kingdom)
**** 5-Bromo-4-ch!oro-3-indoly! phosphate/Nitro blue tetrazoOum
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9. RNA extraction and Bioanalysing
Total RNA was extracted from samples using TRIzol® Reagent
(Invitrogen). Cells in monolayer were scraped with 1 ml TRIzol® per 
75 cm flask and transferred to a microcentrifuge tube. Cartilage expiants 
were snap frozen and pulverised in liquid nitrogen cooled steel chambers 
(Braun Biotech Mikrodismembrator) and suspended in 1 ml TRIzol®. 
Chondrocyte pellet cultures were homogenised with 1 ml TRIzol® by using 
Molecular Grinding Resin and a small pestle (Web Scientific: 786-138PR). 
RNA was separated from TRIzol® by vigorous agitation with chloroform 
(2001/1 ml TRIzol®) and centrifugation at 12,000g for 10 minutes at 4°C. 
Clear supernatant was mixed with isopropyl alcohol and centrifuged at 
12,000g at 4°C to precipitate RNA. RNA pellets were washed in 75% 
ethanol and left until almost dry and then redissolved with RNase-free 
water. RNA samples were purified through RNeasy columns with DNasel 
(Qiagen), according to the manufacturers’ instructions to remove genomic 
DNA and finally eluted in water. RNA quantification and qualification 
were measured by Agilent 2100 Bioanalyzer (Agilent Technologies) 
according to the manufacturers’ instructions.
10. cDNA synthesis
cDNA copies were made from l-13pg RNA with RIN (RNA integrity 
number) 6 or above, except in the reference gene selection study in which a 
fixed amount of 1.5pg RNA was used. In each sample, 2pl Mastermix I 
[1:1 mixture of 500pg/ml oligo (dT) primer (Promega) and lOmM dNTPs
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(Invitrogen)] was added into 20pl RNA solution. RNA mixtures were 
incubated at 65°C for 5 minutes before 7jli1 of Mastermix II [4pl of 5x First 
strand buffer, 2pl of 0.1M DTT; both supplied by Invitrogen, and 1 jllI of 
RNasin (Promega)] was added in to each sample. The mixtures were 
incubated at 42°C for 2 minutes prior to adding lp l Superscript II 
(Invitrogen) and incubated at the same temperature for 50 minutes. The 
reaction was stopped by incubation at 70°C for 15 minutes. The 
synthesized cDNA samples were kept at -20°C until use.
11. Primer design and validation
Equine RNA and DNA sequences were sourced from the NCBI database 
(http.//www.ncbi.nlm.nih.gov/). If the equine sequence was unavailable 
then a multiple species alignment was carried out 
(www.ebi.ac.uk/Tools/clustalw/) and primers designed where there was 
sequence homology. Human exon boundaries were identified using the 
Ensembl Genome Browser (http://www.ensembl.org/index.htmlV and 
where possible, primers were designed to cross predicted exon boundaries. 
The primers were designed based on the above sequences using Primer 
Express (Applied Biosystems) software or Roche primer design 
(https://www.roche-applied-science.eom/l or Primer3 software 
(http://primer3.sourceforge.net/). Primer efficiencies were validated 
using a standard curve derived from equine tendon cDNA (a ten fold 
dilution series with five measuring points).
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12. Real-time (quantitative) polymerase chain reaction (qPCR)
PCR reactions were performed in 386-well PCR plates (Applied
Biosystems). In each well, 4.6pl cDNA was mixed with 0.1 pi water 
(molecular biology grade), 0.3pi of 300 nM forward and reverse primers 
mixture and 5 pi SYBR® Green PCR master mix. The plates were securely 
sealed with Optical adhesive covers (Applied Biosystems) and processed 
in a 7900HT Fast Real time PCR system (Applied Biosystems) using 
standard amplification conditions. The initial dénaturation was performed 
at 95°C for 10 minutes. Forty cycles of amplification were performed. 
Each cycle involved a dénaturation step of 15 seconds at 95 °C and 
followed by 60 seconds primer annealing at 60°C. After the last cycle, a 
dissociation curve was performed at 95°C for 15 seconds and 60°C for 15 
seconds in order to ensure one product of amplification. Each reaction was 
run in triplicate. PCR products were measured and analysed by SDS 
software (v 2.2.1. Applied Biosystems) and then normalized to previously- 
selected reference genes (see Chapter IV).
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C h a p t e r  I I I
GLUCOSE TRANSPORTATION IN CHONDROCYTES UNDER 
HYPOXIA
This work has been accepted for publication in the Journal of 
Orthopedic Research (see Appendix)
Introduction
Articular cartilage is an avascular tissue. Nutrients and oxygen are 
delivered by diffusion from blood vessels of the underlying bone and from 
the synovial fluid (Lee and Urban 1997). The oxygenation gradients within 
the tissue have been estimated to be 6-10% at the articular surface to less 
than 1% 0 2 at the deepest layer (Falchuk et al. 1970; Lund-Olesen 1970; 
Treuhaft and McCarty 1971; Silver 1975; Kiaer et al. 1988; Ferrell and 
Najafipour 1992). However, chondrocytes appear to adapt very well to 
oxygen and nutrient limited environments (Rajpurohit et al. 1996). Both 
anabolic activity and cell survival of chondrocytes were maximized when 
they are cultured in vitro under low oxygen tensions compared to normoxic 
and anoxic conditions (Grimshaw and Mason 2000; Hansen et al. 2001; 
Domm et al. 2002; Schneider et al. 2004).
The main source of metabolic energy in chondrocytes is glucose which is 
taken up by a family of substrate specific membrane proteins known as 
glucose transporters (GLUTs). GLUT isoforms differ in their substrate
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specificity, tissue distribution and cellular localisation. Articular 
chondrocytes and intervertebral disc cells express a number of glucose 
transporter proteins including GLUT1, GLUT3 and GLUT9 (Mobasheri et 
al. 2002 b). GLUT1 and GLUT3 are hypoxia responsive isoforms 
(Semenza 2001 b) which are regulated by the transcription factor and 
oxygen sensor protein, hypoxia-inducible factor 1 (HIF-l)(Mobasheri et al. 
2005 a; Richardson et al. 2008).
Chondrocytes generate energy mainly by anaerobic glycolysis (Lee and 
Urban 1997), which produces 18-19 times less ATP per molecule of 
glucose than aerobic respiration (Ahlqvist 1984). Therefore, chondrocytes 
must be able to manage glucose transport and metabolism effectively to 
provide sufficient energy within the constraints of what is available in 
cartilage. Recent studies (Mobasheri et al. 2006), (Zhang et al. 1999) have 
shown that chondrocytes are capable of maintaining their metabolic 
balance when deprived of glucose or exposed to the hypoxia mimetic 
cobalt chloride (C0CI2). C0CI2 induces hypoxic conditions by inhibiting 
iron-dependent HIF-prolyl hydroxylases (Dery et al. 2005) so that the 
ubiquination and proteosome degradation of HIF-la are blocked.
Osteoarthritis (OA) leads to progressive and permanent loss of articular 
cartilage. Joint injury, the major cause of OA in the horse (Mcllwraith 
2002), leads to synovial effusion and increasing vascularisation in response 
to inflammation and healing processes and this may disturb or alter the
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oxygen supply within the synovial environment (Blake et al. 1989). 
Osteochondritis dissecans (OCD) is categorised as a developmental 
orthopaedic disease, involving a failure of endochondral ossification which 
is associated with a failure of vascular invasion from the subchondral bone 
and leads to development of cartilage lesions that can become detached at a 
later date (Mcllwraith 2002). The ischemia-reperfusion from the neo- 
vascularisation process in traumatic joints before OA development (Blake 
et al. 1989) and the ischemic necrosis of the subchondral bone during OCD 
formation may cause fluctuations in oxygen levels and result in metabolic 
imbalance by disturbing glucose transport.
The aim of this study was to test the hypothesis that chondrocytes are able 
to adapt their energy metabolism under hypoxia, using low oxygen (1% 
0 2) or exposure to a hypoxia mimetic (cobalt chloride). We also 
investigated whether expression of a key hypoxia responsive glucose 
transporter (GLUT1) varied in normal cartilage compared to degenerative 
cartilage, such as found in osteoarthritis (OA) and osteochondritis 
dissecans (OCD).
Materials and Methods 
Reagents
All tissue culture reagents were from Invitrogen. 2-Deoxy-D-[2,6-3H] 
glucose and NACS104 aqueous scintillation cocktail were from Amersham 
Biosciences. Polyclonal antibodies against GLUT1 were donated by Dr
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S.A. Baldwin (University of Leeds, UK). The GLUT1 antiserum was 
developed in rabbits against the C-terminus of rat-GLUTl (residues 477- 
492). We have previously confirmed that this GLUT1 antibody recognizes 
GLUT1 across a diverse number of mammalian species including rat, 
human, dog, sheep and horse (Mobasheri et al. 2005 b). Anti-rabbit IgG 
conjugated with FITC was obtained from Sigma.
Cartilage source
Normal equine articular cartilage was obtained from horses aged between 
2-12 years old, euthanased for clinical reasons at the Philip Leverhulme 
Equine Hospital, University of Liverpool. Normal, OA and OCD cartilage 
expiants were also collected and processed for mRNA isolation.
Chondrocyte isolation and culture
Cartilage for chondrocyte cultures was obtained from healthy horse joints 
only. Each sample was rinsed and chondrocytes were isolated to culture in 
monolayers (see Chapter II). All experiments were performed on first 
passage cells.
Chondrocyte proliferation and viability
Equine chondrocytes were expanded in monolayer and subcultured to 
passage one in 25cm2 tissue culture flasks. The cultures were divided for 
two experiments. A set of cultures was cultured either under 1% or 20% 0 2 
from the first day. Chondrocytes were washed with PBS and trypsinised 
before they were counted. Each culture was counted daily for seven days 
using a haemocytometer. Another set of chondrocyte monolayers was
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maintained under 20% O2 until nearly confluent and then treated with 1% 
O2 or 20% O2 with or without 75 pM C0CI2 for 48 hours. The viability and 
numbers of chondrocytes was assessed using trypan blue dye exclusion and 
counted in a haemocytometer. The study was performed in triplicate using 
three different donors.
Deoxy-D-[2,6-3H] glucose uptake
Net glucose transport was determined by measuring the uptake of non- 
metabolisable deoxy-D-[2,6-3H] glucose into equine chondrocytes in 24- 
well plates in the presence and absence of the glucose transport inhibitor, 
cytochalasin B (20pM). Monolayer chondrocyte cultures were 
preconditioned in 20% or 1% O2 with and without 75pM C0CI2 for 48 
hours and rinsed with PBS three times. The uptake of deoxy-D-[2,6-3H] 
glucose (0.5 (iCi/ml culture medium) was assayed for 2 hours at 37°C in 
modified DMEM lacking glucose, pyruvate and serum. The 24-well plates 
were washed three times with ice-cold PBS and the chondrocytes lysed 
with a cell lysis solution consisting of 0.5 % (v/v) SDS and 0.5 % (v/v) 
Nonidet in PBS. Aliquots (45 0(_tl) of the cell lysis solution were mixed with 
3.55ml of aqueous scintillation cocktail (NACS104; Amersham 
Biosciences) and counted in a scintillation counter (Packard). The 
remaining 50pl aliquots of the cell lysis solution were used to determine 
total cell protein content using the Lowry protein assay (Lowry et al. 1951) 
and 2-deoxyglucose uptake was normalized to total cell protein. All uptake 
experiments were carried out in triplicate and repeated under identical
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conditions (at least three times) and the data are presented as percentage 
change in total deoxy-D-[2,6-3H] glucose uptake.
GLUT-1 Western blot
A whole cell lysate, extracted from first passage equine chondrocytes using 
RIPA buffer, was run on SDS-PAGE using 10% acrylamide and 
transferred to a PVDF membrane. The membrane was probed with GLUT 1 
antibody for 2 hours and with alkaline phosphatase conjugated anti-rabbit 
IgG for 1 hour at room temperature. SIGMA FAST™ BCIP/NBT was used 
as the substrate. A secondary antibody control was also performed.
Fluorescence activated cell sorting (FACS) analysis of GLUT1 
expression
Nearly confluent first passage monolayer equine chondrocytes were 
maintained in 25 cm2 tissue culture flasks under 20% 0 2 or 1% 0 2 for 48 
hours. After being trypsinised, the isolated cells were transferred to 1.5 ml 
Eppendorf tubes and washed using PBS containing 1% FCS followed by 
centrifugation at 1400 rpm for 5 minutes. Chondrocytes were fixed with 
3.7% paraformaldehyde for 10 minutes at ambient temperature and 
permeabilised with 0.05% Triton X 100 in PBS for 10 minutes at 4°C. The 
cells were incubated with anti-GLUT-1 polyclonal antibody at the dilution 
of 1:600 in PBS, followed by goat anti-rabbit IgG conjugated with FITC at 
1:40 in PBS, each for 30 minutes at 37°C in light protective containers. 
Between each step the washing was performed as described above. The 
final washing and resuspension were done using PBS before transferring to
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5 ml (12 x 75 mm) polystyrene round-bottom tubes (Becton Dickinson) 
and analysis by FACScan (Becton Dickinson) by gating 10,000 events. 
The morphological profile of the cells was detected by combining forward 
light scatter (FSC) and side light scatter (SSC). The detectors were set as 
follows: FCS (threshold): 200; FSC: E-01; SSC: 319 and FLI: 408 and the 
parameters were: FSC-H: 5.0; SSC-H: 1.2 and FL-1 H: log. The 
autofluorescence, expressed from unstained chondrocytes and the non­
specific staining from secondary antibody were subtracted in each 
experiment (Fig 3.1). The data were analysed by WinMDI 2.8 (free 
downloadable software; http://facs.scripps.edu/software.html) to obtain the 
number of cells expressing fluorescence and mean fluorescent intensity 
(MFI) in each sample.
Fig 3.1 FACS Density plots and histograms generated by WINMDI 2.8 software. 
The top panel shows density plot of 10,000 chondrocytes and gated regions. The 
bottom panel shows fluorescence events of gated areas. The areas cleared from 
interference of auto-fluorescence and secondary antibody are marked (Ml).
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RNA and cDNA preparation and real-time PCR to detect changes in 
the levels of GLUT1 expression
Total RNA was extracted from chondrocyte monolayers and cartilage 
explants from normal, OA and OCD horses using the method described in 
Chapter II. The mRNA expression of GLUT-1 was assessed in monolayer 
cultures (n = 3) of equine chondrocytes exposed to 20% O2 or 1% O2 with 
and without 75 pM C0CI2 for 24 hours and the cartilage explants from 
normal (n = 6), OA (n = 8) and OCD (n = 5) horses. The qPCR was 
performed with the following primers designed by Primer3: forward 
primer; 5-AGCAGCCTGTGTACGCCAC-3' and reverse primer; 5'- 
CTCGTTCCACCACAAACAGC-3'. PCR products were measured and 
normalized by the selected reference genes.
Reference gene selection
The candidate reference genes and their primers are shown in Table 3.1. 
They were selected on the basis that they belong to different functional 
classes. Some of the primer sequences were from a reference gene study 
using equine skin (Bogaert et al. 2006). The rest of the candidate reference 
gene primers using in this study were self designed using the same method 
as in primer design and validation (seeChapter II). Expression of all seven 
candidate reference genes were analysed across the chondrocyte monolayer 
cultures («=5) exposed to 20% 0 2 or 1% 0 2 with and without 75 pM CoCl2 
or 100 ng/ml IL-ip for 24 hours. Another analysis was done across normal 
(n = 6), OA (n = 8) and OCD (n = 5) cartilage to investigate the expression
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of five candidate reference genes (HPRT-1, TBP, GAPDH1, GNB2L1 and 
18S). The most stable pair of genes was identified using downloadable 
software; GeNorm (http://medgen.ugent.be/~ivdesomp/genorm/) and 
Normfinder (http://www.mdl.dk/publicationsnormfinder.htm).
according to the software instructions.
Table 3.1 Candidate reference gene list
Symbol done name Accession
Code
primers 5'-3’ Efficiency 
on equine 
tendon
References
GAPOH (1) Gtyceraldehyde-3- 
phosphate dehydrogenase
AF157626 Fw: GCATCGTGGAGGGACTCA 
Rv: GCCACATCTTCCCAGAGG
-3.317 Roche
GAPDH/2) Glyeera!dehyde-3- 
phosphate dehydrogenase
AF157626 Fw: TGACCCCCTAACATATTGAGAGTCT 
RV: GCCCCTCCCCTTCTTCTG
-3.139 Primer Express
ACTB Actin, beta AF035774 Fw: CCAGCACGATGAAGATCAAG 
Rv: GTGGACAATGAGGCCAGAAT
-3.333 Bogaett et al, 
2006
TBP TATA box binding protein NM.001075742 Fw: TGCTGCTGTAATCATGAGGGTAA 
Rv: TCCCGTGCACACCATTTTC
-3.54 Primer Express
HPRT-1 Hypoxanthine
phosphoribosyttransferase l
AY372182 Fw: GGCAAAACAATGCAAACCTT 
Rv: CAAGGGCATATCCTACGACAA
-3.35 Bogaert et al. 
2006
1ÔS Ribosomal protein. 10$ AJ311673 Fw: GGCGTCCCCCAACTTCTTA 
Rv: GGGCATCACAGACCTGTTATTG
-3.241 Primer Express
GNB2L1 Guanine nucleotide binding 
protein
NM_006098 Fw: CCTTGTGCTTCAGTCCCAAT 
Rv: CAATGATCTTGCCCTTCAAGT
-3.241 Roche
Statistical analysis
Paired /-test and one way ANOVA with Dunnett’s multiple comparison 
test was performed by GraphPad Prism software (v.4.01). Paired /-test was 
used to compare chondrocyte proliferation under normoxia and hypoxia. 
One way ANOVA was used for other analyses.
Results
Chondrocyte proliferation and viability
Chondrocyte monolayer cultures maintained under normoxia (20% O2) and 
hypoxia (1% O2) showed similar cell numbers in the first three days of 
culture. After day 4, there was net growth of cells and the increase of
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chondrocytes numbers in normoxia was more than in hypoxia but it was 
not significantly (£>>0.05) increased (Fig 3.2a). Chondrocytes survived very 
well after treatments with different oxygen tensions and C0CI2. The 
viabilities were almost 100% of the total chondrocytes in every treatment 
(Fig 3.2b).
(a) (b)
-m- 20%O2
Fig 3.2 Numbers and viability of equine chondrocytes under hypoxia and 
normoxia. (a) Numbers of chondrocytes at the first passage from day 0 to day 7 
under 20% and 1% O2 (b) Chondrocytes viability after being cultured under 
normoxic and hypoxic conditions with or without 75 pM CoCl2. Data represents in 
percentage of total chondrocytes. The error bars represent SEM.
Deoxy-D-[2,6-3H] glucose uptake
To determine potential alterations in glucose transport across equine 
chondrocyte membranes in response to differential oxygen levels, the 
effects of normoxia (20% O2), hypoxia (1% O2) and a hypoxic mimetic 
(75pM C0CI2) were analysed on the uptake of deoxy-D-[2,6-3H] glucose in 
normal equine articular chondrocytes. The average uptake by the control 
group (20% O2) was set as 100%. Both hypoxia and C0CI2 significantly 
increased glucose transport in equine chondrocyte cultures (Fig 3.3) 
(p<0.05). Moreover, the combination of hypoxia and C0CI2 had an additive 
effect on glucose uptake comparing to hypoxia or C0CI2 alone (Fig 3.3)
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(p<0.01). Cytochalasin B was effective in inhibiting deoxy-D-[2,6-3H] 
glucose uptake (p<0.01).
0.00
0.05 I
o.io ^
0.15 3
0.20 3
■o
0.25 3
0.30
(Û
O
o
Fig 33  Effect of hypoxia (1% 0 2), cobalt chloride (75pM) and the combined 
treatment on 2-deoxy-D-[2,6-3H] glucose uptake by first passage equine articular 
chondrocyte monolayer (n=3). Results represent percentage glucose uptake by 
comparison to the control group (20% 0 2) (Average uptake in the control group 
was taken as 100%, which is approximately 0.123pmol/min/mg protein). The 
error bars represent SEM.* p<0.05; ** p<0.01.
GLUT1 western blot
The expression of GLUT1 protein by equine chondrocytes was 
demonstrated by Western blotting using rabbit anti-GLUT 1 antibody. Two 
immunoreactive bands were detected at around 45-50 kDa (Fig 3.4). The 
difference of the two GLUT1 appeared on the blot was probably due to 
glycosylation (Bimbaum et al. 1986; Kasaniki et al. 1987). A secondary 
antibody control blot showed no non-specific reaction of the anti-rabbit 
IgG antibody.
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Fig 3.4 Immunoblot of GLUT1 (arrows) from a whole-cell lysate of first passage 
equine chondrocytes. The blot is shown in parallel with a Coomassie stained gel 
and a secondary antibody only (no primary antibody used) control blot run with 
the same sample.
Fluorescent activated cell sorting (FACS) analysis
Examples of FACS density plots and histograms of each treatment are
shown in Fig 3.5. The analysis indicated that approximately 90% of all 
groups of chondrocytes expressed GLUT1 membrane protein (Table 3.2); 
however, statistical analysis revealed no difference in the number of 
chondrocytes that bound the GLUT 1 antibody among all different oxygen 
tension and CoCl2 treatments. Further analysis showed that the intensity of 
GLUT1 expression in chondrocytes exposed to 1% 0 2, CoCl2 and the 
combination of those 2 treatments was significantly increased (Fig 
3.6)(p<0.05) indicating that in response to hypoxic treatment, cells had 
increased numbers of GLUT1.
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Control (20% O ,) 1 * 0 , C oCI, 1% 0,+CoCI,
Fig 3.5 Examples of FACS density plots and histograms in each chondrocyte 
treatment (Ml = marker of area after subtraction of possible non-specific 
fluorescence of secondary antibody and chondrocyte auto-fluorescence).
Table 3.2 Mean ± standard error of number of chondrocytes that expressed 
GLUT1 (from 10,000 gated cells)
T re a tm e n t M e a n  ± S E
Control 8 9 9 7 .3 3 ±  4 1 5 .5
H ypoxia  (1 %  0 2) 9 3 0 0 .7 8  ± 4 4 5 .1
7 5  pM  C o C I2 9 4 2 7 .8 9  ±  2 4 6 .8 2
Hypoxia  +  C o C I, 9 4 1 9 .2 2 ±  2 8 5 .5 0
1200-1
1100-
1000-
C o n t r o l  1 % 0 2 C o C l j  1 0/<O2+ C o C I 2
Fig 3.6 Changes in equine chondrocytes GLUT1 protein expression assessed by 
FACS analysis using first passage equine chondrocytes in monolayer after 
exposure of to hypoxia (1% 0 2), cobalt chloride (75pM) and the combined 
treatment for 48 hours. The results indicate mean fluorescent intensity (MFI) per 
chondrocyte. The experiment was done with 3 different chondrocyte donors. The 
error bars represent SEM.* p<0.05.
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Reference gene selection for qPCR analysis
The real-time PCR assays were designed to detect and quantify expression 
of commonly used reference genes (Table 3.1). The stability of gene 
expression across different samples was analysed using GeNorm and 
Normfinder software. The stability values and the ranking of the candidate 
genes from both forms of analysis in the study with chondrocyte cultures 
and a study of normal versus diseased cartilage study are shown in Table 
3.3. Although the ranking of the candidate genes was somewhat different 
between the two programs, HPRT-1 and TBP were identified, in both 
studies and both analyses, to be the most stably expressed pair of genes and 
were selected for use as the reference genes for the rest of this study. 
Normfinder also indicated GAPDH(l) as the best single reference gene in 
the normal-disease cartilage tissue study.
Table 3.3 Stability value and ranking of candidate reference gene expression
Nonnfinder GeNorm Stability
Experiment Gene Stability value Rank Gene Value Rank
HPRT-1* 0.195 1 HPRT-1 0244047225 1
TBP* 0.204 2 TBP 0244047225 2
Eqtine chondrocyte GNB2L1 0244 3 G A P D H (I) 0547GS329 3
18S 0.283 4 GAP0H(2) 0.560551071 4
G A P O H (I) 0336 5 GNB2L1 0602052909 5
GAPDH(2) 0378 6 18S 0650220526 6
ACTB 0451 7 ACTB 0712836738 7
G A P D H (I) 0048 1 HPRT-1 0.643906 1
Norme! and HPRT-1* 0055 2 TBP 0.643906 2
TBP* 0058 3 G A P D H (I) 0.728417 3
explants GNB2L1 0.117 4 GNB2L1 0.890601 4
188 0.141 5 IBS 1248013 5
*The best oombinafion of two genes by Nonrfinder
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GLUT1 mRNA expression
The relative expression of GLUT1 mRNA was quantified by real-time 
PCR assay using SYBR® Green. The Ct values of all samples were 
normalised with the mean Ct values of the selected reference genes, which 
were HPRT-1 and TBP. There was an up-regulation of GLUT1 expression 
in chondrocytes exposed to 1% O2 and 75 pM C0CI2: however; only a 
combination of both treatments showed a statistically significant increase 
(p<0.05) (Fig 3.7a).
In contrast, examination of GLUT 1 mRNA expression in cartilage tissue 
identified that in OA cartilage its abundance was significantly decreased 
(Fig 3.7b)(p<0.01) compared to normal cartilage. In OCD samples, 
expression of GLUT 1 was also decreased but this reduction did not reach 
statistical significance. In summary, this data indicated some suppression 
in transcription of GLUT 1 in pathological cartilage.
Fig 3.7 GLUT1 mRNA expression (a) study of first passage equine chondrocyte 
monolayers after exposure to normoxia (20% 0 2), hypoxia (1% 0 2), and/or 75 pM 
cobalt chloride for 24 hours using 5 different donors and (b) study in normal («=  
6), osteoarthritis (OA) («=8) and osteochondritis dissecans (OCD) (n= 5) cartilage 
explants. The analysis was done in triplicate. The error bars represent SEM.* 
p<0.05; ** p<0.01.
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Discussion
In this study of chondrocyte physiology we observed that equine 
chondrocytes survived very well under hypoxia in the presence of a 
hypoxia mimic environment confirming a result from previous report 
which showed chondrocyte viability under hypoxia for up to 11 days 
(Schneider et al. 2004). An enhanced transportation of glucose by equine 
chondrocytes in a low oxygen environment is supportive of previous 
studies in equine chondrocytes using CoCl2 (Mobasheri et al. 2006). This 
may suggest either an attempt to maintain the basal cellular energy status 
or increasing metabolic demand of the chondrocytes in response to hypoxic 
conditions. However, Schneider and colleaques (2004) demonstrated that 
ATP content of equine chondrocytes is stable under various oxygen 
concentrations. Therefore, it is unlikely that chondrocytes increase their 
energy demand under hypoxia.
The inhibition of glucose uptake by cytochalasin B indicates that the 
glucose uptake is mediated by sodium-independent glucose transporters 
(McNulty et al. 2005). Glucose transporter 1 (GLUT1) is known to be the 
most abundant GLUT expressed by most cell types, including 
chondrocytes and is considered to function as a ‘house keeping’ glucose 
transporter. In this role, GLUT1 maintains basal glucose uptake for 
metabolic reactions (Mobasheri et al. 2002 a). GLUT1 is also reported to 
be a ‘hypoxia-responsive’ glucose transporter in various tissues (Vannucci 
et al. 1996; Behrooz and Ismail-Beigi 1997; Zhang et al. 1999), especially
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in cancer cells which collectively exhibit the Warburg effect (reviewed by 
Airley and Mobasheri 2007). This observation was confirmed by our 
investigation of chondrocyte GLUT1 protein expression. We found that 
although most of the chondrocytes examined expressed some GLUT1 
protein, the physical (1% O2) and chemical (C0CI2) hypoxia signals 
significantly increased the amount of GLUT1 that is expressed on each 
chondrocyte.
However, the glucose uptake results were not fully concordant with the 
GLUT1 protein expression data, especially in chondrocytes exposed to a 
combination of hypoxia and C0CI2. While glucose uptake showed an 
additive effect of the combined hypoxia treatment, GLUT1 expression was 
at the same level as individual 1% O2 and C0CI2 treatments, suggesting the 
involvement of other glucose transporters. There is a strong possibility that 
other glucose transporters such as GLUT3 and GLUT9 are also involved in 
this response and are regulated by hypoxia as their expression has been 
confirmed in human chondrocytes (Shikhman et al. 2001; Mobasheri et al. 
2002 b). GLUT3 is known to be the high affinity glucose transporter 
(Mobasheri et al. 2002 b) and could have a role in regulating glucose 
transport under such stimuli where chondrocytes have a very high 
metabolic demand to maintain their function. Furthermore, GLUT3 has 
been found to be upregulated in a number of hypoxic tumours along with 
GLUT 1 (reviewed by Airley and Mobasheri 2007).
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We also investigated the gene expression of GLUT1, in response to low 
oxygen tension and the presence of cobalt chloride, using quantitative, real­
time PCR. While GLUT1 protein expression was significantly higher in 
hypoxic conditions, GLUT1 mRNA expression whilst elevated, did not 
reach statistical significance. The smaller response in GLUT1 mRNA 
expression to hypoxia or C0CI2 stimulation suggested that increasing the 
expression of GLUT1 gene may not be the main mechanism used by 
chondrocytes to regulate glucose metabolism under low oxygen 
environment; other mechanisms may be involved including post- 
translational regulation (i.e. recruitment and activation of pre-existing 
GLUT1 transporters). Zhang and colleagues (Zhang et al. 1999) have 
reported that the acute response to hypoxia is mainly mediated by 
enhanced function of the existing glucose transporters, especially GLUT1, 
while the regulation at transcriptional level of GLUT 1 is found to increase 
in chronic hypoxia. However, our data did identify that the combination of 
hypoxia and CoCl2 treatment caused a reproducible and significant 
increase in GLUT1 mRNA levels, indicating transcription of GLUT1 can 
be significantly increased acutely, dependent on the relevant stimuli.
In the second part of our study, we focused on the transcription of the 
GLUT1 gene in equine joint diseases. We compared GLUT1 expression in 
normal cartilage and cartilage derived from joints with either OA or OCD. 
Interestingly, our findings indicated decreased GLUT1 transcription in OA
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and OCD specimens with a greater reduction and statistical significance in 
the OA samples, suggesting compromised glucose metabolism especially 
in OA chondrocytes. The observed reduction of GLUT1 transcription may 
be a consequence of fluctuations in oxygenation caused by systemic effects 
or disturbances in the vascular supply during pathological processes (Blake 
et al. 1989). However, HIF-1, the key protein linking oxygen tension and 
GLUT1 expression in equine chondrocytes has not yet been investigated in 
this species. Although there is evidence of increased HIF-1 a and GLUT1 
protein levels in human OA cartilage, possibly in order to compensate for 
the increase in ATP demand (Pfander et al. 2005), we identified 
downregulation of equine GLUT1 mRNA in equine OA cartilage 
suggesting failure to maintain an energy supply in equine degenerative 
cartilage.
Conclusion
Hypoxia and the osteoarthritic process have significant effects on glucose 
transport and metabolism in chondrocytes. Hypoxia increases the rate of 
glucose uptake and regulation of GLUT1 transporters whilst OA and OCD 
lead to a reduction in transcription of GLUT1 mRNA. These data may 
indicate a failure of chondrocytes in OA cartilage to maintain metabolic 
and structural glucose levels in joint disease.
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C h a p t e r  I V
EQUINE CARTILAGE DEGRADATION AND CHONDROCYTE 
CATABOLISM UNDER HYPOXIA
Introduction
Articular cartilage in the adult is an anatomically avascular tissue deriving 
oxygen by diffusion from synovial fluid and the subchondral bone (Lee 
and Urban 1997). The oxygenation gradient as low as 1% exists within 
healthy articular cartilage (Falchuk et al. 1970; Lund-Olesen 1970; 
Treuhaft and McCarty 1971; Silver 1975; Kiaer et al. 1988; Ferrell and 
Najafipour 1992); hence, chondrocytes are likely to live physiologically in 
a microenvironment that is hypoxic relative to other tissues. Functional 
adaptations of chondrocytes to hypoxia have been reported (Schipani et al. 
2001; Pfander and Gelse 2007). A key protein in this adaptation is hypoxia 
inducible factor-1 (HIF-1) which has been shown to be involved in 
maintaining energy generation and cellular survival of hypoxic 
chondrocytes (Rajpurohit et al. 1996). It has also been reported that the 
anabolism and survival of chondrocytes is maximal when they were 
cultured in vitro under low oxygen tension compared to normoxic and 
anoxic conditions (Grimshaw and Mason 2000).
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Although studies have provided evidence for the beneficial effects of 
hypoxia on cartilage matrix production (Grimshaw and Mason 2000; 
Murphy and Sambanis 2001 b; Malda et al. 2004 a), there is little 
information regarding its effects on cartilage matrix catabolism. One study 
using IL-1 stimulated bovine chondrocytes demonstrated that alterations in 
transcription levels of genes associated with cartilage matrix production 
and catabolism degeneration occurred under hypoxic and reoxygenation 
stress conditions (Martin et al. 2004).
Catabolism of cartilage extracellular matrix, which is mainly comprised of 
proteoglycan and type II collagen, leads to a biomechanically inferior 
tissue, and causes pathological changes such as in osteoarthritis. Although 
proteoglycan can be rapidly replaced, collagen loss may be irreversible 
(Eyre 2004). The degradation of cartilage matrix is mediated largely by 
members of the matrix metalloproteinases (MMPs) family of degradative 
enzymes. They are secreted in latent form and have a role in degradation of 
cartilage matrix upon activation (Nagase and Woessner 1999). The 
regulation of MMP activity can be controlled at the level of synthesis, 
proenzyme activation and inhibition of activated enzymes by tissue 
inhibitors of metalloproteinases (TIMPs). Proinflammatory cytokines have 
been known to induce cartilage catabolism (Mclnnes and Schett 2007) 
through up-regulation of these enzymes. In vitro, using porcine and bovine 
cartilage, it has been shown that interleukin-1 (IL-1) and tumour necrosis
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factor alpha (TNF-a) can drive this degenerative process particularly when 
combined with oncostatin M (OSM) (Cawston et al. 1999; Morgan et al.
2006).
In the present study, we aimed to examine the relationship between 
oxygen concentrations and equine cartilage catabolic processes by 
assessment of gene expression, enzyme production and activation and also 
matrix degradation. We also report a variation of cytokine response in 
equine articular cartilage in comparison to that reported in other species, 
which could be useful information for further cartilage degradation studies 
using equine tissue.
Materials and methods 
Reagents
All human recombinant cytokines were from Peprotech. MMP-13 
fluorogenic substrate was from Calbiochem. SYBR® Green PCR master 
mix was from Applied Biosystems.
Cartilage degradation model
Normal equine (age 4-25 years old) cartilage was rinsed and cultured as 
cartilage explants (see Chapter II). After 24 hours of being cultured, 
cartilage explants were divided into 5 groups of treatments, which were 
untreated control; TNFa; IL-1P; OSM and the combination of IL-ip and 
OSM, with a concentration of 20ng/ml of each human recombinant 
cytokine. Cultures were maintained either under 20% or 1% oxygen for 5
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days in the short-term experiments («=3), 4 weeks in the long-term 
experiments («=3), and 24 hours for mRNA studies (n=3). The 
experiments were performed in quadruplicate for each horse.
Proteoglycan degradation
Cartilage explant culture media were collected daily in short-term 
experiments and weekly in long-term experiments. The remaining cartilage 
was digested with lmg/ml papain in 0.1 M sodium-phosphate buffer (pH 
6.5), containing 5mM N-acetyl cysteine and 5mM EDTA, at 65°C 
overnight. Media and papain-digests were assayed for sulphated 
glycosaminoglycan using the DMMB assay (see Chapter II). The data 
were analysed by Ascent software (Thermo Labsystems). The results are 
shown as percentage of total GAGs in each explants sample.
Collagen degradation
The papain-digests and tissue culture media collected from the long-term 
experiment were analysed for collagen release using the hydroxyproline 
assay (see Chapter II). The data were analysed by Ascent software 
(Thermo Labsystems). The results are shown as percentage of total 
hydroxyproline present in the cartilage explant.
MMP-13 fluorogenic substrate assay optimisation
The MMP-13 enzymatic activity assay was optimised using serial dilutions
of active MMP-13 containing media from a canine monocyte cell line 
(DH82) (donated by Miss Natalie Gabriel) stimulated with lpg/ml 
lipopolysaccharide (LPS) for 18 hours. The FCS was tested for its
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interference with the assay by using medium containing 0%, 1% or 10% 
FCS. Two concentrations (lOpM and lOOpM final concentration) of the 
MMP-13 fluorogenic substrate peptide (MCA-Pro-Cha-Gly-Nva-His-Ala- 
Dpa-NH2) (Knauper et al. 1996 a), were used for substrate optimisation. 
The plate was read every 30 minutes up to 240 minutes to define the best 
reading point (see MMP-13 assay below for the assay method).
MMP-13 fluorogenic assay
MMP-13 enzymatic activity was assessed using the MMP-13 fluorogenic 
substrate (MCA-Pro-Cha-Gly-Nva-His-Ala-Dpa-NH2) (Calbiochem), 
which is preferentially cleaved by MMP-13 (Knauper et al. 1996 a). 
Medium samples (40pi) from equine cartilage (n=2) explant cultures were 
incubated in black 96 well-plates with assay buffer (50pl) (50 mM HEPES, 
200 mM NaCl, 1 mM CaC12, 0.01% (v/v) Brij-35, pH 7.3) and a final 
substrate concentration of lOpM. Serial dilutions of active MMP-13 
containing serum-free media from a canine monocyte cell line (DH82) 
were included on each plate to ensure a linear relationship between MMP- 
13 activity and substrate cleavage over the required range. Aliquots of 
DMEM were also included in order to determine the assay background. In 
order to obtain values for total (latent and active) MMP-13 levels in the 
explants medium, activation of the latent enzyme was performed by 
incubation with 0.5mM p-aminophenylmercuric acetate (APMA) at 37°C 
for 1 hour prior to addition of the substrate. Both active and total MMP-13 
generated fluorescence were measured (FLx800 microplate reader; Bio-
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TEK Instrument Inc.), adjusting the excitation wavelength to 325 nm and 
emission to 393 nm after incubation of samples with substrate for 3 hours 
at 37°C. The data were analysed by KCjunior software (Bio-TEK) and 
represented as the percentage of each control group. The assay was 
performed only with samples taken at week 3, where the most significant 
collagen release was identified.
Quantitative Polymerase Chain Reaction (qPCR)
Twenty-four hours cytokine treated and the control cartilage explants were
snap frozen and pulverised in liquid nitrogen cooled steel chambers (Braun 
Biotech Mikrodismembrator) before RNA and cDNA preparation (see 
Chapter II). Table 4.1 shows the candidate genes selected for this 
cartilage degradation study. PCR reactions were performed using SYBR® 
Green PCR master mix and 300nM primer concentration. All data was 
normalised with a pair of reference genes, HPRT and TBP.
Table 4.1 Candidate gene list of cartilage degradation study
S y m b o l G e n e  n am e p rim e rs  5 '-3 ’ E ffic ie n c y  o n  
e q u in e  
c a rtila g e
M M P -1 3 Matrixm etalloproteinase 
13 (C o llag en ase  3)
F w  C T G G A G C T G G G C A C C T A C T G
Rv: A T T T G C C T G A G T C A T T A T G A A C A A G A T
-3 .0 2 7
M M P -2 Matrixm etalloproteinase 
2  (G elatinase  B )
Fw : C C C C G G G C C C T G G A G T T G G  
Rv: A T C G C T G C G G C C T G T G T C T G T G
-3 .3 5 8
Col2a1 T y p e  II collagen F w  A A T A A C C T G A A T C C A G A A A C A A C A C A  
Rv: G C G T G A C T G G G A T T G G A A A G
-3 .2 7 3
TIM P -1 T is s u e  inhibitor of 
m etalloproteinase 1
F w  A T C C C C T G C A A A C T G C A G A G T  
Rv: G C C C T T G T C A G A G C C T G T G A
-3 .1 5 4
T IM P -2 T is s u e  inhibitor of 
m etalloproteinase 2
F w  A G A G T T G T T G A A A G T C G A C A A G C A  
Rv: A C C G A G C G A T C A C T C A G G A A
-3 .0 9 8
T IM P -3 T is s u e  inhibitor of 
m etalloproteinase 3
F w  C C T A C T T C C C C A T T A G C C A G T C T  
Rv: A C A G G G T T T T C T C T G G T T G G T T T
-3 .2 2 8
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Statistical analyses
Two-way ANOVA with Bonferroni post-hoc test was performed using 
Graphpad Prism software (V. 4.01) to compare the effect of oxygen level 
and cytokines or the effect of oxygen level for each parameter at each 
matched time point.
Results
Proteoglycan degradation
The effect of human recombinant cytokines and oxygen tensions on equine 
cartilage explant («=3) proteoglycan degradation was measured using the 
DMMB assay. The accumulative GAG release of non-cytokine treatment 
explants ranged from 12% at day 1 (Fig 4.1) to 60% of total GAG at Day 
28 (Fig 4.2). All cytokine treatments were able to promote GAG loss 
within the first week of culture (p<0.0001; data not shown). About 25% of 
total GAG was released into the tissue culture medium from the second 
day of treatment, and continued to 75% by day 5 (Fig 4.1) and 90% by the 
end of the long-term experiment (Fig 4.2). However, oxygen tensions had 
no significant effect on the release of GAG throughout the study (Fig 4.1 
and 4.2). There were slight differences between levels of GAG release by 
control explants between 20% and 1% 0 2. In short-term experiments, 
normoxia treated samples released GAGs more than those under hypoxia 
while it was opposite in the long-term experiment. However, the difference 
did not reach statistical significance.
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Fig 4.1 Accumulative GAG release during short-term (5 days) treatment with 
proinflammatory cytokine and hypoxia. The results represent as percentage of 
total explants GAG content. Equine cartilage explants («=3) were cultured under 
20% or 1% 0 2 with 20ng/ml human recombinant IL-ip, TNFa, OSM or 
combination of IL-1 p and OSM (I+O). Each treatment was performed in 
quadruplicate. Tissue culture medium was collected daily. GAG released into 
tissue culture medium was analysed by DMMB assay in duplicate manner. The 
error bars represent SEM.
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Fig 4.2 Accumulative GAG release during long-term (4 weeks) treatment with 
proinflammatory cytokine and hypoxia. The results represent as percentage of 
total explants GAG content. Equine cartilage explants (n=3) were cultured under 
20% or 1% 0 2 with 20ng/ml human recombinant IL-ip, TNFa, OSM or 
combination of EL-ip and OSM (I+O). Each treatment was performed in 
quadruplicate. Tissue culture medium was collected weekly. GAG released into 
tissue culture medium was analysed by DMMB assay in duplicate manner. The 
error bars represent SEM.
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Collagen release
Collagen degradation was determined using the hydroxyproline assay. Fig 
4.3 illustrates the time course of collagen release from equine cartilage 
explant culture stimulated with various human recombinant cytokines at 
the two different oxygen tensions. While proteoglycan degradation occured 
almost immediately, collagen release was undetectable during the first 
week. Unexpectedly, hydroxyproline in the medium of cartilage treated 
with TNFa was obviously increased at the second week and continued 
increasing up to 20% of total hydroxyproline at week 4. This indicates 
potent TNF-induced collagen degradation whilst other cytokines, including 
the combined treatment with IL-1 and OSM, had no effect at all. There was 
no statistical difference in collagen release between normoxic and hypoxic 
treated samples.
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Fig 4.3 Accumulative collagen release during long-term (4 weeks) treatment 
with proinflammatory cytokine and hypoxia. The results represent as percentage 
of total explants collagen content. Equine cartilage explants (n=3) were cultured 
under 20% or 1% 0 2 with 20ng/ml human recombinant IL-ip, TNFa, OSM or 
combination of IL-ip and OSM (I+O). Each treatment was performed in 
quadruplicate. Tissue culture medium was collected weekly. Collagen degradation 
released into tissue culture medium was determined by measuring released 
hydroxyproline (see Chapter II). The assay was done in duplicates. The error 
bars represent SEM.
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MMP-13 fluorogenic assay optimization
In testing for interference due to the presence of FCS on the assay, the rate 
of substrate quenching was sharply increased in the media containing FCS 
and the fluorescence detection was out of range (data not shown). 
Therefore, FCS was avoided in this cartilage degradation study.
The two concentrations of the fluorogenic substrate, both lOOpM and 
lOpM were able to give fluorescence within the range that the assay can 
detect (Fig 4.4) over the 210 minutes recording period. The fluorescence 
data collected by 180 minutes is shown in Fig 4.5. The MMP-13 activity 
signals from both concentrations of the substrate generated almost linear 
curves and the 1 OpM was selected for the assay.
IOO j iM  substrate 1 0 ^ M  substrate
-Neat
- 1:2
-1:4
-1:8
-1:16
-  assay buffer
-Neal
- 1:2
-1:4
- 1:8
-1:16
-  assay buffer
Fig 4.4 Optimisation of the MMP-13 activity fluorogenic assay. Samples were 
in serial dilutions of medium from LPS-stimulated DH82 cells. Two 
concentrations, lOOpM (left) and 10pM (right), of substrate were used and the 
fluorescence was observed over 210 minutes of incubation. The backgrounds of 
the assay were subtracted.
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Fig 4.5 Standard curve of MMP-13 activity by fluorogenic assay in serial 
dilutions of medium from LPS-stimulated DH82 cells with lOOpM and lOpM 
substrate at 180 minute.
MMP-13 synthesis and activation
The activity of MMP-13, a major collagenase of cartilage, was measured in 
the tissue culture medium harvested from cultures where cartilage explants 
(«=2) were incubated with and without cytokine treatment at week 3, 
where the significant collagen degradation in TNF-a stimulated explants 
was identified. Increases in total MMP-13 were found in response to most 
cytokine treatments, except OSM. Interestingly, increased levels of active 
MMP-13 (in the absence of APMA activation) activity were seen in TNF- 
stimulated explants cultured at 20% 0 2 (Fig 4.6). However under 1% 0 2, 
the increased levels of active MMP-13 were not as high as in 20% 0 2 (Fig
4.6).
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Fig 4.6 MMP-13 activity in tissue culture medium samples of equine cartilage 
explants with differing oxygen and cytokine treatments. Cartilage explants (w=2 
horse) were cultured under 20% or 1% 0 2 with 20ng/ml human recombinant IL- 
ip, TNFa, OSM or combination of IL-1 p and OSM at week 3, where the collagen 
degradation was observed. The enzyme activity was measured by the expression 
of fluorescence of cleaved fluorogenic MMP-13 substrate. The assay was 
performed with or without 0.5mM /?-Aminophenylmercuric acetate (APMA) 
activation at 37°C for 1 hour in order to detect total or active MMP-13 
respectively. The graph shows average fluorescent activity and in each control 
group, the activity was set as 100 %.
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mRNA expression of MMP-13, Col2al, TIMP-1, TIMP-2, TIMP-3 and 
MMP-2
MMP-13 mRNA was highly up-regulated (p<0.001) in cartilage treated 
with TNF and IL-1, both in normoxia and hypoxia. OSM had no effect on 
MMP-13 regulation, while a combination of IL-1 and OSM showed some 
effect, which was smaller than that of IL-1 alone and reached statistical 
significance (p<0.05) only at 20%O2 (Fig 4.7). No oxygen effect was 
found when comparing the expression of each cytokine treatment between 
normoxia and hypoxia.
While MMP-13 was very cytokine responsive, MMP-2 was constitutively 
expressed at a very low level and was only significantly regulated (p<0.05) 
by IL-1 in normoxia treatment (Fig 4.7). Type II collagen (col2al) mRNA 
was down-regulated O<0.05) by IL-1, OSM and the combined treatment 
of these two cytokines when cultured under normoxia. However under 
hypoxic conditions, only OSM significantly inhibited (p<0.05) expression 
of col2al. Analysis of oxygen effects on MMP-2 and col2al expression in 
individual cytokine treatment did not show any significant differences 
between hypoxia and normoxia.
TIMP-1 expression was slightly increased by IL-1 and OSM but this was 
only significant under 1% oxygen treatment (IL-1; p<0.05, OSM; p<0.01) 
while combination of these two cytokines significantly increased TIMP-1 
transcription in both 20% 0 2 O<0.05) and 1% 0 2 (p<0.01). TNF did not 
show any effect on TIMP-1 regulation. Although TIMP-1 expression
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seemed to be slightly up-regulated by both IL-1 and OSM, TIMP-2 
expression was significantly down-regulated by TNF, IL-1 and the 
combined IL-1-OSM treatments (p<0.001). OSM alone also had a down- 
regulatory effect on TIMP-2 transcription but it was significant only at 
1%02 (p<0.05). IL-1 was the only cytokine that played a role in TIMP-3 
regulation and even then was only effective in normoxia. The increased 
TIMP-3 transcription in normoxia-IL-1 treated samples was significantly 
higher than hypoxic samples (p<0.05).
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Fig 4.7 Effect of oxygen and proinflammatory cytokines on the expression of 
genes involved in cartilage turnover (MMP-13, MMP-2, col2al, TIMP-1, TIMP-2 
and TIMP-3). Equine cartilage expiants («=3) were cultured under 20% 
(normoxia) or 1% 0 2 (hypoxia) with 20ng/ml human recombinant IL-lß, TNFa, 
OSM or combination of IL-lß and OSM for 24 hours. The error bars represent 
SEM.*p<0.05; **/?<0.01; ***/?<0.001.
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Discussion
Hypoxia is believed to be the normal physiological environment of 
chondrocytes in cartilage, relative to better vascularised tissues. Despite 
there being numerous publications indicating that a low oxygen level 
confers an advantage on chondrocyte deposition of cartilage matrix, there 
is relatively little information about the effects of hypoxia on chondrocyte- 
mediated catabolic processes.
Our results agreed with other catabolic studies by showing that cartilage 
responds to cytokines by degrading/releasing proteoglycan very quickly 
while collagen loss is only detectable some considerable time after GAG 
loss (Hui et al. 2001; Little et al. 2005; Morgan et al. 2006). In our study 
the amounts of GAG and collagen released under normoxic and hypoxic 
conditions were not significantly different, suggesting neither adverse nor 
positive effects of oxygen level on cartilage structural degradation. 
However, it is known that aggrecan can be degraded by both aggrecanases 
and MMPs (reviewed by Dudhia 2005): the question whether there is any 
change in the proportion of aggrecanse and MMP activities in GAG 
degradation under different oxygen concentrations still remains.
Stimulation of cartilage explants using IL-1, OSM and the combination of 
these two cytokines, which is commonly used to induce cartilage 
degradation in human and bovine studies (Elliott et al. 2001; Hui et al. 
2001; Morgan et al. 2006), successfully induced GAG loss but had no
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effect at all on collagen release in our equine system. In a study using 
normal equine cartilage from the metacarpophalangeal and carpal joints, 
collagenolysis was reported to be inducible by IL-1 alone (Little et al. 
2005) but we were unable to replicate this finding using femoral cartilage 
explants. Surprisingly, TNFa was the only cytokine that was capable of not 
only inducing GAG release but also collagen degradation and this was 
reproducible in our system. This is not the first report of a species- or site- 
specific variation in the response of chondrocytes. In man, collagenolysis 
by nasal chondrocytes is much easier to stimulate than in articular 
chondrocytes using the same cytokine stimulations (Morgan et al. 2006). It 
was suggested that contribution of factors such as cell density, collagen 
cross links and glycation in each specific site could be the explanation of 
this variation (Morgan et al. 2006).
Degradation of the collagenous network is due to MMP activity both 
during normal tissue remodelling and during pathological changes. MMP- 
13 preferentially cleaves type II collagen (Knauper et al. 1996 a) and our 
results showed increased level of total MMP-13 measured at week 3 
following TNF and IL-1 treatment of explants. However, approximately 
50% of the MMP-13 produced by IL-1 stimulated explants was in the 
inactive form while TNF-induced explants under normoxia produced 
mainly (almost 90%) active enzyme. This data correlates well with the
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collagen degradation results, confirming the important role for MMP-13 in 
collagen breakdown.
The extent of collagen release induced in response to TNF treatment was 
similar in both hypoxia and normoxia and this agreed with the expression 
of total MMP-13 in both levels of oxygen. However, the active MMP-13 in 
hypoxia appeared to be lower than demonstrated under normoxia. This 
observation would suggest that there may be other collagenases (e.g. 
MMP-1 and MMP-8) or other factors involved in MMP-13 activation 
under hypoxia. There have been reports indicating that MMP-13 zymogen 
can be activated by other matrix metalloproteinases such as stromelysins 
(Barksby et al. 2006 b) and membrane-type 1 MMP (MT1-MMP; MMP- 
14) (Knauper et al. 1996 b). MMP-14 (MT1-MMP) upregulation has been 
reported in hypoxic bovine chondrocyte cultures (Martin et al. 2004), 
therefore MMP-14 could potentially be a factor activating MMP-13 in 
hypoxic environments.
The response of equine cartilage explants at gene transcription level was 
also included in our study. As predicted, MMP-13 mRNA expression 
increased in TNF and IL-1 treatments and showed a significant correlation 
with the actual enzyme production. Hypoxia was previously reported to 
enhance the expression of many MMPs including MMP2 and MMP-13 in 
rabbit fibrocartilagenous chondrocytes (Yamaguchi et al. 2005) but we 
were unable to identify such an effect in our equine articular cartilage
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study. Another study using bovine articular chondrocytes showed that 
hypoxia did not markedly affect levels of MMP gene expression but 
significant changes were found following reoxygenation stress (Martin et 
al. 2004). There was also greater inhibition of type II collagen and 
aggrecan core protein gene expression when bovine chondrocytes were 
treated in combination with IL-1 and hypoxia (Martin et al. 2004). Despite 
inhibition of col2al expression by OSM and IL-1 similar to previous report 
(Kuroki et al. 2005), there was no hypoxia effect on col2al gene 
expression in our study.
The expression of tissue inhibitors of metalloproteinases (TIMP) genes was 
quite varied and depended on the TIMP species and cytokine stimulation. 
Our study confirmed findings from previous studies that have identified 
upregulation of TIMP-1 by many proinflammatory cytokines (Hui et al. 
2001; Martin et al. 2004; Kuroki et al. 2005; Morgan et al. 2006); however, 
one study using bovine nasal chondrocytes identified a down-regulation of 
TIMP-1 gene expression when stimulated with a combination of IL-1 and 
OSM (Hui et al. 2001). TIMP-2 expression was reported to increase in an 
IL-1 stimulated canine chondrocyte study (Kuroki et al. 2005) but it was 
down-regulated in our study. However, the oxygen level had no effect on 
either TIMP-1 or TIMP-2 gene expression. TIMP-3 was the only gene 
whose expression was affected by oxygen but this finding is in contrast to a 
previous report using chondrocytes from rabbit temporomandibular joints.
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While TTMP-3 expression after stimulation with IL-1 was up-regulated and 
suppressed by hypoxia in our study, Yamaguchi et al.(2005) demonstrated 
a down-regulation by IL-1 and up-regulation by hypoxia.
Conclusion
In conclusion, among the cytokines used in our study, TNF was able to 
promote equine articular cartilage matrix degradation and have significant 
effects along all the degradative pathways studied i.e. GAG release, 
collagen release, MMP-13 production and activity. Hypoxia seems to have 
opposite, yet very small effects on cartilage. The response of chondrocytes 
to cytokines was faster and stronger than to changes in oxygen level 
resulting in net degradation of cartilage which could not be balanced by 
low oxygen tension.
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C h a p t e r  V
EFFECT OF HYPOXIA ON NEO-CARTILAGE SYNTHESIS OF 
EQUINE CHONDROCYTES
Introduction
Cartilage lacks the ability to completely restore itself once it is injured or 
degenerated. Attempts have been made to search for a solution to the 
problem of cartilage repair. One approach, which has been used for human 
joint repair is cartilage regeneration using autologous chondrocyte 
implantation (Brittberg et al. 1994; Peterson et al. 2000). More recently, 
the use of adult stem cells has been explored (reviewed by Chen et al. 
2006), with the aim of generating constructs of neo-cartilage with 
structural and functional properties comparable to native tissue. The 
induction and stability of chondrocyte phenotype and prevention of 
chondrocyte dedifferentiation are major concerns in all approaches to 
cartilage engineering.
Chondrocytes in native tissue synthesise the proteoglycan aggrecan and a 
heterotypic collagen fibrillar network with type II collagen as major and 
type IX and XI collagen as minor components, in order to construct and 
maintain the cartilage matrix (Freeman 1979). The synthesis of these 
macromolecules has been used to define the chondrocyte phenotype.
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Following their isolation from cartilage, expansion of chondrocytes in 2-D 
monolayer cultures in order to get sufficient numbers of cells drives them 
towards fibroblastic morphology and synthesis of type I, III and V collagen 
instead of type II, IX and X (Mayne et al. 1976; Benya et al. 1977; Benya 
et al. 1978). They also lose the expression of aggrecan core protein 
(Schnabel et al. 2002). The result of these phenotypic changes is 
production of an extracellular matrix with inferior biomechanical 
properties (von der Mark et al. 1977; Watt 1988).
Interactions between chondrocytes and the surrounding matrix are 
important in the stabilisation of their morphology and functions (Shakibaei 
et al. 1997). Culture systems which support chondrocytes within three- 
dimensional environment, thereby maintaining the round appearance of the 
cells and mimicking their natural habitat, maintain their phenotype stability 
(Hàuselmann et al. 1994; Gregory et al. 1999; Gugala and Gogolewski 
2000). Alginate bead (Guo et al. 1989), agarose gel (Benya and Shaffer 
1982), polymer scaffolds (Woodfield et al. 2002) and pellet cultures 
(Zhang et al. 2004) have all been demonstrated to prevent or reverse 
dedifferentiation of chondrocytes.
Chondrocytes are usually maintained in culture under normoxic conditions. 
However, oxygen concentrations within cartilage tissue are relatively low 
compared to other tissues and low compared to most culture environments. 
Chondrocytes have been reported to adjust their metabolism to compensate
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for an environment lacking in oxygen (Rajpurohit et al. 1996) by shifting 
to anaerobic respiration. Also, evidence of correlation between low oxygen 
levels and chondrogenesis has been reported e.g. culture of mouse embryo 
forelimb under low oxygen tension resulted in increased deposition of 
safranin-o positive matrix (Hirao et al. 2006) and culture of nasal 
chondrocyte under low oxygen tensions resulted in increased deposition of 
type II collagen and aggrecan in pellet culture (Malda et al. 2004 a).
Hypoxia has been reported to favour proliferation, matrix synthesis and 
stimulation of chondrocytic (re)differentiation (see Table 5.1). However, 
conflicting data have also been produced indicating that finding«; from 
studies are not always consistent (see Table 5.1). Several investigators 
reported that there were no difference in the production of matrix 
molecules and chondrocyte proliferation between normoxia and hypoxia. 
Moreover, it was found that those parameters were higher under more 
aerobic conditions than low oxygen tensions.
Chondrocytes can respond to various cytokines and growth factors by 
altering their metabolic activity towards anabolism or catabolism. 
Transforming growth factor-P (TGF-P) has been shown to have a major 
positive influence on cartilage matrix synthesis (reviewed in Trippel 1995; 
Grimaud et al. 2002) and has been used in cartilage repair and engineering 
studies (Glowacki et al. 2005). There is however, no information to date 
on the
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Table 5.1 Summary of data reported in the literature regarding the influence of 
low oxygen tension on proliferation, cartilaginous matrix synthesis, phenotype 
stability and (re)differentiation of chondrocytes and other cells (adapted from Henrotin 
et al. 2005). AC = articular cartilage, NC = nasal cartilage, OA = osteoarthritis, coll = collagen.
Cell or Tissue Species Type of cUture Oxygen tensions Effect on ECM Effect on Reference
hypoxla/normoxia and cells mRNA
■  Positive effects of hypoxia I
Primary AC Bovine Monolayer 5/20 TColl II (Hansen et al.
TColl IX 
¿Coll I
tProliferation
2001)
Primary AC Bovine Alginate 10/20 ttPeDet volume (Grimshaw and
(after liberated 
from bead)
Mason 2000)
Primary AC Bovine Alginate 5/20 TColl II (Domm et al. 
2002)
Primary AC Equine Alginate (at 14 5/21 TLiving cells (Schneider et
days) ¿Apoptosis al. 2004)
Dedifferentiate AC Bovine Alginate 5/20 TColl It (Murphy and
TAgg Sambanis
2001 a)
Dedifferentiate AC Bovine Alginate 5/20 TColl II (Domm et al.
TColl IX 
¿Coll I
2002)
Dedifferentiate AC Human Alginate 5/20 TColl II (Murphy and
TAgg Polak 2004)
TSOX9
Dedifferentiate NC Human Pellet 5/20 fGAG (Malda et al.
TColl II 2004 a)
1/20 TTGAG
TColl II
Primary AC Bovine Alginate/Collagen 5/20 ¿Ratio of Coll TRatio of (Kurz et aL
l/lll membrane ll/Coll I Coll 2004)
culture ll/Coll I
Primary AC Bovine Porous polyacetic 5/20 |GAG (Saini and
acid construct Wick 2004)
Primary AC (OA) Human Collagen l/lll 5/20 TProDne and (Scherer et al.
membrane culture sulphate
corporation
2004)
Dedifferentiate AC Bovine Collagen l/lll 5/20 TColl II (Kurz et al.
membrane culture 2004)
Primary AC Bovine Polyurethane 5/21 ¿GAG TColl II (Wemike et al.
scaffold ¿Coll II TAgg 2008)
¿Coll I ¿Coll I
Dermal fibroblast Human Porous collagen 5/19 TC-4-SPG (Mizuno and
(for sponge containing Glowacki
chondroinduction) DBP 2005)
Mice embryo Murine Organ culture 5/20 TSafranirvO (Hirao et aL
forelimb positive area 
¿Coll X
2006)
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Table 5.1 (Continued)
Ceil or Tissue Species Type of ciiture Oxygen tensions Effect on ECM Effect on Reference
hypoxla/normojda and cells mRNA
1 Negative effects of hypoxia I
Primary AC Bovine Cartilage explant 6/24 ¿Sulphate (Ysart and
corporation Mason 1994)
Primary AC Bovine Multilayer 5/20 ¿GAG (Murphy and
¿Proliferation Sambanis
¿Collagen 2001 b)
1/20 UGAG 
¿¿Prol iteration 
¿¿Collagen
Primary AC Bovine Alginate 5/20 ¿Pellet volume (Grimshaw and 
Mason 2000)
0.1/20 ¿Pellet volume ¿rRNA
yield
Primary AC Equine Alginate (at 14 1/21 ¿Apoptosis (Schneider et
days) ¿Living cells 
¿Necrotic cells
al. 2004)
Pluripotent MS cell Murine Monolayer 5/20 ¿ALP activity ¿Coll II (Hirao et al
line (C3H10T1/2) ¿GAG ¿Coll X 2006)
¿Mineralization ¿Sox9
¿Runx2
I No effect of hypoxia I
Dedifferentiate AC Human Pellet 5/20 No (Adesida et al
response
in
Coll II 
Colli 
SOX9
2007)
Primary AC Bovine Porous polyacetic 5/20 +/-Collagen (Saini and
acid construct Wick 2004)
use of TGF-P in combination with hypoxia and it is not known whether or 
not they have a synergistic effect on matrix synthesis.
This chapter describes studies in which the effects of hypoxia and TGF-03 
on cartilage matrix synthesis were investigated. Studies were carried out 
using equine chondrocytes in pellet culture system. The study was divided 
into two experiments. The aim of the first experiment was to compare the 
effect of 20% and 1% oxygen on cartilage matrix synthesis by equine
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chondrocytes. In the second experiment, the matrix production of equine 
chondrocytes responded to a growth factor, TGF-P3, in combination with 
low oxygen tension was explored.
Material and methods 
Sources of chondrocytes
Chondrocytes used in these studies were from two sources of normal 
equine cartilage; femoropatellar (stifle; age 5-7 years old) and 
metacarpophalangeal/ tarsophalangeal (fetlock; age unidentified) joints. 
Each experiment was performed using cartilage from three different 
donors. Chondrocytes were isolated and cultured in pellet form as 
described in Chapter II. Sufficient numbers of chondrocytes were 
isolated from the stifle joints and these were pelleted directly following 
isolation. However, low yields of chondrocytes were obtained from fetlock 
joints. Therefore, the fetlock-derived cells, which were used in the second 
experiment, were expanded as described in Chapter II in order to obtain 
sufficient numbers of cells to culture as pellets.
Chondrocyte pellet culture
Equine chondrocyte pellets were cultured in a 96-well plate system (see 
Chapter II). In experiment 1, the pellets were maintained either under 
20%C>2 or 1 % 02 for 14 days. In experiment 2, the pellets were cultured in 
the same conditions and for the same period of time but with or without the 
addition of 10ng/ml recombinant human TGF-P3. All treatments were
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done in triplicates (two pellets per replicate). Tissue culture media were 
collected every other day and replenished. At the end of the culture period, 
chondrocyte pellets were either weighed (only performed in experiment 2 
due to limited number of pellets in experiment 1) or processed for RNA 
extraction using Trizol® or GAG, hydroxyproline and DNA analysis 
following papain digestion (lmg/ml; lOOpl per pellet). Pepsin digestion 
was used in the pellet preparation for collagen protein extraction (see 
Chapter II).
Analysis of matrix components
Papain digested pellets and tissue culture medium samples were analysed 
for the deposition and release of GAG and collagen using DMMB and 
hydroxyproline assay respectively (see Chapter II).
Neo-cartilage synthesis gene expressions
Methods of preparing RNA and cDNA preparation were as described in 
Chapter II. However, to improve recovery, the pellets were homogenised 
using Molecular Grinding Resin before RNA extraction. The expression of 
aggrecan core protein (agg), type I collagen (collal), type II collagen 
(col2al) and sox9 was measured using qPCR with SYBR Green® 
mastermix. Primers were validated as described in Chapter II and their 
sequences are listed in Table 5.2.
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Table 5.2 Genes and primers used in cartilage matrix synthesis study
S ym b ol G e n e  nam e P rim e r 5 ’-3' E ffic ie n c y on 
equ in e  cartilage
agg Aggrecan core protein Fw: GAGGAGCAGGAGTTTGTCAACA 
Rv: CCCTTCGATGGTCCTGTCAT -3.322
c o lla i T yp e  I collagen Fw: AGAGCATTTGCCCAACATTGT 
Rv: CATGGGAAAGGATGAAAACGA -3.193
col2a1 T yp e  II collagen Fw: AATAACCTGAATCCAGAAACAACACA 
Rv: GCGTGACTGGGATTGGAAAG -3.273
sox9 sox9 Fw: CTTTGGTTTGTGTTCGTGTTTTGT 
Rv: AGAGAAAGAAAAAGGGAAAGGTAAGTTT -3.329
Collagen separation by SDS-PAGE
Collagen molecules were extracted from chondrocyte pellets by pepsin 
digestion using lOOpl of pepsin (lmg/ml in 0.5M acetic acid; Sigma) per 
pellet for 24 hours at 4°C. Samples were freeze-dried and reconstituted 
again with H2O (25pi per pellet). Proteins were denatured by boiling for 4 
minutes with sample buffer (see Chapter II). P-mercaptoethanol (0.05% 
(v/v)) was added in order to reduce disulphide bonds in the protein. Equal 
amounts of each pellet sample was loaded onto each well of SDS gels with 
a resolving gel of 7% (w/v) acrylamide and a stacking gel of 4% (w/v) 
acrylamide. Electrophoresis was run for approximately 45 minutes at 200V 
and subsequently, the gels were stained with Coomassie Brilliant blue stain 
(see Chapter II) for 2 hours. Gels with separated proteins was scanned 
after destaining (see Chapter II) and the image was analysed by Scion 
Image software
(http://www.scioncorp.com/pages/scion image windows.htmt. to 
compare the intensity of stain associated with protein bands.
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Mass Spectrometry
Protein bands separated by SDS-PAGE were dried and sent to the 
Wellcome Trust Centre for Cell-Matrix Research, Faculty of Life 
Sciences, University of Manchester, where samples were trypsinised and 
separated by reverse-phase chromatography and analysed by positive ion 
electrospray ionization mass spectrometry/mass spectrometry (ESI- 
MS/MS) using a Quadrupole-Time of Flight (Q-ToF) mass spectrometer to 
define the amino acid sequences of the peptide fragments (Rousseau et al.
2007). Data acquired were analysed using SWISSPROT and a custom 
equine database collected from Entrez Protein Database 
(http://www.ncbi.nlm.nih.gov) if available. Otherwise, the alignment 
between known peptide sequences from other species and equine genome 
database from Ensembl (www.ensembl.org) was performed to obtain 
predicted equine proteins.
Western blot for type II collagen
Western blots were performed to confirm expression of type II collagen in 
equine chondrocyte pellet cultures. Pepsin (lmg/ml; lOOpl per pellet) 
digests of each sample were freeze-dried and reconstituted with 25 pi H20 . 
The reconstituted pellet extracts were mixed with sample buffer (5 times 
concentration) and denatured with or without reduction by (S- 
mercaptoethanol (0.05%v/v) before loading onto SDS gels with equal 
amount of each sample. Electrophoresis and western blot on PVDF 
membrane were performed as described previously (see Chapter II).
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Primary antibody used in this study was AVT6E3, a monoclonal antibody 
raised against human type II collagen. The blots were incubated with 1:10 
dilution of hybridoma supernatant containing AVT6E3 antibody for 
overnight at room temperature and with 1:5,000 dilution of alkaline 
phosphatase conjugated anti-mouse IgG (SIGMA) for 1 hour and room 
temperature. Interactions with the primary and secondary antibodies were 
detected by using the alkaline phosphatase substrate, SIGMA FAST™ 
BCIP/NBT (5-Bromo-4-chloro-3-indolyl phosphate/Nitro blue 
tétrazolium).
Results
Experiment 1 : Study of the effect of hypoxia on pellet cultures using 
fresh equine chondrocytes harvested from the femoropatella joint (n=3 
horses)
1. GAGs and total collagen synthesis
Equine chondrocyte pellets cultured under both 20%O2 and 1%02 were 
disc-shape and remained intact until harvesting at day 14. Analysis of 
GAG deposition within the pellet showed that normoxic pellets contained 
higher (approximately 2 times) amount of GAG than hypoxic pellets (Fig 
5.1a). Similarly, accumulative GAG release measured in tissue culture 
medium from normoxic samples was also higher than hypoxic samples 
(Fig 5.1c) indicating a suppression of proteoglycan synthesis in 
chondrocytes cultured under hypoxia. However, the trends of decreasing 
GAG deposition and release when the pellets were cultured under hypoxia
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in this experiment were not significant. There was no difference in 
collagen deposition and release between the two oxygen levels (Fig 5.1b 
and 5. Id).
Fig 5.1 Synthesis of GAG and collagen in primary equine chondrocyte pellet 
cultures (n=3) under 20% O2 and 1% O2. (a) GAG and (b) collagen deposition 
within pellet cultures Pellets were digested with lmg/ml papain at 65 °C overnight 
prior to analysis using DMMB and hydroxyproline assays. Tissue culture medium 
samples were also collected every other day and analysed for GAG (c) and 
collagen (d) release. The error bars represent SEM.
2. Identification of collagen type II and other pepsin-resistant 
components of the pellet matrix by mass spectrometry
To confirm the identity of the bands that were observed by SDS-PAGE,
the bands were cut out for mass spectrometry analysis, the result of which 
are shown in Fig 5.2. Band A (migrating to the same distance as the type II 
collagen marker, with an apparent molecular weight of 140kDa) and the
D2 04 OS DS 010 012 D14
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lower molecular weight band B were cut out individually. Band C was 
believed to be the pepsin used for pellet digestion as shown in comigration 
with the same molecular weight of pepsin. Band C resolved into two bands
when the samples were reduced using P-mercaptoethanol; however, they
were cut and analysed together.
Porcine 
type II —  
Collagen 
marker
0 ~ ‘~
Band C
Pepsin
Porcine 
type II — .  
Collagen 
marker
Fig 5.2 Pepsin digested chondrocyte pellets resolved by SDS-PAGE using 7% 
acrylamide and stained with Coomassie blue. Equine chondrocyte pellets were 
digested with 2mg/ml hyaluronidase for 2 hours at ambient temperature followed 
by lmg/ml pepsin in 0.5M acetic acid (lOOgl/pellet) at 4°C for overnight. 
Samples were freeze-dried and reconstituted with H20  (25pil/pellet) and denatured 
with reduction by boiling with 14.3M P-mercaptoethanol (Sigma) at 1:20 in 
sample buffer for 4 minutes. Equal amounts of each pepsin digested pellet were 
loaded into each well. Electrophoresis of pepsin alone is also shown. A standard 
preparation of pepsinised porcine type II collagen (2 mg/ml; donated by Dr. Anne 
Vaughan-Thomas) was used to identity bands co-migrating with type II collagen. 
Three bands (Band A, Band B and Band C) were analysed by mass-spectrometry 
analysis.
The peptide fragmentation data from ESI MS/MS analysis was matched 
against SWISSPROT (http://www.expasy.org/sprot/), and MSDB (M) 
(http://csc-fserve.hh.med.ic.ac.uk/msdb.html) databases. The data for 
matches with matrix molecules obtained are summarised in Table 5.3.
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Table 5.3 Protein fragments of ESI-MS/MS matched with SWISSPROT and 
MSDB (M) database.
Sample Accession nisnber Protein Number of peptides matched
Band A P02458 Collagen alpha 1(11) chain precursor 2
Band B P12111 Collagen alpha 3(VI) chain 2
Band C P12111 Collagen alpha 3(VI) chain 1
P10915 Hyaluronan link protein 1
All of the above related to human sequences. In order to gain more 
comprehensive analysis, a custom database collected from equine amino 
acid sequence database from NCBI or predicted sequences of equine 
collagen proteins by alignment with other species was also included. It was 
shown that Band A had a matched to alpha 1 chain of equine type II 
collagen while Band B matched to equine alpha 3 chain of type VI 
collagen. However, Band C still did not match to pepsin as expected but 
matched to equine alpha 3 chain of type VI collagen and hyaluronan 
binding protein (Table 5.4).
Table 5.4 Protein fragments of ESI-MS/MS matched with custom database of 
equine amino acid sequences. Blue letters represents matched sequences.
Sample Acession
Number
Protein Sequences
B a n d  A N P _ 0 0 1 075233 a  1 (II) 1011 g p tg k q g d rg e a g a q g p m g p a g p a g a rg lp  1040
B a n d  B X P _0 0 1 9 1 6 4 6 7 a  3  (VI) 1961 qraseelrqegvralilvglervanlerlm  1990 
2031 p ck csgq rgd rgp igsigp k gvp ge d gyrg  2050
B a n d  C X P  001916467 
Q28381
a  3  (VI)
H A  and P G  linking 
Protein
2031 p ck csgq rgd rgp igsigp k gvp ge d gyrg  2050 
281 kdgaqiakvgqifaaw kllgydrcdagw la 310
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3. Immunoblotting of pepsin-resistant proteins using a type II 
collagen specific monoclonal antibody
Western blot was performed using the AVT6E3 antibody to confirm the
expression of type II collagen in chondrocyte pellet cultures. Positive 
immunoreaction was found in porcine type II collagen marker as well as 
the protein bands migrating to the same distance on the gel (Fig 5.3). The 
antibody did not cross-react with type I collagen.
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Fig 53 Type II collagen Western blot. SDS-PAGE (left) and Western blot 
(right) using AVT6E3 antibody to probe against type II collagen. The standards 
were porcine pepsinised type I and type II collagen containing samples (donated 
by Dr. Anne Vaughan-Thomas). Samples were pepsin digested equine 
chondrocyte pellets. The blot was incubated with supernatant from the 6E3 
antibody-producing hybridoma cell line at 1:10 dilution for overnight at room 
temperature and with alkaline phosphatase conjugated anti-mouse IgG at dilution 
of 1:5,000 for 1 hour at room temperature.
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4. Quantification of type II collagen deposited in the pellet cultures
From SDS-PAGE, ESI-MS/MS data and western blot analysis, it was
confirmed that the protein in band A was type II collagen. Coomassie 
stained gels from pellet cultures («=2) maintained at 1% and 20% oxygen 
was scanned and plotted for the intensity of each band by Scion Image 
software (Fig 5.4).
t-  CN< m o o
Fig 5.4 SDS-PAGE analysis of pepsin digested chondrocyte pellets (n=2) using 
Coomassie stain (left) and image analysis for intensity of each protein band by 
Scion Image (right). Samples were equivalent volumes of pepsin digests of fresh 
equine chondrocyte pellets loaded onto each well and run alongside a porcine type 
II collagen marker. Samples were reduced with P-mercaptoethanol prior to 
electrophoresis.
Intensity values of SDS-PAGE resolved protein bands (Band A, Band B, 
Band Cl and C2) were compared between hypoxia and normoxia cultures
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(n -2). Pellets cultured under hypoxia had lower levels of type II collagen 
compared to normoxic pellets (Fig 5.5). The intensity of Band B, Band Cl 
and C2 between the two oxygen levels was also measured but the results 
showed no trend of higher or lower intensity between the treatments (data 
not shown).
20%0 ,
Fig 5.5 Quantification of type II collagen in SDS-PAGE gel. Comparison of 
average intensity of type II collagen protein bands (Band A) on Coomassie- 
stained SDS-PAGE gels (after analysis by Scionlmage) from pepsin digested 
pellets («=2) cultured under normoxia (20% 02) and hypoxia (1% 02).
5. Gene expression studies
Expression levels of genes associated with matrix synthesis was performed 
using real-timePCR and normalised to expression levels of HPRT and TBP 
mRNA, which were selected as reference genes (see Chapter IV). 
Aggrecan core protein (Agg), type I collagen (collal) and sox9 mRNA 
were significantly down regulated when the pellets were cultured under 
hypoxia compared to normoxia (p<0.001,/X0.05 and/?<0.01 respectively).
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Type II collgen (col2al) mRNA levels also showed a tendency towards 
lower expression in hypoxic pellets but this was not significant (Fig 5.6).
?o
c0
1
collai
20%O, 1%Oj
col2a1
Fig 5.6 Comparison of expression of genes involved cartilage matrix synthesis, 
type II collagen (col2al), type I collagen (collai), aggrecan core protein (agg) 
and sox9, in chondrocyte pellets cultured (n=3)under normoxia (20% 0 2) and 
hypoxia (1% 0 2). */7<0.05; **/?<0.01; ***/><0.001.
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Experiment 2: Study of the effects of low oxygen tension and TGF-P3 
on pellet cultures using first passage equine chondrocytes originally 
from metacarpophalangeal joint.
1. Pellet formation, weight and DNA content
Variation in shape and size of pellets was observed (Fig 5.7). Spherical 
shape was found in normoxic pellets cultured with TGF-P3 
supplementation while without growth factor, pellets were disc-like in 
shape. Under hypoxia (1% O2), chondrocyte pellets were bigger than under 
normoxia and were disc-like in shape and hyaline in their appearance. 
TGF-P3 did not affect the pellet size either in hypoxia or normoxia 
treatment.
20% 0 ? 1mm 20%Oj+TGF 1mm
r r m m m
1% 02 1mm 1%Oj+TGF 1mm
I I M iITTTl
Fig 5.7 Photography of equine chondrocyte pellets. First passage equine 
(fetlock) chondrocyte pellets were maintained in 20% 0 2, 20% 0 2 with TGF-P3 
(lOng/ml), 1% 0 2 and 1% 0 2 with TGF-P3. Pellets were photographed 
immediately upon removal from culture medium at 14 days. Scale bar =lmm.
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Pellet weight followed the trend of pellet size (Fig 5.8a). There was no 
TGF-03 effect on pellet weight but weight of hypoxic pellets were 
significantly increased compared to normoxic ones (p<0.001). Also pellets 
treated by hypoxia alone were significantly heavier than those treated by 
TGF-P3 alone. Differences in DNA content in each treatment were not 
significant although 1%C>2 pellets seemed to contain more DNA per pellet 
than 20%C>2 pellets (Fig 5.8b).
(a) (b)
I---------------------- — I
Fig 5.8 Comparison of weight and DNA content of first passage equine 
chondrocyte pellets (n=3). (a) weight and (b) DNA content of cultures maintained 
under normoxia (20%O2), normoxia with TGF-P3 (lOng/ml), hypoxia (1%02) and 
hypoxia with TGF-P3 (lOng/ml). The error bars represent SEM. ** p<0 01 • *** 
/><0.001.
2. GAG and total collagen synthesis
GAG and collagen content of pellets and medium were analysed by 
DMMB and hydroxyproline assays, respectively. In this experiment, only 
minimal differences between oxygen levels and TGF-P3 treatments were 
observed (Fig 5.9). For collagen synthesis, similar to the previous 
experiment, we observed no difference. GAG synthesis was not inhibited
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by hypoxia but seemed to be highest when the pellets were cultured in 
hypoxia without TGF-P3 treatment although this was not significant.
Fig 5.9 Deposition and release of GAG and collagen of first passage equine 
chondrocyte pellet cultures («=3). (a) GAG and (b) collagen deposition in 
comparing of culures maintained normoxia and hypoxia and with or without TGF- 
p3 supplement. Accumulative GAG and collagen release into tissue culture 
medium are also shown (c and d, respectively).
3. Quantification of collagen type II in pellet matrix by SDS-PAGE 
and staining with Coomassie blue
Coomassie stained proteins resolved by SDS-PAGE of pepsin digested 
first passage equine chondrocyte pellets («=3) were analysed using Scion 
Image software (Fig 5.10). Variation between animals was observed 
however, pellets cultured under hypoxia appeared to produce more type II 
collagen (Band A) than normoxia although this difference was not 
significant. TGF-P3 had no significant effect on collagen type II synthesis 
(Fig 5.11). Band B proteins in this study were not apparent. The levels of
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the bottom two bands (Band Cl and C2) were also measured (Fig 5.10) but 
were not altered in response to treatments (data not shown).
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Fig 5.10 Pepsin digested pellet («=3) protein separation on SDS-PAGE with 
Coomassie stain (left) and image analysis for intensity of each protein band by 
Scion Image (right). Samples loaded were equivalent volumes of pepsin digests of 
first passage equine chondrocyte pellets run alongside the porcine type II collagen 
marker. Samples were reduced with p-mercaptoethanol prior to electrophoresis.
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Fig 5.11 Comparison of intensity of type II collagen protein bands (Band A) on 
Coomassie stained SDS-PAGE gel (after analysis by Scionlmage) from pepsin 
digested pellets («=3) cultured under normoxia (20%O2), normoxia with TGF-P3 
(lOng/ml), hypoxia (1%02) and hypoxia with TGF-P3. The error bars represent 
SEM.
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4. Gene expression studies
Analysis of gene expression levels in the first passage equine chondrocyte 
pellets was performed by real-time PCR is shown in Fig 5.12. Surprisingly, 
the results were in contrast to the previous experiment. Expression of 
aggrecan core protein (agg) mRNA was not suppressed but was highest 
when the pellets were under hypoxia without TGF-P3 treatment and this 
correlated well with result of GAG deposition using DMMB assay. 
However, the significant difference on agg mRNA expression appeared 
only between pellets that were treated with TGF-P3 alone and those that 
were treated with hypoxia alone. Hypoxia showed the down-regulation 
effect on collal gene. TGF-P3 seemed to up-regulate coll a 1 but this was 
not significant. There was no significance in type II collagen (col2al) 
mRNA expression. Interestingly, it was clearly shown that hypoxia 
significantly up-regulated Sox9 expression, however, no TGF-P3 effect 
was found on this gene.
I l l
agg co lla i
Fig 5.12 Comparison of expression of genes involved in cartilage matrix 
synthesis, aggrecan core protein (agg), type II collagen (col2al), type I collagen 
(collai) and sox9, in first passage equine chondrocyte pellet (n= 3) cultured under 
normoxia (20%C>2), normoxia with TGF-03 (10ng/ml), hypoxia (1%C>2) and 
hypoxia with TGF-(33. The error bars represent SEM.* p<0.05; ** p<0 01 • *** 
/><0.001.
Discussion
Pellet culture was selected for use in this study as it was demonstrated that 
it stabilises chondrocyte phenotype and the matrix deposited is similar to 
native cartilage (Zhang et al. 2004). Oxygen is one important factor in 
cartilage tissue engineering due to the fact that cartilage, in vivo, is 
relatively hypoxic. Although chondrocytes are able to survive under a wide
1 1 2
range of oxygen tensions (Brighton et al. 1974; O'Driscoll et al. 1997; 
Grimshaw and Mason 2000; Schneider et al. 2004), atmospheric condition 
has been considered to be hyperoxic to chondrocytes. There is evidence of 
adverse effects of high oxygen tension on chondrocyte metabolism i.e. 
senescent changes (Nevo et al. 1988) and apoptosis (Schneider et al. 2004) 
possibly resulting from disturbance of oxidation-reduction status of the 
cells (Lotz et al. 1999). In contrast, low oxygen levels that mimic oxygen 
tensions within native cartilage have been reported to have beneficial 
effects on chondrocyte survival, phenotype stability and (re)differentiation; 
however, findings of hypoxic effects are controversial (see Table 5.1).
Our results also showed conflicting data. Hypoxia had no positive but 
rather negative effects on neo-cartilage synthesis in one experiment while it 
was able to induce matrix production in another experiment. By using 
pellet cultures of fresh equine chondrocytes isolated from femoro-patella 
joints, hypoxia appeared to inhibit GAG and type II collagen synthesis. 
This also correlated well with gene expression of agg, col2al and sox9. On 
the other hand, opposite findings were shown in another experiment using 
pellet cultures of first passage equine chondrocytes originally from 
metacarpo/tarsophalangeal joints. In the latter study, hypoxia increased not 
only pellet size and weight but also sox9 expression regardless of TGF 
treatment.
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It has been reported that chondrocytes in each zone of cartilage have 
different matrix production activities (Aydelotte et al. 1992). It is therefore 
possible that chondrocytes from mixed zones may cause variation in their 
response to stimuli including oxygen levels. Although, in both experiments 
described in this chapter, chondrocytes were collected from full-thickness 
cartilage, the two joints differ in articular cartilage thickness [average 
thickness stifle; 1.5-2 mm (Frisbie et al. 2006) and fetlock; 0.5-1 mm 
(Norrdin et al. 1999)] and may therefore contain different proportions of 
cells from each zone which could contribute to the differing results 
observed.
Another possibility which may equally affect chondrocyte responses is the 
passage of cells in monolayer prior to pellet culture. Previous reports have 
demonstrated the ability to regain the chondrocytic phenotype of cells 
previously dedifferentiated in monolayer culture before redifferentiation 
process is impaired (Murphy and Polak 2004; Darling and Athanasiou 
2005). It is possible that our equine chondrocytes were dedifferentiated 
during expansion stage and may have been unable to fully recover their 
phenotype to that of primary chondrocytes during the subsequent 
redifferentiation phase of pellet culture.
In general, hypoxia seemed to have greater effects, either positive or 
negative, on GAG synthesis than on total collagen production as measured 
by the hydroxyproline assay. However, the hydroxyproline assay
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determines total collagen synthesized by the pellets but is not specific to 
any types of collagen. To be more specific, analysis of type II collagen was 
performed by measuring the intensity of Coomassie stained protein bands 
on SDS-PAGE gels loaded with pellet protein extracted with pepsin. 
Pepsin cleaves the majority of non-triple helical collagenous proteins, 
including the non-collagenous termini (telopeptides) of collagen 
molecules. Hence, it releases and solubilises the triple-helical domains of 
collagen from the highly cross-linked telopeptide regions. Type II collagen 
bands were confirmed by comparison with a standard on SDS-PAGE, by 
mass-spectrometry and also, western blot. Image analysis of SDS-PAGE 
resolved protein revealed that although oxygen tension had not much effect 
on total collagens, type II collagen was responsive to hypoxia (again either 
positive or negative depending on the experimental design).
As the amount of total collagen was not disturbed by hypoxia, the question 
of what type of collagen compensated for the alteration of type II collagen 
deposition remains. There is a possibility that chondrocytes produced type 
I collagen to compensate for type II but this may only apply to the second 
experiment that showed a lower level of type II collagen but higher 
collagen type I gene expression under normoxia; this cannot explain 
chondrocyte behaviour in the first experiment. It should be noted that the 
alpha 1 chains of both type I and type II collagen co-migrate on SDS- 
PAGE, but no alpha 2 chain of type I collagen was detected, nor was type I
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collagen detected by mass spectrometry in the analyses. Perhaps more than 
one type of collagen should be considered when trying to account for the 
difference in collagen composition. Type VI collagen was identified by 
mass-spectrometry results but this type of collagen is a very large molecule 
(McDevitt et al. 1988) and unlikely to migrate as far as the position of the 
band that was indicated to be type VI collagen unless it has been degraded. 
However, the expression of type VI collagen should be one of the priorities 
for future cartilage synthesis study as it is abundant in pericellular matrix, 
which promoted neo-synthesis of cartilage matrix (Graff et al. 2003). It 
would also be interesting to investigate other types of collagen e.g. type IX 
and XI, which are involved in stabilization of type II collagen.
Our chondrocyte pellets were very small (~lmm in diameter) compared to 
previous reports. Zhang and co-workers (Zhang et al. 2004) demonstrated 
that chondrocyte pellets from sterna of chick embryos were approximately 
ten times larger in size (-9-10 mm in diameter). However, taking into 
account the reduced numbers of cells (20-fold less cells) used in the 
experiment described in this chapter, the pellet formation was actually 
comparable to theirs. However, difference in species, age or developmental 
stage of the tissue and pellet culture system should be considered.
In the study of interaction between TGF and hypoxia, we found that 
normoxia reduced pellet size and weight regardless of TGF treatment and 
that these two parameters correlated well with each other but were not in
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complete agreement with GAG content, which rather followed the trend of 
DNA content. The reduction of GAG content of normoxic culture was 
proportionately much less than the extent of reduction in pellet weight. It is 
known that weight of cartilage tissue is mainly from water trapped by 
GAG, however, difference in collagen fibre orientation between pellet 
culture and native cartilage (Zhang et al. 2004) also probably leads to 
difference in expansion capacity of the matrix. It was also possible that 
normoxia may alter fibre orientation within the pellets so that it does not 
allow ECM expansion while absorbing water despite GAG existing. The 
shape and appearance of normoxic pellets also support this speculation. 
Again, differences in fibrillar collagen may indicate altered collagen type.
TGF has been shown to regulate chondrocyte matrix synthesis (Glowacki 
et al. 2005) and a study has demonstrated an additive effect between a 
growth factor (FGF-2) and hypoxia on chondrogenic signals in meniscus 
cells (Adesida et al. 2006). So we hypothesised that we could find an 
interaction between TGF and hypoxia on chondrocytes. However, TGF 
had no significant effect on matrix synthesis in our study either under 
normoxia or hypoxia. A review by Trippel (Trippel 1995) has suggested 
that the response of chondrocytes to TGF is complex. The actions of TGF 
are varied and sometime opposite depending upon surrounding conditions. 
A study using bovine nasal cartilage found an increasing GAG turnover 
but not deposition after TGF treatment (Xu et al. 1996) while we observed
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no increase but rather decrease in both proteoglycan synthesis and release. 
However, for type II collagen deposition, both our and the previous studies 
showed similar findings that TGF had no effect. These support the finding 
that TGF effects can be unpredictable when the types of cells and/or 
culture conditions are changed. In addition, a study using mesenchymal 
stem cells indicated that TGF alone was not sufficient to induce 
chondrogenesis but was able to synergise with Sox-9, -5 and -6 proteins 
(Sox-trio) (Ikeda et al. 2004). The use of Sox-trio proteins in combination 
with TGF should be for a subject for further study as it is probably able to 
provide more promising results than TGF alone. In addition, It was shown 
that GAG synthesis in chondrocytes expanded in monolayer in the 
presence of a growth factor prior to seeding on scaffolds was increased 
(Martin et al. 1999; Martin et al. 2001). Therefore, alternatively, applying 
TGF treatment at the expansion phase of chondrocytes before pelleting 
should be considered for future study.
Finally, of course, we should consider the possibility that the use of 
recombinant human growth factors to stimulate cells from other species 
may not be reproducible. However, until recombinant equine growth 
factors become available for comparison, this question remains 
unanswered.
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Conclusion
The finding from our study in equine chondrocytes indicated that the 
effects of hypoxia on cartilage matrix neo-synthesis are generally 
equivocal. Oxygen tensions may promote cartilage matrix synthesis when 
chondrocytes have previously been dedifferentiated but inhibit such 
function in primary cells. TGF had effect neither on its own nor in 
combination with hypoxia. Hence, it is probably not the best 
chondroinductive factor for equine neo-cartilage synthesis. Chondrocyte 
behavior on matrix synthesis under different oxygen levels may seem 
complicated due to involvement of many factors. However, a number of 
considerations for further studies of the effects of oxygen levels include 
microscopic evaluation of the orientation of ECM substances, synthesis of 
other molecules related to ECM network e.g. type IX and XI collagens, 
decorin, biglycan etc., the effects of chondrocyte passage (from the same 
joint) and also interactions with other factors e.g. IGF or FGF. Our current 
data are interesting and suggest that exploring the contribution of these 
additional analyses in future studies would provide a more complete 
picture and help us to understand the role of hypoxia on cartilage matrix 
production and formation.
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C h a p t e r  VI
HIF-lALPHA PROTEIN EXPRESSION IN EQUINE 
CHONDROCYTES (PRELIMINARY STUDY)
Introduction
Hypoxia inducible factor (HIF) is a key regulator of cellular responses to 
hypoxia. Chondrocytes can modulate their oxygen consumption in 
response to hypoxia (Haselgrove et al. 1993) and remain viable even after 
prolonged culture in <0.1% 0 2 (Grimshaw and Mason 2000). It is possible 
that HIF may also play important roles in chondrocyte survival and 
maintenance of fundamental homeostasis in the normally hypoxic articular 
cartilage and may also be involved in maintaining chondrocytes in 
pathologic cartilage (Yudoh et al. 2005).
HIF-la is a short lived protein and the kinetics of HIF-1 a expression varies 
among different organs. In liver and kidney, as shown by immunoblot 
analysis, HIF-1 a reaches maximal levels after 1 hour and gradually 
decreases to baseline levels after 4 hours o f continuous hypoxia (Stroka et 
al. 2001). In the brain, however, H IF-la is maximally expressed after 5 
hours and declines to basal levels by 12 hours (Stroka et al. 2001). By 
immunohistochemistry, the HIF-la subunit was not detectable in normal 
human articular cartilage or benign cartilage tumours (Lin et al. 2004).
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However, chondrosarcoma cell lines and chondrocytes maintained under 
0.2% O2 expressed this a subunit after as little as 30 minutes of hypoxia 
and expression continued for at least 48 hours (Aigner et al. 2004).
HIF expression has been widely studied in tumours and cancer cells 
(Masson et al. 2001). Regulation of HIF-1 in many cancer cells is 
manipulated at the transcription level by cytokines and hormones (Déry et 
al. 2005) as well as some effects being observed at the post-translation 
level. However, this is not the case in the physiology of normal cells, 
including chondrocytes, in which HIF is mainly regulated post- 
translationally. Therefore, HIF studies in normal cells tend to focus on 
protein levels using antibodies, i.e. immunoblot and 
immunohistochemistry, to identify HIF protein expression. Also the 
electrophoresis mobility gel shift assay has been used to detect HIF DNA- 
binding activity after the protein is identified (Gamer and Revzin 1981).
So far, there has been no report of HIF protein expression in the horse. To 
study how equine chondrocytes function under hypoxia, HIF was 
potentially the first important key leading us to a better understanding of 
any physiological adaptation. This part of the study aimed to identify and 
compare the expression of HIF-1 a in equine chondrocytes in hypoxic and 
normoxic conditions. Human cell lines, prostate cancer (PC3) and 
chondrosarcoma (C28), were used as positive controls of HIF-1 a 
expression. PC3 have been reported to express this protein (Palayoor et al.
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2003) whereas there is no report for C28 but they are very similar to 
normal human chondrocytes in other regards. Although this initial part of 
the hypoxia study was not able to deliver clear answers due to the 
limitations of the detection techniques, there was some interesting 
information generated which may be useful for further HIF studies.
Materials and Methods 
Reagents
Anti-human HIF-la polyclonal antibody was from SantaCruz (SC-10790). 
Anti-human HIF-la monoclonal antibody was from BD transduction 
Laboratories (H72320-050). Sepharose 4B CNBr powder was from 
Pharmacia Fine Chemicals. Chondroitinase ABC (EC 4.2.2.4) was from 
SIGMA (C-3667). Trypsin EDTA was from Invitrogen (25300-054). For 
Western blotting, protein standards were SeeBlue® pre-stained standards 
from Invitrogen (LC-5925) and High weight range molecular markers from 
Sigma (M3788).
Tissue sources and cell cultures
Equine cartilage (aged 4-8 years) and muscle samples were derived from 
horses which were euthanased for clinical reasons. Isolated chondrocytes 
were cultured either in a 2-dimensional system as monolayers or in a 3- 
dimensional system as alginate bead cultures. Canine chondrocytes (from 
normal joints of dogs euthanased for clinical reason apart from joint 
diseases with the owner consent) in alginate bead cultures were provided
123
by Dr. Sue Bell. A human prostate cancer cell line (PC3) and a human 
chondrosarcoma cell line (C28) were cultured and used as positive controls 
for HIF-la protein expression. The cell lines were cultured only in the 
monolayer system because of their aggressive proliferation.
For hypoxia experiments, cells were cultured under 2-5% oxygen tension, 
which has been used to provide hypoxic conditions for chondrocyte 
cultures in many experiments (Grimshaw and Mason 2000; Hansen et al. 
2001; Domm et al. 2002; Richardson et al. 2003; Barry and Murphy 2004; 
Matsushita et al. 2004; Moussavi-Harami et al. 2004; Schneider et al. 
2004), or were cultured under 20% oxygen for normoxia control. A seven- 
day period was selected as the basic duration for all chondrocyte 
treatments, while the cell lines were cultured under such conditions no 
longer than 3 days to prevent their overgrowth. The viability of cells was 
checked in each culture system by the trypan blue dye exclusion method.
Nuclear extraction from equine muscle
All steps were performed at 2-8°C. Horse muscle (total 2 g) was diced into 
small pieces and each 0.5g tissue aliquot was mixed with 2.5ml low salt 
buffer (see Chapter II: nuclear extraction). The tissue was homogenised 
using a Dounce homogeniser. The muscle suspension was then centrifuged 
at 850g for 10 minutes at 4°C. After discarding the first supernatant, 
homogenisation with low salt buffer was repeated and the suspension was 
then centrifuged again at 15,000g for 3 minutes at 4°C to separate the
124
cytosolic fraction. After removed the cytosolic fraction, the sediment was 
re-suspended and homogenised with high salt buffer (see Chapter II: 
nuclear extraction) and agitated on ice for 2 hours before it was centrifuged 
at 15,000g for 5 minutes at 4°C. The supernatant, which contained the 
nuclear extract was collected and measured for protein content by Lowry’s 
protein assay (see Chapter II).
Immunoblotting
Whole cell lysates or nuclear proteins (see Chapter II) were extracted 
from alginate bead or monolayer cultures. In some experiments, samples 
were pre-treated with enzymes prior to SDS-PAGE. Chondroitinase ABC 
was applied in an experiment to test whether or not proteoglycan (produced 
by chondrocytes in alginate bead culture) interfered with protein resolving 
in PAGE gels. Cell lysate samples were treated with the enzyme (0.0075 
units per sample) and incubated at 37°C for 4 hours before sample buffer 
was added. Trypsin EDTA treatment was used in an experiment to 
eliminate remaining pericellular proteins of chondrocytes, after they had 
been liberated from alginate beads, which may interfere with protein 
migration on SDS-PAGE. Chondrocytes were pre-treated with or without 
trypsin EDTA (1:10 dilution in PBS), which was eventually neutralised by 
DMEM supplemented with 10%FCS, before the cells were washed with 
PBS and processed for nuclear extraction.
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Unless stated otherwise, for PAGE, 20pg of protein were loaded into each 
well of 7% vertical SDS-PAGE gels. SeeBlue® pre-stained standards 
(Invitrogen) were used as molecular weight markers and blot transferring 
controls on each blot while the Sigma high molecular weight range was 
used as dual standards in some experiments. DTT (5mg/ml) was added to 
the sample buffer in order to reduce disulphide bonds in the protein 
samples. The gels were run at 200V for electrophoresis and the resolved 
proteins were transferred to PVDF (Millipore) membrane using the Tris- 
Glycine buffer system at 150 V for 1 hour. Membranes were blocked by 
5% skimmed milk. Primary antibodies were HIF-la polyclonal antibody 
(SantaCruz) or HIF-la monoclonal antibody (BD transduction) (see 
Chapter II for antibody dilutions and secondary antibodies used in this 
study). The blots were developed by enhanced chemiluminescence (ECL) 
(see Chapter II).
Stripping and reprobing immunoblot
Immunoblots that had been developed using non-precipitating substrates 
such as ECL can be stripped and reprobed if  the blots are stored securely in 
PBS at 4°C (for long-term storage, a preservative such as 0.02%sodium 
azide may be considered). Thus, after immunodetection with one antibody, 
the blots were submerged in stripping buffer (lOOmM 2-mercaptoethanol, 
2%SDS, 62.5mM Tris-HCl pH 6.8) and incubated at 50°C for 30 minutes 
with gentle agitation. The membrane was washed two times each for 10
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minutes with PBST. Probing new antibodies were then used as previously 
described.
HIF-la separation by affinity chromatography
To purify putative HIF-la protein detected in immunoblots, affinity 
chromatography was performed. Samples were prepared from 2 sources; 
7.5pg and 175jag ofnuclear extracts and cytosolic fractions respectively of 
equine chondrocytes in alginate beads (approximately 1 million cells) and 
1.2mg and 6mg of nuclear extracts and cytosolic proteins respectively from 
equine muscle (2g). Samples were diluted in PBS to make up to 4 ml each.
Sepharose 4B CNBr powder was transformed to a semi-solid gel by adding 
an excess of 0.1M NaHC03, pH 9.0. After leaving the gel to swell 
properly, 160pg of anti-HIF-la polyclonal antibody (SantaCruz) was 
applied for coupling with 5 ml of gel at room temperature overnight on a 
roller mixer. Non-ligated CNBr sites on the Sepharose gel were blocked by 
50mM glycine in 0.1M NaHC03, pH 9.0 for 2 hours at room temperature. 
0.1M sodium formate pH 3.0 and 5mM NaHC03 were respectively used 
for washing the gel over a sintered glass funnel under suction. After that, 
the Sepharose gel was transferred into the 10 ml syringe cylinder which 
was connected to a pump and rinsed with PBS at 140 drops (~lml) per 
fraction. Each subsequent equine samples were then loaded to the system 
separately and incubated on the gel matrix for 30 minutes at room 
temperature. Non-binding proteins were run through the column with
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excess PBS. The bound proteins were eluted with 5 mM NaOH pH 11.2 
and neutralized with 0.7M TrisHCl pH 7.8 at 1:10 dilution. The eluted 
fractions were collected and measured by a spectrophotometer at 280 nm 
wavelength. Pooled fractions containing each peak of protein were 
measured by a spectrophotometer (for protein content) and were run on 7% 
SDS-PAGE gels and transferred to PVDF membrane prior to probing with 
anti-HIF-la polyclonal antibody (SantaCruz) in an attempt to identify 
purified or enriched HIF-1 a.
Results
Immunoblot
The PC3 cell line has been previously shown to express HIF-1 a (Goda, 
2003). Therefore, these cells were chosen to be a positive control. 
However, our ECL immunoblot using anti-HIF-la polyclonal antibody 
(SantaCruz) results showed positive immunoreactive bands migrating at 
approximately 55-64 kDa instead of 120 kDa as identified in previous 
reports. The chondrosarcoma cell line (C28) also showed positive 
immonoreaction at 55 kDa but to a much lesser extent. In contrast, equine 
chondrocytes in alginate beads cultures showed intense but diffuse bands 
migrating at approximately 148-250 kDa (Fig 6.1). Equine chondrocytes in 
monolayer cultures also expressed 55-60 kDa proteins reactive with HIF- 
la  antibody similar to C28 and PC3 (Fig 6.2). Different oxygen level 
treatments (20% and 2% 02 or 20% and 5%Q2) did not have a significant
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effect on HIF-la immunoblot results (Fig 6.1 and 6.2). Using DTT to 
reduce the disulphide bonds in samples did not change the appearance of 
immunoreactive bands compared to unreduced samples (Fig 6.3). Positive 
reactions of around 90-120 kDa protein were found in samples from canine 
chondrocytes in alginate bead cultures (Fig 6.4). Sample treated with 
trypsin EDTA in this experiment did not show different results compared 
to untreated samples. There was no non-specific reaction from the 
secondary antibody in any cell culture samples. However, unexpectedly, 
non-specific reactions of HIF-la polyclonal antibody (SantaCruz) were 
detected with Sigma standards (Fig 6.4).
Equine chondrocytes Equine chondrocytes 
(alginate beads) (monolayers)
20%O, 5%Oj 20%O2 5%Oj  20%02 5%02 20%O2 5%Oj
Fig 6.1 Western blot chemiluminescence; immunoreactivity of anti-HIF-la 
with nuclear extracts (20pg; unreduced) from samples cultured under 20% or 5% 
0 2. Samples were equine chondrocytes in alginate bead and monolayer cultures, 
prostate cancer cell line (PC3) and human chondrosarcoma cell line (C28) 
maintained either under 20% or 5% 0 2 for 1 week for equine chondrocytes and 
for 3 days for PC3 and C28 cell lines.
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Fig 6.2 Western blot chemiluminescence; immunoreactivity of anti-HEF-la with 
whole cell lysates (20pg; unreduced) from samples cultured under 20% 0 2 or 2% 
0 2. Sample were equine chondrocytes in alginate bead, prostate cancer cell line 
(PC3) and human chondrosarcoma cell line (C28) maintained under 20% 0 2 or 
2% 0 2 for 1 week for equine chondrocytes in alginate beads and 3 days for PC3 
and C28 cell lines.
Eq uin e  chondrocytes
(alginate b ea ds) C 2 8  P C 3
22 -----
Fig 63  Western blot chemiluminescence; immunoreactivity of anti-HIF-la with 
whole cell lysates (20pg) with or without disulfide reduction. Samples were 
equine chondrocytes in alginate bead culture, C28 and PC3 maintained at 2% 0 2 
for 1 week for equine chondrocytes and for 3 days for C28 and PC3 cell lines. 
Reduced samples were treated with 5mg/ml DTT and boiled for 4 minutes before 
loading on the SDS-PAGE.
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Fig 6.4 Western blot chemiluminescence; immunoreactivity of anti-HIF-1 a with 
nuclear extract (20 pg; unreduced) of canine chondrocytes in alginate beads 
(provided by Dr. Sue Bell) previously treated with or without 1:10 trypsin EDTA 
(Invitrogen) in sterile PBS after being liberated from alginate beads. Trypsin was 
neutralised by DMEM supplemented with 10% FCS before the cells were washed 
with PBS and processed for nuclear extraction. Non-specific binding of HIF-la 
polyclonal antibody to the Sigma molecular weight marker (high weight range) is 
also shown.
It was possible that these very high molecular protein bands which 
consistenly appeared in alginate bead samples resulted from protein 
migration blockage by proteoglycans, which would have been produced 
during the 3-dimensional culture. To eliminate proteoglycans, samples 
from alginate beads were treated by chondroitinase ABC at 37°C for 4 
hours before loading on to the electrophoresis gels. However, the result 
remained similar between chondroitinase-treated and untreated samples 
(Fig 6.5).
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Fig 6.5 Western blot chemiluminescence; immunoreactivity of anti-HIF-la 
polyclonal antibody with whole cell lysates of equine chondrocytes in alginate 
beads with or without chondroitinase ABC treatment. Cultures were maintained 
under 20% O2 or 2% O2 for 1 week. The whole cell lysates (20pg) were incubated 
with a 1:10 dilution of chondroitinase ABC in PBS at 37°C for 4 hours before 
loading on SDS-PAGE with sample buffer.
Anti-HIF-la antibody (BD transduction) was applied as an alternative 
antibody which might potentially give a more specific reaction with HIF- 
la  protein than the polyclonal antibody. An immunoblot, previously 
probed with polyclonal antibody, was stripped (No remaining 
immunoreaction was found by ECL after stripping) and reprobed with 
monoclonal antibody. The binding reaction of the monoclonal antibody 
differed from that obtained previously with the polyclonal antibody. 
Alginate bead samples had no reaction with this antibody at all while 
chondrocyte monolayers and the C28 cell line expressed bands at around
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55 kDa. However, the antibody gave non-specific reaction with samples of 
the PC3 cell line (Fig 6.6).
Equine chondrocyte 
(alginate beads) 
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Equine chondrocyte 
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(a)
Equine chondrocyte 
(monolayers)
20%0j « O j  C28 PCS
(b)
Equine chondrocyte 
(monolayers)
20%Oj 9%0,  C26 PCS
Fig 6.6 Western blot chemiluminescence; comparing immunoreactivity of anti- 
HIF-la polyclonal antibody (1:200 dilution; SantaCruz) and anti-HIF-la 
monoclonal antibody (1:250 dilution; BD transduction). Whole cell lysates (20pg; 
unreduced) were prepared from equine chondrocyte in alginate bead and 
mononalyers maintained either in 20% O2, 5% 0 2 or 2% 0 2) PC3 and C28 cells 
were cultured in 5% 0 2. (a) immunoreaction of anti-HIF-la polyclonal antibody. 
The blot was stripped and re-developed with ECL to ensure complete elimination 
of the remaining activity after stripping. The blot was reprobed with anti-HIF-la 
monoclonal antibody. The result of monoclonal antibody is shown in (b).
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HIF-la purification
Affinity chromatography was used in an attempt to purify or concentrate 
putative HIF-la protein identified in immunoblots. Unfortunately, 
beginning with very small amounts of nuclear protein prepared from 
chondrocyte cultures resulted in fractions too dilute to detect any peaks of 
protein (data not shown).
Potential sources of equine HIF-la positive control were then considered. 
Although there has been no report of HIF-la in the horse, positive HIF-la 
expression in mouse muscle (Stroka et al. 2001) suggested that horse 
muscle may be useful source of equine HIF-la. Therefore, horse muscle 
was collected and prepared for nuclear proteins. Affinity chromatography 
using anti-HIF-la polyclonal antibody was performed. The pooled 
fractions from each peak were analyzed by western blot 
chemiluminescence. Unfortunately, there was non-specific 
immunoreactivity of the anti-rabbit IgG, which was used as the secondary 
antibody, with horse muscle extracts (Fig 6.7).
134
(a) (c)
SIGMA P1 P2 S ee Blue9 P3 P4
(b) (d)
Fig 6.7 HIF-la affinity chromatography of nuclear (a) and cytosolic (b) protein 
fractions from equine muscle extracts using anti-HIF-la polyclonal antibody. 
Samples from pooled fractions of each peak (nuclear extract : PI = fraction 4-10; 
P2 = fraction 15-30, cytosolic fraction: P3 = fraction 34; P4 = fraction 6-7) of 
chromatography were run on SDS-PAGE along with SIGMA (high molecular 
weight range) and SeeBlue® markers and followed with ECL immunoblot (c). 
Secondary antibody control is also shown (d).
Discussion
Using anti-human HIF-la polyclonal antibody, canine chondrocytes in 
alginate beads were the only cell type in our study that expressed protein 
bands close to expected molecular weight (~120 kDa) for HIF-la. Equine
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chondrocytes in alginate bead cultures consistently showed much larger 
proteins detected on immunoblots while monolayer cultures of equine 
chondrocytes and PC3 and C28 cell lines showed protein bands of much 
lower molecular weight. Apart from these variations in molecular weight, 
we also observed no oxygen regulation of the proteins that had positive 
reaction with this antibody. Absence of non-specific reaction from the 
secondary antibody indicated that the reactions were entirely from this 
HIF-la polyclonal antibody.
A study by Chun and his colleagues (2002) identified a human HIF-la 
splice variant protein, H IF-la516 (60-75 kDa) which was not regulated by 
oxygen levels (Chun et al. 2002). Although alginate bead cultures were 
unlikely to express this H IF-la form because the protein bands were much 
higher in molecular weight, it was possible that our monolayer cultures 
expressed this splice variant of HIF-la. If so, this may indicate preferential 
expression of the lower molecular weight variant by cells cultured in 2- 
dimension (monolayer) system.
However, to date, there is no report of any HIF-la isoform that is larger 
than 120 kDa. We thought that the very high molecular weight protein 
expressed by equine chondrocytes in alginate beads was possibly from 
binding between HIF protein and proteoglycan or pericellular proteins 
produced by 3-D cultured chondrocytes but this was ruled out following
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digestion using chondroitinase (for PG) and trypsin EDTA (for pericellular 
protein).
Affinity chromatography using the HIF-1 polyclonal antibody with equine 
muscle nuclear proteins was able to detect 120 kDa bands. Unfortunately, 
there was, to some degree, non-specific binding from the secondary 
antibody with these extracted muscle proteins. If the HIF-1 a antibody had 
reacted with HIF-1 a in equine muscle extracts, it could have confirmed 
that HIF-1 a with molecular mass of 120kDa was not expressed by equine 
chondrocytes. However, the non-specific reaction of the antibodies limited 
the ability to confirm HIF-1 a expression in horse muscle.
It is also possible that the protein bands detected in our immunoblots were 
not HIF-1 a. The 120 kDa HIF-1 a  may have been expressed in equine 
chondrocytes in undetectable level or was not expressed at all. There are 
several reasons why HIF-1 a may be absent in our experiments. First, the 
seven-day duration of hypoxic treatments in chondrocytes may be long 
enough to drive chondrocytes back to a basal stage as they are in cartilage 
where HIF-1 a may be undetectable (Lin et al. 2004). Second, HIF-1 a is a 
short lived protein. A  study demonstrated in vitro that nuclear HIF-1 a 
protein level was rapidly decreased within 4-8 minutes upon reoxygenation 
(Groulx and Lee 2002). In our experiment, reoxygenation conditions were 
unavoidable, especially during harvesting procedures which took more 
than 5 minutes, unless the fully hypoxic system was used. Third, it is also
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possible that the chondrocytes may preferentially express other a-subunits 
such as HIF-2a, which was reported to play a dominant role in hypoxic 
chondrocyte gene regulation studies (Lafont et al. 2007), than HIF-la. If 
these statements are true in our experiments, the results could be indicating 
just the non-specific reactions from HIF-la antibodies. It is unfortunate 
that the two anti-human HIF-la antibodies we had available were unable to 
detect this molecule in the horse. Maybe there are significant species 
differences in HIF-1 a protein structure or the levels of expression are much 
lower in the horse.
Conclusion
HIF-1 a has been considered to be a key factor regulating cellular 
homeostasis under hypoxic conditions. Attempts to identify HIF-1 a in 
equine chondrocytes and human cell lines revealed some interesting data 
although HIF-la expression in these cells was not positively confirmed in 
our studies, probably due to limitations in the available detection reagents. 
Consistent appearances of protein bands in each culture type may indicate 
variation of positive HIF-1 a protein expressions at least between 2- 
dimension and 3-dimension systems. However, those proteins may not be 
the wild type HIF-1 a  as they were not hypoxia regulated. Apart from HIF- 
1 a, other subunits should be included in the studies of the hypoxia effect.
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C h a p t e r  V I I
GENERAL DISCUSSION
Low oxygen supply causes severe damage to vascularised organs e.g. 
brain, heart, liver, etc. but this does not occur in non-vascularised tissues 
including articular cartilage. The avascular nature of this tissue provides a 
relatively hypoxic and low-nutrient habitat for chondrocytes. However, the 
level of oxygen that may be defined as ‘hypoxia’ for highly vascularised 
tissues may not be able to be applied to articular cartilage. Oxygen tension 
within cartilage is estimated to be as low as 1% although the exact 
concentration has never been confirmed. For this reason, in this study 1% 
oxygen was chosen to represent oxygen tension of cartilage in vivo 
throughout our in vitro studies.
In pathologic joints, oxygen levels can fluctuate (Blake et al. 1989) and 
tend to be lower than in normal joints (Pfander and Gelse 2007). Although 
oxygen supply may increase following neo-vascularisation within the 
inflamed joint tissues or because of increasing diffusion through cartilage 
fissures, there may be a higher metabolic demand of chondrocytes in these 
conditions. Scar formation after inflammatory processes in synovial 
membrane may lead to an increased thickness of the overall synovial 
membrane and an increased distance between vascularised synovial tissue
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and articular cartilage, and thus could lead to oxygen insufficiency to 
chondrocytes and the tissue may be exposed to ‘pathologic hypoxia’. 
Again, the oxygen concentration within pathologic cartilage has never been 
precisely identified. Due to a lack of information of precise oxygen levels 
which define physiological and/or pathological hypoxia of chondrocytes, 
the term ‘hypoxia’ used to describe our studies is considered equivalent to 
1% oxygen (unless stated otherwise).
Maintaining metabolic energy is necessary for every cell type, including 
chondrocytes in order to survive and function properly. It has been 
reported that chondrocytes are able to manage cellular energy efficiently 
even in oxygen scarce environments (Rajpurohit et al. 1996). Our results 
(Chapter III) confirmed their ability to adjust their glucose transportation, 
which is the first step of glucose utilisation, when they were cultured in 
low oxygen conditions, by increasing GLUT1 and glucose uptake, possibly 
to compensate for low ATP production by the glycolytic pathway. 
Chondrocytes are known to use anaerobic glycolysis as the major energy 
generating pathway (Lee and Urban 1997); however, it was shown that 
they switched towards oxidative phosphorylation when they were grown as 
monolayers (Heywood and Lee 2008). The present glucose uptake assay 
has a limitation in that it can be applied only to monolayer cultures. 
Therefore, it is difficult to confirm that our findings reflect the actual 
metabolic reaction of chondrocytes under hypoxia in vivo. An assay which 
is applicable in 3-D cultures, that allows maintenance of chondrocytic
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phenotype to that seen in native cartilage, would be useful in this regard. In 
addition, to confirm chondrocyte ability to maintain cellular energy under 
hypoxia, other factors involved in glucose metabolism pathway apart from 
glucose transportation, eg. glucose utilisation by hexokinase or lactate 
production, should be included in future studies.
It is known that glucose is not only important for ATP production but also 
is the substrate for synthesis of UDP-hexoamine and UDP-glucuronic acid 
(Qu et al. 2007) which are important components of GAGs. If  the 
investigation of glucose transportation using monolayer culture in this 
study reflected what occurs in native cartilage or 3-D cultures, it is possible 
that increasing glucose transportation under hypoxic environments may not 
only be important for energy maintenance but also for matrix synthesis, 
which is more favourable in chondrocytes in 3-D than in monolayer 
cultures. However, our findings, in a matrix synthesis study, cannot 
confirm a greater GAG production in chondrocyte pellet cultures although 
monolayer culture revealed increased glucose uptake under hypoxia. This 
could mean that enhanced glucose transportation is probably used mainly 
for energy maintenance rather than matrix production. This is still yet to be 
explored in a culture system where phenotype is maintained and which is 
amenable to the investigation of both glucose utilisation and matrix 
synthesis.
The pathological conditions of articular cartilage in vivo were mimicked by 
catabolic induction using various human recombinant proinflammatory
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cytokines (Chapter IV). Here we have, for the first time, investigated the 
effect of oxygen levels on cytokine-induced cartilage matrix degradation. 
The results showed that there was no significant alteration of GAG and 
collagen degradation of cytokine-induced cartilage explants comparing 
between 20% and 1% O2. Nonetheless, hypoxia resulted in a trend of 
reduction of TNF-induced MMP-13 activity. The possibility of catabolic 
involvement under low oxygen condition by other MMPs, such as MT1- 
MMP and other collagenases (MMP-1 and MMP-8) was suggested (see 
Chapter IV). However, measuring MMP-13 activity using the available 
fluorogenic substrate is not entirely specific for MMP-13. MMP-1 and 
MMP-8 have been shown to cleave this substrate but at lower rates 
(Knauper et al. 1996 a). Therefore, it has to be accepted that there might be 
interference from other MMPs secreted from cartilage explants in this 
assay. This could have been excluded by using a specific MMP-13 
inhibitor (Johnson et al. 2007).
Measurement of TIMPs were also included in the study but only at the 
mRNA level as an attempt to study TIMP protein and activity by reverse- 
zymography using MMP-2 and MMP-9 (generated from canine cell lines) 
was not successful (data not shown)/It may be that equine TIMPs are not 
able to inhibit canine MMPs. For this reason, the balance between MMPs 
and their inhibitors under hypoxia are not yet fully understood.
Interestingly, from this study (Chapter IV), we found that rhTNF-a is the 
most effective cytokine inducing changes in equine cartilage compared to
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the rest of our cytokine panel (IL-1, OSM and combined IL-1 and OSM) 
because it was able to degrade not only GAG but also collagen in cartilage 
explants through increased MMP-13 production and activation. This 
finding is even more interesting when comparing the response of our 
equine cartilage explants to cartilage explants of other species, i.e. human 
and bovine, from previous reports (Elliott et al. 2001; Hui et al. 2001; 
Morgan et al. 2006). In these studies, human and bovine cartilage explants 
responded well to IL-1 and even better to the IL-1/OSM combination. The 
explanation for this species variation is still not known. However, it is 
unlikely that human recombinant IL-1 and OSM were not able to bind to 
the receptors on equine chondrocyte membrane as it was clearly shown 
that we could trigger the successful induction of GAG degradation by all 
human recombinant cytokines including IL-1 and OSM. It may be that 
equine chondrocytes react differently in cytokine signalling pathways in 
collagen degradation; this requires further investigation.
TNF-a is known to be able to stimulate intracellular IL-1, which progresses 
subsequent catabolic pathways (Verbruggen et al. 2007). It is possible that 
human-recombinant TNF-a triggered the intracellular equine IL-1 and 
started the cascades of protease activity to degrade collagen. To study this, 
an IL-1 antagonist would be useful for indicating the role of intracellular 
IL-1 in conjunction with rhTNF-a. A study in human OA cartilage has 
demonstrated that blockade of TNF-a and IL-1 using their antagonists 
could suppress MMP-1, -3 and -13 and therefore reduce type II collagen
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degradation and GAG release (Kobayashi et al. 2005). If collagen 
degradation by rhTNF-a in our cartilage explant model represented an 
important role for native equine TNF-a catabolic pathways in vivo, it 
would also be interesting to investigate the effect of TNF-a antagonist in 
clinical equine OA studies.
Adult articular cartilage has a very slow repairing process once it is injured 
(Eyre et al. 2006). For this reason, regeneration of this tissue is almost 
impossible. Cartilage tissue engineering is one of the potential approaches 
to regenerate a homogeneous and functional cartilage matrix. However, 
over the last decade, there has been an issue whether or not the 
atmospheric oxygen tension which has been used in chondrocytes cultures 
in vitro is suitable for cartilage neo-construction that is to be clinically 
applied. The outcome for this debate is still unclear and controversial both 
from literature surveys and from the results of our studies. In Chapter V, 
we observed the differing anabolic responses of chondrocytes (pellet 
cultures) from different joints and with differing numbers of passages. 
Although the actual cause of these confounding findings is not identified, 
there is one possibility that should not be overlooked. Oxygen gradients 
may have been generated within the pellets and chondrocytes in the same 
pellet may be exposed to different oxygen concentrations while the 
parameters were assessed as an average. Moreover, using gas phase 
oxygen intervention has a limitation in that it is difficult to confirm the 
actual oxygen level that the cultures are exposed to after diffusion through
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liquid medium (Malda et al. 2004 b). Taken together, the possibility that 
chondrocytes were exposed to heterogenous oxygen levels may be one of 
the causes of these inconsistent findings. And it would be interesting to 
know if the HIF expression pattern in each pellet zone could help to 
identify the oxygen situation within the chondrocyte pellets or other 3-D 
constructs.
The recombinant human TGF-P used in our equine cartilage matrix 
synthesis experiments appeared not to be effective although it has been 
reported to have chondroinductive effects on human mesenchymal stem 
cells (Fan et al. 2008) and chondrocytes from other species (Glowacki et 
al. 2005; Byers et al. 2008). It could be that species variation is an issue, in 
that recombinant human TGF-P3 may not bind to its receptors on equine 
chondrocytes or it could be that the concentration of 10 ng/ml TGF-P3 was 
too high. One study reported that high concentrations (5 and 10 ng/ml) of 
TGF-P 1 provided the best matrix stimulatory effect on a 3-D constructed 
equine chondrocytes at 7 days of culture period but at 14 days (the same 
observation point as our study) a lower concentration (1 ng/ml) delivered 
more effective stimulation (Fortier et al. 1997). We do not know whether 
or not this situation also occurs with TGF-P3 but it will be an interesting 
issue for the future studies. In addition, recently, a study using bovine 
chondrocytes on a 3-D construct has reported reproducible and rapid 
matrix production by using a transient application of TGF-P3 (Byers et al.
2008), which would reduce time and cost in chondrocyte cultures for
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matrix synthesis studies compared to continuous TGF-03 stimulation and 
may also be applicable to equine chondrocyte cultures.
Hypoxia inducible factor (HIF) is considered a key protein regulating cells 
under oxygen scarce environments (Wenger 2000). It was included in this 
study because it could have been a key mediator and explained the data 
from the studies of glucose transportation and matrix degradation and 
synthesis under hypoxia. Although a number of studies were able to 
identify HIF-la protein expression (Stroka et al. 2001; Lin et al. 2004; 
Yudoh et al. 2005), we found equine proteins that interacted positively 
with HIF-la antibodies but could not confirm its identity in equine 
chondrocytes (Chapter VI). Perhaps chondrocytes express HIF-la in 
undetectable levels or there may be a lack of cross reaction between the 
relevant equine epitope and the antibodies. It is also possible that HIF is 
rapidly destroyed during the harvesting processes under atmospheric 
condition. This may be prevented by using a full hypoxic system that 
allows hypoxic maintenance from harvesting of cartilage throughout the 
culture experiments or by using HIF stabiliser e.g. dimethyloxalylglycine 
(DMOG) which can inhibit prolyl-hydroxylases (Irwin et al. 2007).
In retrospect, it would have been valuable to explore the upregulation of 
HIF-2a and its role in the regulation of responses to hypoxia. Recent 
studies (Lafont et al. 2007) have shown that the long-term hypoxic
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induction of chondrocyte phenotype is driven by sustained upregulation of 
HIF-2a. This would be very interesting to investigate further in the horse.
Overall, although the key protein regulating cells under hypoxia, HIF, 
could not be identified, this thesis has demonstrated the ability of 
chondrocytes to manage energy balance under hypoxic conditions and this 
is supportive of the hypothesis. However, hypoxia did not result in 
antagonising matrix catabolism. Indeed it has no significant effect in this 
regard and hypoxia could not provide a promising positive outcome in 
matrix production. Based on the findings from this study, there is not 
enough evidence to confirm that there is a real benefit of low oxygen 
tension being applied in chondrocyte culture systems.
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ABSTRACT: Articular chondrocytes exist in an environment lacking in oxygen and nutrients due to the avascular nature of cartilage. The 
main source of metabolic energy is glucose, which is taken up by glucose transporters (GLUTs). In diseased joints, oxygen tensions and 
glucose availability alter as a result of inflammation and changes in vascularisation. Accordingly, in this study we examined the effects of 
hypoxia and the hypoxia mimetic cobalt chloride (CoCl2) on glucose transport in equine chondrocytes and compared expression of the hypoxia 
responsive GLUT1 gene in normal and diseased cartilage. Monolayers of equine chondrocytes were exposed to 20% 0 2, 1% 0 2, CoCl2 (75 pM), 
or a combination of 1% 0 2 and CoCl2. Glucose uptake was measured using 2-deoxy-D-[2,6-3H] glucose. GLUT1 protein and mRNA expression 
were determined by FACS analysis and qPCR, respectively. GLUT1 mRNA expression in normal and diseased cartilage was analyzed using 
explants derived from normal, OA, and OCD cartilage. Chondrocytes under hypoxic conditions exhibited a significantly increased glucose 
uptake as well as upregulated GLUT1 protein expression. GLUT1 mRNA expression significantly increased in combined hypoxia-CoCl2 
treatment. Analysis of clinical samples indicated a significant reduction in GLUT1 mRNA in OA samples. In OCD samples GLUT1 
expression also decreased but did not reach statistical significance. The increase in glucose uptake and GLUT1 expression under hypoxic 
conditions confirms tha t hypoxia alters the metabolic requirements of chondrocytes. The altered GLUT1 mRNA expression in diseased 
cartilage with significance in OA suggests th a t reduced GLUT1 may contribute to the failure of OA cartilage repair. © 2008 Orthopaedic 
Research Society. Published by Wiley Periodicals, Inc. J  Orthop Res
K eyw ords: equine chondrocyte; GLUT1; hypoxia; osteoarthritis; osteochondritis dissecans
Articular cartilage is an avascular tissue. N utrients and 
oxygen are delivered by diffusion from blood vessels of 
the under lying bone and from the synovial fluid.1 The 
oxygenation gradients w ithin the tissu e have been  
estim ated to be 6-10%  at the articular surface to less  
than 1% O2 at the deepest layer.2“7 However, chon­
drocytes appear to adapt very w ell to oxygen and 
nutrient limited environments.8 Both anabolic activity and 
cell survival of chondrocytes were found to be maximized 
when they were cultured in vitro under low oxygen tensions 
compared to normoxic and anoxic conditions.9-12
The m ain source of metabolic energy in chondrocytes 
is glucose,13 which is  taken up by a fam ily of substrate  
specific m em brane proteins known as glucose trans­
porters (GLUTs). GLUT isoforms differ in their sub­
strate specificity, tissu e distribution, and cellular 
localization. Articular chondrocytes and intervertebral 
disc cells express a number of glucose transporter 
proteins including GLUT1, GLUT3, and GLUT9.14 
GLUT1 and GLUT3 are hypoxia responsive isoform s15 
that are regulated by the transcription factor and oxygen  
sensor protein, hypoxia-inducible factor 1 (HIF-1).16,17
Chondrocytes generate energy m ainly by anaerobic 
glycolysis,1 which produces 1 8 -1 9  tim es less ATP per 
molecule o f glucose than aerobic respiration.18 There­
fore, chondrocytes m ust be able to m anage glucose 
transport and m etabolism  effectively to provide suffi-
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cient energy w ithin  the constraints o f w hat is available in  
cartilage. Recent stud ies19,20 have shown that chondro­
cytes are capable of m aintaining their m etabolic balance 
w hen deprived of glucose or exposed to the hypoxia  
m im etic cobalt chloride (CoCl2).
Osteoarthritis (OA) leads to progressive and perm a­
nent loss of articular cartilage. Joint injury, the major 
cause of OA in horses,21 leads to synovial effusion and 
increasing vascularization in response to inflam m ation  
and healing processes, and th is m ay disturb or alter the  
oxygen supply w ithin the synovial environm ent.22 
Osteochondritis d issecans (OCD) is categorized as a 
developm ental orthopedic disease, involving a failure of 
endochondral ossification, which is associated w ith  a 
failure of vascular invasion from the subchondral bone 
and leads to developm ent of cartilage lesions that can 
become detached at a later date.21 The isch em ia -  
reperfusion from the neovascularization process in 
traum atic jo ints before OA developm ent22 and the 
ischem ic necrosis of the subchondral bone during OCD 
formation m ay cause fluctuations in  oxygen levels and 
resu lt in m etabolic im balance by disturbing glucose 
transport.
The aim of th is study w as to test the hypothesis that 
chondrocytes are able to adapt their energy m etabolism  
under hypoxia, u sing low oxygen (1% 0 2) or exposure to a 
hypoxia m im etic (cobalt chloride). We also investigated  
w hether expression of a key hypoxia responsive glucose 
transporter (GLUT1) varied in normal cartilage compar­
ing to degenerative cartilage, such as found in osteo­
arthritis (OA) and osteochondritis dissecans (OCD).
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MATERIALS AND METHODS
Reagents
All tissue cu ltu re  reagen ts w ere from Invitrogen (Carlsbad, 
CA). Polyclonal antibodies against GLUT1 w ere donated by 
Dr. S.A. B aldw in (U niversity of Leeds, UK). The GLUT1 
antiserum  w as developed in  rabbits against th e  C -term inus of 
rat-G LU Tl (residues 477-492). We have previously confirmed 
th a t this GLUT1 antibody recognizes GLUT1 across a diverse 
number of m am m alian  species including ra ts , hum ans, dogs, 
sheep, and horses.23,24 In  th is  study we used th is  GLUT1 
antibody in  W estern  blots of equine chondrocyte lysates to 
confirm positive im m unoreactivity w ith a  band  m igrating  a t 
45-50 kD a (the expected m olecular w eight for GLUT126) (data 
not shown).
Cartilage Source
Samples w ere collected in  accordance w ith  institu tional 
guidelines w ith  eth ical review  consent and  w ritten  informed 
consent from th e  anim al owners. N orm al equine articu lar 
cartilage w as obtained from the  trochlear ridges and  m edial 
femoral condyles of th e  fem ur of horses aged betw een 2 -  
12 years old, eu thanased  for un re la ted  clinical reasons a t the 
Philip Leverhulme Large Animal Hospital, U niversity of Liver­
pool. OCD cartilage biopsies were harvested from th e  lateral 
trochlear ridge of th e  fem ur (LTRF) from five OCD horses (aged 
4 -7  years) during therapeutic arthroscopic debridem ent of the 
lesions. OA cartilage biopsies were harvested immediately 
postmortem from th e  medial femoral condyle of eight horses 
th a t were eu thanased  as a  consequence of lam eness due to 
severe osteoarth ritis of th e  m edial fem orotibial jo in t w ith 
confirmation of OA by gross postm ortem  and  histological 
analysis in  a ll cases. W here tissue w as harvested  for mRNA 
isolation, th e  cartilage w as placed in  R N A later™  and  then  
transferred  on ice to th e  laboratory for fu rth er processing.
Chondrocyte Isolation and Culture
Cartilage w as rinsed w ith  Dulbecco’s modified Eagles m edium 
(DMEM) w ith  300 units/m L  penicillin G sodium, 300 pg/mL 
streptomycin, and  7.5 pg/mL am photericin B, cu t into sm all 
pieces, and digested overnight w ith  0.1% type I collagenase 
(EC 232.582.9 from C ld s tr id iu m  h is to ly tic u m )  a t  37°C. Isolated 
cells were w ashed and  cu ltu red  as a  monolayer in DMEM w ith 
1 g/L glucose, L-G lutam ine, and pyruvate, supplem ented w ith 
10% fetal calf serum , 100 units/m L penicillin G sodium, 100 pg/ 
mL streptom ycin, and  2.5 pg/mL am photericin B. All cell 
culture experim ents w ere perform ed on first passage chon­
drocytes (the first passage after th e  expansion phase in 
monolayer; cells w ere seeded a t 5000 cells/cm2) and  used in 
experiments w hen they  w ere approxim ately 80% confluent 
(estimated by ligh t microscopy).
2 -D e o x y -D -[2 ,6 -3H ]  G lucose (2 -D O G )  Uptake
Net glucose tran sp o rt w as determ ined by m easuring the 
uptake of nonm etabolizable 2-deoxy-D-[2,6-3H] glucose (Amer- 
sham  Biosciences, Piscataw ay, N J) using  th e  protocol pre­
viously published.24,26 Monolayer equine chondrocytes were 
preconditioned in  20% or 1% 0 2 w ith or w ithout 75 pM CoCl2 
for 48 h. T he glucose up take  assay was th en  perform ed using
0.5 pCi/mL 2-DOG in  modified DMEM lacking glucose, 
pyruvate, and  serum  a t 37°C for 2 h  w ith a  presence or 
absence of th e  glucose tran sp o rt inhibitor, cytochalasin B 
(20 pM). N early 100% chondrocyte viability w as confirmed in a 
separate study. Scintillation counts in  each sam ple w ere 
normalized to  protein  content u sing  th e  Lowry protein  assay.27
Fluorescent Activated Cell Sorting (FA C S ) Analysis of 
G L U T 1  Expression
Im m unostain ing and  FACS analysis w ere carried ou t essen­
tia lly  as described previously.14 N early confluent first passage 
m onolayer equine chondrocytes w ere m ain tained  u nder 20% 
0 2 or 1% 0 2 for 48 h. Trypsinized cells w ere w ashed and  fixed 
w ith  3.7% paraform aldehyde for 10 min. Cells w ere perm ea- 
bilized w ith  0.05%Triton X-100 in  PBS for 10 m in a t  4°C and 
incubated w ith  anti-GLUT-1 polyclonal antibody, w hich h as 
previously been shown to crossreact w ith  equine chondrocytes 
by W estern  blot,24 a t th e  dilution of 1:600 in  PBS, followed by 
goat an tirabb it IgG conjugated w ith FITC (Sigma, St. Louis, 
MO) a t  1:40 in  PBS, each for 30 m in a t 37°C in fight protective 
containers. Im m unolabeled chondrocytes w ere w ashed and 
resuspended in  PBS before being analyzed using  a  FACScan 
(Becton Dickinson, F rank lin  Lakes, N J) by gating  10,000 cells. 
The detectors w ere set as follows: FCS (threshold): 200; FSC: 
E-01; SSC: 319; and  FLI: 408, and  th e  param eters were: FSC- 
H: 5.0; SSC-H: 1.2; and  FL-1H : log. The d a ta  w ere analyzed by 
WinMDI 2.8 (free downloadable software; http://facs.scripps. 
edu/softw are.htm l) to  obtain (1) num ber of cells expressing 
fluorescence and  (2) m ean fluorescent in tensity  (MFI), w hich 
defines an  average GLUT1 expression in  each sample.
R N A  and c D N A  Preparation
Total RNA w as extracted  from chondrocyte m onolayers using  
TRIzol® R eagent (Invitrogen) and purified th rough  RNeasy® 
colum ns w ith  D N asel (Qiagen, C hatsw orth, CA), according to 
th e  m anufacturer’s instructions, to remove genomic DNA. cDNA 
copies w ere m ade from 1.5 pg RNA using  oligo (dT) p rim er 
(Promega, Madison, WI) and th e  reverse transcrip tase  from 
Invitrogen or Prom ega. The synthesized cDNA w ere kep t a t 
-20°C  u n til use. The sam e protocol w as applied for cartilage 
explant RNA and  cDNA preparation  from norm al, OA, and  
OCD cartilage biopsies bu t th e  explants w ere snap-frozen and  
pulverised in liquid nitrogen cooled steel chambers (Braun Biotech 
Mikrodismembrator, Allentown, PA) prior to the RNA extraction.
Reference G ene Selection and Q uantitative Polymerase Chain 
Reaction (qPCR )
The candidate reference genes and  th e ir prim ers are  shown in 
Table 1. They w ere selected on th e  basis th a t  they belong to 
different functional classes.28 Equine RNA and  DNA sequen­
ces w ere sourced from the  NCBI database (http://www. 
ncbi.nhn.nih.gov/). If  th e  equine sequence w as unavailable 
th en  a m ultiple species alignm ent w as carried  out (www. 
ebi.ac.uk/Tools/clustedw/) and prim ers designed w here there  
w as sequence homology. H um an exon boundaries w ere 
identified using  th e  Ensem bl Genome Browser (http://w ww . 
ensem bl.org/index.html), and w here possible, prim ers were 
designed to cross predicted exon boundaries. The prim ers w ere 
designed based on th e  above sequences using  P rim er Express 
(Applied Biosystems, Bedford, MA) softw are or Roche (Indian­
apolis, IN) p rim er design (https://www.roche-applied-science. 
com/). P rim er efficiencies w ere validated using  a standard  
curve derived from equine tendon cDNA (a 10-fold dilution 
series w ith  five m easuring points).
Expression of all seven candidate reference genes w ere 
analyzed across th e  chondrocyte monolayer cu ltures (re =  5) 
exposed to 20% 0 2 or 1% 0 2 w ith and  w ithout 75 pM CoCl2 or 
100 ng/mL IL -ip  for 24 h. A nother analysis w as done across 
norm al (n  =  6), O A  (re =  8), and  OCD (re =  5) cartilage to 
investigate th e  expression of five candidate genes (HPRT-1, 
TBP, GAPDH1, GNB2L1, and 18S). The m ost stable p a ir of
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Table 1. Candidate Reference Gene List
Symbol Gene Name Accession Code P rim ers 5'-3'
Efficiency 
on Equine 
Tendon References
GAPDH (1) Glyceraldehyde-3-phos- 
phate  dehydrogenase
AF157626 Fw: GCATCGTGGAGGGACTCA 
Rv: GCCACATCTTCCCAGAGG
-3 .317 Roche
GAPDH(2) Glyceraldehyde-3-phos- 
pha te  dehydrogenase
AF157626 Fw: TGACCCCCTAACATATTGAGAGTCT 
Rv: GCCCCTCCCCTTCTTCTG
-3 .139 Prim er
Express
ACTB Actin, beta AF035774 Fw: CCAGCACGATGAAGATCAAG 
Rv: GTGGACAATGAGGCCAGAAT
-3 .333 B ogaert e t al, 
20065
TBP TATA box binding 
protein
NM OO1075742 Fw: TGCTGCTGTAATCATGAGGGTAA 
Rv: TCCCGTGCACACCATTTTC
-3 .5 4 Prim er
Express
HPRT-1 H ypoxanthine phospho- 
ribosyltransferase I
AY372182 Fw: GGCAAAACAATGCAAACCTT 
Rv: CAAGGGCATATCCTACGACAA
-3 .3 5 B ogaert 
e t al, 20065
18S Ribosomal protein, 18S AJ311673 Fw: GGCGTCCCCCAACTTCTTA 
Rv: GGGCATCACAGACCTGTTATTG
-3 .241 Prim er
Express
GNB2L1 G uanine nucleotide 
binding protein
NM_006098 Fw: CCTTGTGCTTCAGTCCCAAT 
Rv: CAATGATCTTGCCCTTCAAGT
-3.241 Roche
genes w as identified using two downloadable software pro­
grams; GeNorm (http://m edgen.ugent.be/~jvdesom p/genorm /) 
and N orm finder (http://www.mdl.dk/publicationsnormfin- 
der.htm ), according to th e  software instructions. PCR reactions 
were perform ed in  a 10 pL volume using SYBR® G reen PCR 
m aster m ix (Applied Biosystems) and  300 nM prim er concen­
tration  and  processed by 7900HT Feist Reed tim e PCR system  
(Applied Biosystems) using standard  amplification conditions. 
The d a ta  w ere analyzed by SDS software (v 2.2.1; Applied 
Biosystems). The pair of reference genes th a t had  th e  most 
consistent expression, represented  by th e  lowest stability 
value, w as selected. The mRNA expression of GLUT-1 was 
assessed using  monolayer cultures (re =  3) of equine chondro­
cytes exposed to 20% 0 2 or 1% 0 2 w ith  and w ithout 75 pM CoCl2 
for 24 h  and  th e  cartilage explants from norm al (re =  6), OA 
(re =  8), and  OCD (re =  5) horses. The qPCR w as perform ed w ith 
the sam e protocol described above using the  following primers: 
forward prim er; 5'-AGCAGCCTGTGTACGCCAC-3' and 
reverse prim er; 5'-CTCGTTCCACCACAAACAGC-3'. These 
prim ers w ere designed by the Prim er3 softw are (http:// 
primer3.sourceforge.net/) using publicly available sequences 
from th e  NCBI D atabase. PCR products w ere m easured and 
norm alized against th e  selected reference genes.
Statistical Analysis
One-way analysis of variance (ANOVA) w ith D unnett’s m ulti­
ple com parison te s t w as perform ed by G raphPad  Prism  
software (v.4.01) to compare trea tm en t or diseased groups 
with th e  control or norm al groups, respectively.
RESULTS
2 -D e o x y -D - [2 ,6 -3H ]  G lu c o s e  U p ta k e
Figure 1 shows the alteration of 2-DOG transport rates. 
The data are represented as percentage of th e control 
(100% ± 0 .1 2 3  pmol/min/m g protein). The uptake was 
significantly increased ip  <  0.05) both in  hypoxia (1% 
0 2) and CoCl2. An additive effect of the combined 1% 0 2 
and CoCl2 was observed ip  <  0.01). Cytochalasin B 
effectively inhibited 2-DOG uptake ip  <  0.01).
F lu o re sc e n t A c tiv a te d  C e ll S o rtin g  (F A C S ) A n a lys is
FACS analysis indicated that approximately 90% of all 
groups of chondrocytes expressed GLUT1 protein  
(Table 2) w ith a confirmation by statistical analysis  
that there w as no significant difference between  
normoxia and hypoxia treatm ents. However, the in ten ­
sity of GLUT1 protein expression, which w as repre­
sented as m ean fluorescent in tensity  (MFI), in  
chondrocytes exposed to 1% 0 2 or CoCl2 w as signifi­
cantly increased (Fig. 2) ip  <  0.05). The combination of 
those two treatm ents had a tendency of increasing
200-I 1-0.30
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F ig u re  1. Effect of hypoxia (1% 0 2), cobalt chloride (75 pM), and 
the combined treatm ent on 2-deoxy-D-[2,6-3H] glucose uptake by 
first passage equine articular chondrocyte monolayers (re = 3). The 
cultures were preconditioned for 48 h in such treatm ents prior to 
exposure to 0.5 pCi/mL in glucose and pyruvate free DMEM at 37°C 
for 2 h  in the presence and absence of 20 pM cytochalasin B. Results 
represent percentage glucose uptake to the control group (20% 0 2) 
(average uptake in the control group was taken as 100%, which is 
approximately 0.123 pmol/min/mg protein). The error bars repre­
sent SEM.*p < 0.05; **p < 0.01; ***p <  0.001.
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Table 2. Number of Chondrocytes (Mean, Standard 
Deviation, and Standard Error) That Expressed GLUT1 
(from 10,000 Gated Cells)
Treatment Mean
Standard
Deviation
Standard
Error
Control 8997.33 ±  1246.55 ±  415.52
Hypoxia (1% 0 2) 9300.78 ±  1335.25 ±  445.08
75 pM CoCl2 9427.89 ±  740.45 ±  246.82
Hypoxia +  CoCl2 9419.22 dh 856.50 ±  285.50
GLUT1 expression compared to the control but th is was 
not significant.
Reference G e n e  S e le c tio n  fo r  q P C R  A n a ly s is
The real-tim e PCR assays were designed to detect and 
quantify expression of commonly used  reference genes 
(Table 1). The stability of gene expression across 
different sam ples w as analyzed u sing  GeNorm and 
Normfinder software. The stability values and the  
ranking of th e candidate genes from both forms of 
analysis in  th e study w ith chondrocyte cultures and a 
study of norm al versus diseased cartilage study are 
shown in Table 3. A lthough the ranking of the candidate 
genes was som ew hat different betw een the two pro­
grams, HPRT-1 and TBP were identified, in  both studies 
and both an alyses, to be the m ost stably expressed pair 
of genes and w ere selected to use as the reference genes 
for the rest of th is study. Normfinder identified GAPDH(l) 
as the best single reference gene in  the norm al-disease 
cartilage t issu e  study.
G L U T 1  m R N A  Expre ssio n
The relative expression of GLUT1 mRNA w as quanti­
fied by real-tim e PCR assay. The Ct values of all 
samples w ere norm alised w ith the m ean Ct values of 
the selected reference genes, which were HPRT-1 and 
TBP. There w as an upregulation of the GLUT1 mRNA
1200-1
C o n tro l 1°/c02 C o C I2 10/<O2+ CoCI2
F igure 2. Changes in equine chondrocyte GLUT1 protein 
expression assessed by FACS analysis using first passage equine 
chondrocytes in monolayer culture after exposure to hypoxia (1% 
0 2), Cobalt Chloride (75 pM) and the combined treatm ent for 48 h. 
The results the represented as mean fluorescent intensity (MFI). 
The experiment was done with three different cartilage donors. The 
error bars represent SEM.*p < 0.05; **p<  0.01; ***p<  0.001.
expression in sam ples exposed to 1% 0 2 and 75 pM 
CoCl2; however, only a combination of both treatm ents 
showed a statistically  significant increase (p  <  0.05) 
(Fig. 3a). In contrast, exam ination of GLUT1 mRNA  
expression in cartilage tissue, as shown in Figure 3b, 
identified that in  OA cartilage its  abundance was 
significantly decreased (p < 0.01) compared to normal 
cartilage. In OCD sam ples, expression of GLUT1 was 
also decreased but th is reduction did not reach sta t­
istical significance.
DISCUSSION
In th is study w e observed enhanced glucose uptake by 
equine chondrocytes in  a low oxygen environm ent and a 
highly significant increase in  glucose transport in  
hypoxia combined w ith  hypoxia m im etic, suggesting  
an increased m etabolic dem and of th e chondrocytes in  
response to hypoxia. This is  supportive of previous 
studies in  equine chondrocytes u sing CoCl2.19 The 
inhibition of glucose uptake by cytochalasin B indicates 
that the glucose uptake is m ediated by sodium -inde­
pendent glucose transporters.29 Glucose transporter 1 
(GLUT1) is  known to be the m ost abundant GLUT 
expressed by m ost cell types, including articular 
chondrocytes and intervertebral disc cells.17,30 GLUT1 
is  generally considered to function as a “housekeeping” 
glucose transporter and in th is role, GLUT1 m aintains  
basal glucose uptake for m etabolic reactions.13 GLUT1 
is  also reported to be a “hypoxia-responsive” glucose 
transporter in  various tissu es,20,31,32 especially in 
cancer cells that collectively exhibit th e Warburg effect 
(reviewed in ref. 33). This observation w as confirmed by 
our investigation of chondrocyte GLUT1 protein expres­
sion. We found that although m ost of the chondrocytes 
exam ined expressed some GLUT1 protein, the physical 
(1% 0 2) and chem ical (CoCl2) hypoxia signals signifi­
cantly increased th e am ount of GLUT1 that is expressed  
in  each chondrocyte.
However, the glucose uptake resu lts were not fully  
concordant w ith  the GLUT1 protein expression data, 
especially in  chondrocytes exposed to a combination of 
hypoxia and CoCl2. Although glucose uptake showed an 
additive effect o f the combined hypoxic treatm ent, 
GLUT1 protein expression w as more or less at the sam e 
level as individual 1% 0 2 and CoCl2 treatm ents. One 
plausible explanation for th is observation is an increase 
in  the translocation of preexisting GLUT1 protein from 
subcellular com partment to th e cell m em brane20 in an 
extrem ely hypoxic environm ent. It is also possible that 
other glucose transporters, such as GLUT3 and GLUT9, 
which have recently been shown to be expressed in  
chondrocytes,14,34 are involved in th is process. GLUT3 is 
known to be a high-affinity glucose transporter,13 and 
could have a role in  regulating glucose transport under 
such stim uli where chondrocytes have a very high  
m etabolic dem and to m aintain their m atrix synthesis  
function. Furthermore, GLUT3 has been found to be 
upregulated in a num ber of hypoxic tum ours along w ith  
GLUT1 (reviewed in ref. 33). We could not identify
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Table 3. Stability Value and Ranking of Candidate Reference Gene Expression
Experiment Gene
Normfinder
Stability
Value Rank Gene
GeNorm
Stability
Value Rank
Equine chondrocyte HPRT-1“ 0.195 1 HPRT-1 0.244047225 1
cultures TBPa 0.204 2 TBP 0.244047225 2
GNB2L1 0.244 3 GAPDH(l) 0.54765329 3
18S 0.283 4 GAPDH® 0.560551071 4
GAPDH (1) 0.336 5 GNB2L1 0.602052909 5
GAPDH (2) 0.378 6 18S 0.650220526 6
ACTB 0.451 7 ACTB 0.712836738 7
Normal and diseased GAPDH (1) 0.048 1 HPRT-1 0.643906 1
cartilage expiants HPRT-1“ 0.055 2 TBP 0.643906 2
TBP° 0.058 3 GAPDH(l) 0.728417 3
GNB2L1 0.117 4 GNB2L1 0.890601 4
18S 0.141 5 18S 1.248013 5
“The best combination of two genes by Normfinder.
equine GLUT3 and GLUT9 gene sequences, and the 
prediction of primer sequences from other species was 
not successful. Therefore, GLUT3 and GLUT 9 qPCR 
could not be performed in th is study. Another alternative  
to explain this phenomenon is perhaps changes in hexoki- 
nase activities as there has been evidence of alterations in 
hexokinase expression and activities by hypoxia.35,36
We successfully investigated th e expression of the  
GLUT1 gene in response to low oxygen tension and the  
presence of cobalt chloride, u sing quantitative, real-tim e 
PCR. A lthough GLUT1 protein expression w as signifi­
cantly higher in hypoxic conditions, mRNA expression, 
while elevated, did not reach statistical significance. The 
sm aller response in GLUT 1 mRNA expression to hypoxia 
or C0CI2 stim ulation suggests that increasing the expres­
sion of GLUT1 gene may not be the m ain mechanism used  
by chondrocytes to regulate glucose m etabolism  under a
low oxygen environment; other m echanism s m ay be 
involved including increased GLUT1 mRNA stability  
and posttranslational regulatory m echanism s (i.e., 
recruitm ent and activation of preexisting GLUT1 trans­
porters). Zhang and colleagues20 have reported that the  
acute response to hypoxia is  m ainly m ediated by 
enhanced function of the ex isting glucose transporters, 
especially GLUT1, w hile the regulation at transcrip­
tional level o f GLUT1 is found to increase in  chronic 
hypoxia. However, our data did show that the com bina­
tion of hypoxia and CoCl2 treatm ent caused a reprodu­
cible and significant increase in  GLUT1 mRNA levels, 
indicating that the transcription of GLUT1 can be 
significantly increased acutely, dependent on th e rele­
vant stim uli.
The reference gene selection w as addressed in our 
studies as it is reported that hypoxia is able to alter the
F ig u re  3. GLUT1 mRNA expression (a) study in first passage equine chondrocyte monolayers after exposure to normoxia (20% 0 2), 
hypoxia (1% 0 2), and/or 75 pM cobalt chloride for 24 h using cartilage from five different donors, and (b) study in normal (re =  6), osteoarthritis 
(OÀ) (re =  8), and osteochondritis dissecans (OCD) (re = 5) cartilage expiants. The analysis was done in triplicate. The error bars represent 
SEM.*p < 0.05; **p < 0.01; ***p < 0.001.
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expression of glyceraldehyde-3-phosphate dehydrogen­
ase (GAPDH),37 which has been commonly used as a 
reference gene in m any chondrocyte quantitative PCR 
analyses. A  reference gene selection study w as therefore 
performed. Two candidate reference genes were selected  
for normalization of GLUT1 mRNA expression in each  
sample. These were HPRT-1 and TBP, and are likely to 
be the m ost u sefu l reference genes for all future studies of 
mRNA experim ent by chondrocytes. However, it should  
be noted that GAPDH, a commonly used  reference gene, 
was shown to be the single m ost stably expressed gene in  
our panel o f assessed  genes for mRNA quantification of 
in  v iv o  acquired cartilage. This is perhaps not surprising  
given the central role that GAPDH plays in  glucose 
utilization and cellular metabolism.
In the second part o f our study, w e focused on the  
expression of GLUT1 mRNA in equine joint diseases. We 
compared GLUT1 expression in normal cartilage and 
cartilage derived from joints with either OA or OCD. 
Interestingly, our findings indicated decreased GLUT1 
gene expression in OA and OCD specim ens, w ith a 
greater reduction and statistical significance in  the OA 
samples, suggesting that glucose transport is affected in  
diseased jo ints, especially in  OA chondrocytes. The 
observed reduction of GLUT1 transcription m ay be a 
consequence o f fluctuations in oxygenation and nutrient 
supply caused by system ic effects or disturbances in the 
vascular supply during pathological processes.22 How­
ever, HIF-1, th e key protein potentially linking oxygen  
tension and GLUT1 expression in equine chondrocytes, 
has not yet been investigated  in th is species. There is 
evidence of increased expression of H IF -la  and GLUT1 
protein in hum an OA cartilage, possibly in order to 
compensate for th e increase in  ATP dem and.38 In 
contrast, we observed downregulation of equine GLUT1 
mRNA in equine OA cartilage, suggesting failure to 
maintain energy supply in equine degenerative cartilage.
In summary, hypoxia and the osteoarthritic process 
have significant effects on glucose transport and GLUT1 
expression in chondrocytes. Hypoxia increases the net 
rate of glucose uptake and th e regulation of GLUT1 
expression w hile OA and OCD lead to a reduction in  
transcription o f the GLUT1 gene. The altered GLUT1 
mRNA expression in diseased cartilage suggests that 
there m ay be a failure in  the m aintenance of adequate 
levels of m etabolic and structural glucose in  OA 
cartilage. This m ay contribute to and exacerbate the  
poor cartilage repair that is characteristic of degenerate 
cartilage tissu e in  OA.
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